Mitesco (MITI) S-1/A 2 Aug 22 2022 Q1 IPO registration (amended) Financial data

Document And Entity Information

Document And Entity Information	3 Months Ended
	Mar. 31, 2022
Document Information Line Items
Entity Registrant Name	Mitesco, Inc.
Document Type	S-1/A
Amendment Flag	false
Entity Central Index Key	0000802257
Entity Filer Category	Non-accelerated Filer
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Incorporation, State or Country Code	DE
Entity Primary SIC Number	8011
Entity Tax Identification Number	87-0496850
Entity Address, Address Line One	1660 Highway 100 South
Entity Address, Address Line Two	Suite 432
Entity Address, City or Town	St. Louis Park
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55416
City Area Code	844
Local Phone Number	383-8689

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 263,148	$ 1,164,483	$ 64,789
Accounts receivable	55,587	44,313	0
Inventory	30,593	25,314	0
Prepaid expenses	92,684	72,985	0
Total current assets	442,012	1,307,095	64,789
Right to use operating leases, net	3,619,403	3,886,866	310,361
Construction in progress	608,240	1,984,701	417,082
Fixed assets, net of accumulated depreciation	5,701,433	3,476,164	6,282
Total Assets	10,371,088	10,654,826	798,514
Current liabilities
Accounts payable and accrued liabilities	5,004,635	3,976,064	1,069,331
Accrued interest	39,371	7,657	137,522
Derivative liabilities	26,771	0	807,682
Lease liability - operating leases, current	276,639	161,838	8,905
Notes Payable, net of discounts	1,488,321	588,432	0
SBA Loan Payable	460,406	460,406	460,406
Other current liabilities	169,422	169,422	95,256
Preferred stock dividends payable	274,861	195,169	9,967
Total current liabilities	7,740,426	5,558,988	3,028,640
Lease Liability- operating leases, non-current	3,870,321	3,972,964	312,099
Total Liabilities	11,610,747	9,531,952	3,340,739
Commitments and contingencies
Common stock subscribed	128,015	132,163	0
Common stock, Value	2,197,570	2,133,332	1,553,812
Additional paid-in capital	25,517,634	24,295,063	10,340,821
Accumulated deficit	(29,123,526)	(25,478,332)	(14,437,168)
Total stockholders' equity (deficit)	(1,239,659)	1,122,874	(2,542,225)
Current liabilities
Convertible notes payable, net of discount		0	317,405
Convertible note payable, in default		0	122,166
Total liabilities and stockholders' equity (deficit)	10,371,088	10,654,826	798,514
Series A Preferred Stock [Member]
Current liabilities
Preferred stock, Value	0	0	48
Series C Preferred Stock [Member]
Current liabilities
Preferred stock, Value	9,406	9,406	0
Series D Preferred Stock [Member]
Current liabilities
Preferred stock, Value	31,000	31,000	0
Series X Preferred Stock [Member]
Current liabilities
Preferred stock, Value	$ 242	$ 242	$ 262

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($)	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Fixed assets, accumulated depreciation (in Dollars)	$ 151,942	$ 183,988	$ 19,590
Notes payable, discounts (in Dollars)		$ 150,000	$ 756,795
Preferred stock, shares authorized	100,000,000	100,000,000	100,000,000
Common stock, shares authorized	500,000,000	500,000,000	500,000,000
Common stock, par value (in Dollars per share)	$ 0.01	$ 0.01	$ 0.01
Common stock, shares issued	219,756,894	213,333,170	155,381,183
Common stock, shares outstanding	219,756,894	213,333,170	155,381,183
Notes payable, discount (in Dollars)		$ 150,000	$ 756,795
Series A Preferred Stock [Member]
Preferred stock, shares authorized	500,000	500,000
Preferred stock, par value (in Dollars per share)	$ 0.01	$ 0.01	$ 0.01
Preferred stock, shares issued	0	0	4,800
Preferred stock, shares outstanding	0	0	4,800
Series C Preferred Stock [Member]
Preferred stock, shares authorized	3,000,000	3,000,000
Preferred stock, par value (in Dollars per share)	$ 0.01	$ 0.01	$ 0.01
Preferred stock, shares issued	940,644	940,644	0
Preferred stock, shares outstanding	940,644	940,644	0
Series D Preferred Stock [Member]
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, par value (in Dollars per share)	$ 0.01	$ 0.01	$ 0.01
Preferred stock, shares issued	3,100,000	3,100,000	0
Preferred stock, shares outstanding	3,100,000	3,100,000	0
Series X Preferred Stock [Member]
Preferred stock, shares authorized	400,000	27,324
Preferred stock, par value (in Dollars per share)	$ 0.01	$ 0.01	$ 0.01
Preferred stock, shares issued	24,227	24,227	26,227
Preferred stock, shares outstanding	24,227	24,227	26,227
Notes Payable, Other Payables [Member]
Notes payable, discounts (in Dollars)	$ 671,973	$ 411,568
Notes payable, discount (in Dollars)	$ 671,973	411,568
Convertible Debt [Member]
Notes payable, discounts (in Dollars)		0	$ 317,405
Notes payable, discount (in Dollars)		$ 0	$ 317,405

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Revenue	$ 120,376	$ 2,972	$ 115,994	$ 0
Cost of goods sold	588,323	1,713	455,587	0
Gross profit (loss)	(467,947)	1,259	(339,593)	0
General and administrative	2,563,829	952,908	6,058,996	2,533,569
Total operating expenses	2,563,829	952,908	6,058,996	2,533,569
Net Operating Loss	(3,031,776)	(951,649)	(6,398,589)	(2,533,569)
Other income (expense):
Interest expense	(828,325)	(964,988)	(968,471)	(1,515,902)
Loss on legal settlement			(70,000)	0
Gain (loss) on waiver fee shares	198,273	0
Gain (loss) on settlement of accrued salary	15,032	0	0	6,988
Gain (loss) on settlement of accounts payable	(78,235)	6,045	6,045	399,761
Gain (loss) on settlement of notes payable	0	1,836	1,836	35,236
Gain on settlement of warrants			0	235,053
Grant Income	198,273		0	3,000
Gain (loss) on revaluation of derivative liabilities	79,837	(493,455)	(493,455)	508,839
Total other expense	(613,418)	(1,450,562)	(1,524,045)	(327,025)
Loss before provision for income taxes	(3,645,194)	(2,402,211)	(7,922,634)	(2,860,594)
Provision for income taxes	0	0	0	0
Net loss	(3,645,194)	(2,402,211)	(7,922,634)	(2,860,594)
Preferred stock dividends	(79,692)	(20,499)	(185,202)	(75,535)
Preferred stock deemed dividends	0	(332,242)	(3,118,530)	0
Net loss available to common shareholders	$ (3,724,886)	$ (2,754,952)	$ (11,226,366)	$ (2,936,129)
Net loss per share - basic and diluted (in Dollars per share)	$ (0.02)	$ (0.01)	$ (0.06)	$ (0.03)
Weighted average shares outstanding - basic and diluted (in Shares)	213,703,195	187,152,300	203,000,201	105,177,272
Service [Member]
Revenue	$ 92,461	$ 0
Cost of goods sold	577,556	0
Product [Member]
Revenue	27,915	2,972
Cost of goods sold	$ 10,767	$ 1,713

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY (DEFICIT) - USD ($)	Diamond Note 2 [Member] Additional Paid-in Capital [Member]	Diamond Note 2 [Member]	Commitments [Member] Common Stock [Member]	Commitments [Member] Additional Paid-in Capital [Member]	Commitments [Member]	Waiver Fee [Member] Common Stock [Member]	Waiver Fee [Member] Additional Paid-in Capital [Member]	Waiver Fee [Member] Stock Subscribed [Member]	Waiver Fee [Member]	Convertible Debt [Member] Common Stock [Member]	Convertible Debt [Member] Additional Paid-in Capital [Member]	Convertible Debt [Member]	Accounts Payable [Member] Common Stock [Member]	Accounts Payable [Member] Additional Paid-in Capital [Member]	Accounts Payable [Member] Stock Subscribed [Member]	Accounts Payable [Member]	Stock Payable [Member] Stock Subscribed [Member]	Stock Payable [Member]	Series A Preferred Stock [Member] Preferred Stock [Member]	Series A Preferred Stock [Member] Common Stock [Member]	Series A Preferred Stock [Member] Additional Paid-in Capital [Member]	Series A Preferred Stock [Member] Retained Earnings [Member]	Series A Preferred Stock [Member]	Series X Preferred Stock [Member] Preferred Stock [Member]	Series X Preferred Stock [Member] Common Stock [Member]	Series X Preferred Stock [Member] Additional Paid-in Capital [Member]	Series X Preferred Stock [Member]	Series C Preferred Stock [Member] Preferred Stock [Member]	Series C Preferred Stock [Member] Common Stock [Member]	Series C Preferred Stock [Member] Additional Paid-in Capital [Member]	Series C Preferred Stock [Member] Retained Earnings [Member]	Series C Preferred Stock [Member]	Series D Preferred Stock [Member] Preferred Stock [Member]	Series D Preferred Stock [Member] Additional Paid-in Capital [Member]	Series D Preferred Stock [Member] Retained Earnings [Member]	Series D Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Stock Subscribed [Member]	Total
Balance, at Dec. 31, 2019																								$ 262													$ 812,684	$ 8,407,977	$ (11,576,574)	$ 37,186	$ (2,318,465)
Balance, (in Shares) at Dec. 31, 2019																								26,227													81,268,443
Vesting of common stock issued to employees																																						67,623			67,623
Vesting of stock options issued to employees																																						421,502			421,502
Stock issued for services																			$ 48		$ 71,510		$ 71,558														$ 2,000	5,680			7,680
Stock issued for services (in Shares)																			4,800																		200,000
Settlement of derivative liabilities																																					$ 80,000	380,562			$ 460,562
Settlement of derivative liabilities (in Shares)																																					7,999,996				2,151,204
Common stock issued for payable										$ 633,748	$ 999,658	$ 1,633,406													$ 21,511	$ 44,057	$ 65,568										$ 3,869	17,787			$ 21,656
Common stock issued for payable (in Shares)										63,374,555															2,151,204												386,985
Issuance of shares (in Shares)																																					7,999,996				2,151,204
Gain on settlement																	$ (37,186)	$ (37,186)																							$ 399,761
Preferred stock dividends																											(65,568)											(75,535)			(75,535)
Loss for the period																																							(2,860,594)		(2,860,594)
Balance, at Dec. 31, 2020																			$ 48					$ 262													$ 1,553,812	10,340,821	(14,437,168)		(2,542,225)
Balance, (in Shares) at Dec. 31, 2020																			4,800					26,227													155,381,183
Vesting of common stock issued to employees																																						4,008			4,008
Vesting of stock options issued to employees																																						5,942			5,942
Stock issued for services																																					$ 10,961	211,519			222,480
Stock issued for services (in Shares)																																					1,097,358
Common stock issued for payable										$ 339,442	$ 2,314,353	$ 2,653,795
Common stock issued for payable (in Shares)										33,944,157
Sale of stock																												$ 30,000		$ 1,461,283		$ 1,491,283					$ 66,750	1,601,250			1,668,000
Sale of stock (in Shares)																												3,000,000									6,672,000
Warrants issued																														1,268,717		1,268,717
Gain on settlement																																									0
Conversion of Preferred Stock to common stock																			$ (48)	$ 6,000	(5,952)
Conversion of Preferred Stock to common stock (in Shares)																			(4,800)	600,000
Deemed dividend on Preferred Stock																					206,242	$ (206,242)								126,000	$ (126,000)
Preferred stock dividends																							(1,000)				$ (16,392)											(20,499)			(20,499)
Loss for the period																																							(2,402,211)		(2,402,211)
Balance, at Mar. 31, 2021																								$ 262				$ 30,000									$ 1,976,965	17,513,684	(17,171,621)		2,349,290
Balance, (in Shares) at Mar. 31, 2021																								26,227				3,000,000									197,694,698
Balance, at Dec. 31, 2020																			$ 48					$ 262													$ 1,553,812	10,340,821	(14,437,168)		(2,542,225)
Balance, (in Shares) at Dec. 31, 2020																			4,800					26,227													155,381,183
Vesting of common stock issued to employees																																						13,032			13,032
Vesting of stock options issued to employees																																						676,423			676,423
Stock issued for services																																					$ 10,963	211,517			222,480
Stock issued for services (in Shares)																																					1,099,320
Settlement of derivative liabilities (in Shares)																																					479,464
Common stock issued for payable															$ 252,029	$ 252,029																					$ 339,442	2,314,353			2,653,795
Common stock issued for payable (in Shares)																																					33,944,157
Issuance of shares																																					$ 4,795	115,071		(119,866)
Issuance of shares (in Shares)																																					479,464
Sale of stock																												$ 30,000		1,461,283		1,491,283	$ 31,000	$ 1,688,018		$ 1,719,018	$ 66,750	1,601,250			1,668,000
Sale of stock (in Shares)																											24,227	3,000,000					3,100,000				6,672,000
Warrants issued																														1,268,717		1,268,717		1,179,682		1,179,682		261,568			261,568
Gain on settlement																																									0
Conversion of Preferred Stock to common stock																			$ (48)	$ 6,000	(5,952)							$ (20,594)	$ 82,374	(61,780)
Conversion of Preferred Stock to common stock (in Shares)																			(4,800)	600,000								(2,059,356)	8,237,425
Shares issued for exercise of stock options																																					$ 82,816	156,184			$ 239,000
Shares issued for exercise of stock options (in Shares)																																					8,281,668				8,652,668
Net shares issued in connection with settlement agreement																								$ (20)													$ (13,620)	141,550			$ 127,910
Net shares issued in connection with settlement agreement (in Shares)																								(2,000)													(1,362,047)
Deemed dividend on Preferred Stock																					$ 206,242	$ (206,242)								$ 126,000	$ (126,000)			$ 2,786,288	$ (2,786,288)
Preferred stock dividends																							$ (1,000)				$ 0					$ (87,059)				$ (35,327)		(185,202)			(185,202)
Loss for the period																																							(7,922,634)		(7,922,634)
Balance, at Dec. 31, 2021																								$ 242				$ 9,406					$ 31,000				$ 2,133,332	24,295,063	(25,478,332)	$ 132,163	1,122,874
Balance, (in Shares) at Dec. 31, 2021																								24,227				940,644					3,100,000				213,333,170
Vesting of common stock issued to employees																																						1,512			1,512
Vesting of stock options issued to employees																																						167,015			$ 167,015
Settlement of derivative liabilities (in Shares)			1,720,000			1,541,721																															382,353			382,353	1,720,000
Common stock issued for payable													$ 31,797	$ 546,438		$ 578,235
Common stock issued for payable (in Shares)													3,179,650
Issuance of shares			$ 17,200	$ 226,106	$ 243,306	$ 15,417	$ 260,301	$ 91,440	$ 367,158																												$ 3,824	91,764		$ (95,588)
Issuance of shares (in Shares)			1,720,000			1,541,721																															382,353			382,353	1,720,000
Warrants issued	$ 2,213	$ 2,213																																				2,914			$ 2,914
Gain on settlement																																					$ (4,000)	4,000			(78,235)
Gain on settlement (in Shares)																																					(400,000)
Deemed dividend on Preferred Stock																																									226,106
Preferred stock dividends																																						(79,692)			(79,692)
Loss for the period																																							(3,645,194)		(3,645,194)
Balance, at Mar. 31, 2022																								$ 242				$ 9,406					$ 31,000				$ 2,197,570	$ 25,517,634	$ (29,123,526)	$ 128,015	$ (1,239,659)
Balance, (in Shares) at Mar. 31, 2022																								24,227				940,644					3,100,000				219,756,894

CONSOLIDATED STATEMENTS OF CH_2

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY (DEFICIT) (Parentheticals) - Additional Paid-in Capital [Member] - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Preferred stock dividends, per share	$ 3.62	$ 3.62
Preferred stock dividends, stated value per year	10%	10%

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (3,645,194)	$ (2,402,211)	$ (7,922,634)	$ (2,860,594)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	179,886	20,616	182,426	1,572
Amortization of right-to-use asset	267,463	6,237	162,276	4,318
Net gain on settlement of notes payable	0	(1,836)	0	(35,236)
Amortization of financing cost	565,431	0	0	30,000
Gain on waiver fee shares	(198,273)	0
Gain on conversion of accrued salary	(15,032)	0	0	(6,988)
(Gain) on settlement of warrants			0	(235,053)
Loss on conversion of Pref Stock Series A to common stock			0	0
(Gain) loss on revaluation of derivative liabilities	(79,837)	493,455	493,455	(508,839)
Derivative expense			0	125,869
Gain (loss) on settlement of accounts payable	78,235	0	0	(399,761)
Amortization of discount on notes payable	231,180	756,795	756,795	1,128,885
Share-based compensation	168,527	232,430	1,039,843	568,363
Changes in assets and liabilities:
Accounts receivables	(11,274)	0	(44,313)	0
Prepaid expenses	(19,699)	(14,618)	(47,985)	9,721
Due from related party			0	0
Inventory	(5,279)	(1,480)	(25,314)	0
Accounts payable and accrued liabilities	534,132	(366,636)	54,527	522,758
Operating lease liability	12,158	9,726	75,017	6,325
Other current liabilities	0	880	74,166	2,488
Accrued interest	31,714	202,313	205,795	125,310
Net cash used in operating activities	(1,905,862)	(1,064,329)	(4,995,946)	(1,520,862)
CASH FLOWS FROM INVESTING ACTIVITIES
Cash paid for acquisition of fixed assets	(19,223)	(495,360)	(1,928,192)	0
Net cash used in investing activities	(19,223)	(495,360)	(1,928,192)	0
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from private placement of common stock	0	1,668,000	1,668,000	0
Proceeds from sales of Preferred Stock, net of fees	0	2,760,000
Proceeds from notes payable - related parties, net of discount	348,750	0
Proceeds from notes payable, net of discount	675,000	0	0	1,673,406
Proceeds from sale of common stock			51,500	0
Proceeds from convertible notes payable, net of discount			850,000	0
Principal payments on notes payable	0	(177,534)	(179,368)	(171,000)
Net cash provided by financing activities	1,023,750	4,250,466	8,023,832	1,502,406
Net increase in cash and cash equivalents	(901,335)	2,690,777	1,099,694	(18,456)
Cash and cash equivalents at beginning of period	1,164,483	64,789	64,789	83,245
Cash and cash equivalents at end of period	263,148	2,755,566	1,164,483	64,789
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest paid	2,680	0	2,680	2,680
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Stock issued for conversion of debt and accrued interest	0	2,653,795	0	1,633,406
Settlement of derivative liabilities		(1,301,137)	(1,301,137)	460,562
Discount on notes payable due to derivative liabilities			0	1,234,792
Preferred stock dividend	79,692	20,499	185,202	75,535
Deemed dividends on Preferred Stock	0	332,242	3,118,530	0
Capital expenditures included in accounts payable	1,009,471	0	3,291,735	0
Conversion of payable to common stock	500,000	0	252,029	0
Cashless exercise of warrants			0	290,000
Discount on note payable due to warrants			261,568	0
Accounts Payable [Member]
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Conversion of payable to common stock			102,333	0
Accrued Payroll [Member]
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Conversion of payable to common stock			50,000	0
Series A Preferred Stock [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Preferred A stock issued to consultants				0
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Preferred stock dividend		1,000	1,000
Conversion of Preferred stock to common stock	$ 0	6,000	6,000	0
Series C Preferred Stock [Member]
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from sales of Preferred Stock, net of fees			2,760,000	0
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Preferred stock dividend			87,059
Conversion of Preferred stock to common stock			61,781	0
Series D Preferred Stock [Member]
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from sales of Preferred Stock, net of fees			2,873,700	0
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Preferred stock dividend			35,327
Series X Preferred Stock [Member]
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Preferred stock dividend		$ 16,392	$ 0	$ 65,568

Description of Business

Description of Business	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1 Description of Business Company Overview Mitesco, Inc. (the “Company,” “we,” “us,” or “our”) was formed in the state of Delaware on January 18, 2012. On December 9, 2015, we restructured our operations and acquired Newco4pharmacy, LLC, a development stage company which sought to acquire compounding pharmacy businesses. As a part of the restructuring, we completed a “spin out” of our former business line. On April 24, 2020, we changed our name to Mitesco, Inc. Since 2020, our operations have focused on establishing medical clinics utilizing nurse practitioners under The Good Clinic name and development and acquisition of telemedicine technology. In March of 2020, we formed a wholly owned subsidiary, The Good Clinic LLC, a Colorado limited liability company for our clinic business. We opened our first The Good Clinic in Minneapolis, Minnesota in the first quarter of 2021 and have six operating at the time of this filing. We intend on opening up to 50 new clinics in the next three years, in addition to any existing sites we might acquire.	Note 1 Description of Business Company Overview Mitesco, Inc. (the “Company,” “we,” “us,” or “our”) was formed in the state of Delaware on January 18, 2012. On December 9, 2015, we restructured our operations and acquired Newco4pharmacy, LLC, a development stage company which sought to acquire compounding pharmacy businesses. As a part of the restructuring, we completed a “spin out” of our former business line. On April 24, 2020, we changed our name to Mitesco, Inc. Since 2020, our operations have focused on establishing medical clinics utilizing Nurse Practitioners under The Good Clinic name and development and acquisition of telemedicine technology. In March of 2020, we formed an owned subsidiary, Mitesco NA LLC, which holds The Good Clinic LLC, a Colorado limited liability company for our clinic business. The Company had previously established a strategy to address opportunities in Europe seeking technology solutions, or financing situations, through a Dublin based subsidiary, Acelerar Healthcare Holdings Ltd. After a review of its near-term opportunities in North America, the Board of Directors has determined that any efforts in the European community should be discontinued so that it can best focus on its North American operations. In conjunction with this decision the Company for the period ending December 31, 2021, we will take a one-time charge of $12,500 related to the discontinuation and wind down of our European efforts. We opened our first The Good Clinic in Minneapolis, Minnesota in the first quarter of 2021 and have six operating at the time of this filing. We have two additional sites under contract with build-out underway in the Denver metropolitan areas before the end of 2022. We are making plans for up to opening up to 50 new clinics in the next three years, in addition to any existing sites we might acquire.

Financial Condition, Going Conc

Financial Condition, Going Concern and Management Plans	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern [Text Block]	N ote 2 - Financial Condition, Going Concern and Management Plans On November 19, 2021, the Company closed a bridge financing round totaling $3.1 million of a Series D preferred stock sold to investors in a private placement. Each Series D Unit will have a purchase price of $1.00 per Unit, with each Unit consisting of (a) one share of a newly formed Series D Convertible Preferred Stock, par value $0.01 per share (the “Series D Preferred Stock”), (b) one warrant (the “Series A Warrants”) to purchase 2.1 shares of the Company’s Common Stock at a purchase price of $0.50 per whole share of Common Stock, and (c) one warrant (the “Series B Warrants” and together with the Series A Warrants, the “Warrants”) to purchase 2.1 shares of Common Stock at a purchase price of $0.75 per whole share. Pursuant to the Certificate of Designations, Preferences and Rights of the Series D Convertible Preferred Stock of the Company, Inc., filed with the Secretary of State of the State of Delaware on October 18, 2021 (the “COD”), there are 10,000,000 shares of the Company’s preferred stock that have been designated as the Series D Preferred Stock and each share of the Series D Preferred Stock is convertible at the option of the holder thereof, or automatically upon the request of the Company’s underwriters that the Series D Preferred Stock convert to shares of Common Stock or upon listing of the Company’s Common Stock on a national securities exchange. The number of shares of Common Stock issuable upon the conversion of each share of Series D Preferred Stock is calculated by dividing the Conversion Amount (defined in the COD as the Stated Value, $1.05 per share, plus accrued and unpaid dividends) by the $0.25 conversion price (the “Conversion Price”). On November 11, 2021, the Company filed a registration statement on form S/1 in connection with a planned up list to a national exchange. As of the date of this filing the Company has closed on $3,100,000 of its Series D Preferred stock. To achieve our growth strategy, it is anticipated the Company will need to raise additional financing prior to up listing on Nasdaq. We will not proceed with this offering in the event our Common Stock is not approved for listing on the Nasdaq Capital Market though we will continue to seek financing for our expansion and operating needs in the debt or equity markets. The Company) issued a 10% Promissory Note due June 30, 2022, dated December 30, 2021, to the Michael C. Howe Living Trust (the “Lender”). Michael C. Howe is the Chief Executive Officer of the Good Clinic LLC, one of our subsidiaries. The principal amount of the Note is $1,000,000, carries a 10% interest rate per annum, payable in monthly installments, and has a maturity date that is the earlier of (i) six (6) months from the date of execution, or (ii) the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Note payable to the Company for the Note was $850,000 and was funded on December 30, 2021. The amount payable at maturity will be $1,000,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default, as defined in the Note, the principal amount shall bear interest for each day until paid, at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Note contains a “most favored nations” clause that provides that, so long as the Note is outstanding, if the Company issues any new security, which the Lender believes contains a term that is more favorable than those in the Note, the Company shall notify the Lender of such term, and such term, at the option of the Lender, shall become a part of the Note. The Company entered into a debt-for-equity exchange agreement with Gardner Builders Holdings, LLC (the “Creditor”) on January 7, 2022 (the “Agreement”). Pursuant to the Agreement, the Company issued shares of restricted common stock, par value $0.01 per share, of MITI (the “Restricted Shares”) to the Creditor in exchange for the Company Debt Obligations, as defined below. The Agreement settles for certain accounts payable amounts owed by the Company to the Creditor (the “Accounts Payable Amount”) as well as upcoming amounts that will become due between the date of the Agreement and April 1, 2022. The Agreement also settles incurred interest and penalties on the amounts due through January 5, 2022, as well as future interest payments on amounts to be incurred in the first quarter of 2022 (collectively, the “Additional Costs”, and combined with the Accounts Payable Amount, the “Company Debt Obligations”). The Accounts Payable Amount is $500,000, the Additional Costs is $294,912.56 and the conversion price is $0.25. As a result, 3,179,650 Restricted Shares were authorized to be issued. The Company’s Board of Directors approved the Agreement on January 5, 2022. As of March 31, 2022, the Company had cash and cash equivalents of $0.3 million, current liabilities of $7.7 million, and has incurred a loss from operations. The Company intends to a) develop and own primary care clinics operated by nurse practitioners, b) develop and acquire telemedical technologies, and c) evaluate other healthcare related opportunities. The Company’s activities are subject to significant risks and uncertainties, including failing to secure additional funding to execute its business plan. As a result of these factors, there is substantial doubt about the ability of the Company to continue as a going concern for one year from the date the financial statements are issued. The Company’s continuance is dependent on raising capital and generating revenues sufficient to sustain operations. The Company believes that the necessary capital will be raised and has entered discussions to do so with certain individuals and companies. However, as of the date of these condensed consolidated financial statements, no formal agreement exists. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts classified as liabilities that might be necessary should the Company be forced to take any such actions. PPP Loan During March 2020, in response to the COVID-19 crisis, the federal government announced plans to offer loans to small businesses in various forms, including the Payroll Protection Program, or “PPP”, established as part of the Corona Virus Aid, Relief and Economic Security Act (“CARES Act”) and administered by the U.S. Small Business Administration. On April 25, 2020, the Company entered an unsecured Promissory Note with Bank of America for a loan in the original principal amount of approximately $460,000, and the Company received the full amount of the loan proceeds on May 4, 2020. The current balance is $460,406 and the Company is currently in discussions for a) a partial forgiveness and b) the conversion of any remaining balance into a term note. COVID -19 Impact The Company has had some impact on its operations because of the effects of the COVID-19 pandemic, primarily with accessibility to staffing, consultants and in the capital markets, and it is adjusting as needed within its available resources. The Company will continue to assess the effect of the pandemic on its operations. The extent to which the COVID-19 pandemic will continue to impact the Company’s business and operations will depend on future developments that are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, the duration and effect of possible business disruptions and the short-term effects and ultimate effectiveness of the travel restrictions, quarantines, social distancing requirements and business closures in the United States and other countries to contain and treat the disease. While the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, a widespread pandemic could result in significant disruption of global financial markets, reducing the Company’s ability to access capital, which could in the future negatively affect the Company’s liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect the Company’s business and the value of its securities.	Note 2 - Financial Condition, Going Concern and Management Plans On November 19, 2021, the Company closed a bridge financing round totaling $3.1 million of a Series D preferred stock sold to investors in a private placement. Each Series D Unit will have a purchase price of $1.00 per Unit, with each Unit consisting of (a) one share of a newly formed Series D Convertible Preferred Stock, par value $0.01 per share (the “Series D Preferred Stock”), (b) one warrant (the “Series A Warrants”) to purchase 2.1 shares of the Company’s Common Stock at a purchase price of $0.50 per whole share of Common Stock, and (c) one warrant (the “Series B Warrants” and together with the Series A Warrants, the “Warrants”) to purchase 2.1 shares of Common Stock at a purchase price of $0.75 per whole share. Pursuant to the Certificate of Designations, Preferences and Rights of the Series D Convertible Preferred Stock of the Company, Inc., filed with the Secretary of State of the State of Delaware on October 18, 2021 (the “COD”), there are 10,000,000 shares of the Company’s preferred stock that have been designated as the Series D Preferred Stock and each share of the Series D Preferred Stock is convertible at the option of the holder thereof, or automatically upon the request of the Company’s underwriters that the Series D Preferred Stock convert to shares of Common Stock or upon listing of the Company’s Common Stock on a national securities exchange. The number of shares of Common Stock issuable upon the conversion of each share of Series D Preferred Stock is calculated by dividing the Conversion Amount (defined in the COD as the Stated Value, $1.05 per share, plus accrued and unpaid dividends) by the $0.25 conversion price (the “Conversion Price”). As of the date of this filing the Company has closed on $3,100,000 of its Series D Preferred stock. To achieve our growth strategy, it is anticipated the Company will need to raise additional financing prior to up listing on Nasdaq. We will not proceed with this offering in the event our Common Stock is not approved for listing on the Nasdaq Capital Market though we will continue to seek financing for our expansion and operating needs in the debt or equity markets. Mitesco, Inc. (the “Company”) issued a 10% Promissory Note due June 30, 2022 (the “Note”), dated December 30, 2021, to the Michael C. Howe Living Trust (the “Lender”). Michael C. Howe is the Chief Executive Officer of the Good Clinic LLC, one of our subsidiaries. The principal amount of the Note is $1,000,000, carries a 10% interest rate per annum, payable in monthly installments, and has a maturity date that is the earlier of (i) six (6) months from the date of execution, or (ii) the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Note payable to the Company for the Note was $850,000 and was funded on December 30, 2021. The amount payable at maturity will be $1,000,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default, as defined in the Note, the principal amount shall bear interest for each day until paid, at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Note contains a “most favored nations” clause that provides that, so long as the Note is outstanding, if the Company issues any new security, which the Lender believes contains a term that is more favorable than those in the Note, the Company shall notify the Lender of such term, and such term, at the option of the Lender, shall become a part of the Note. The Company entered into a debt-for-equity exchange agreement with Gardner Builders Holdings, LLC (the “Creditor”) on January 7, 2022 (the “Agreement”). Pursuant to the Agreement, the Company issued shares of restricted common stock, par value $0.01 per share, of MITI (the “Restricted Shares”) to the Creditor in exchange for the Company Debt Obligations, as defined below. The Agreement settles for certain accounts payable amounts owed by the Company to the Creditor (the “Accounts Payable Amount”) as well as upcoming amounts that will become due between the date of the Agreement and April 1, 2022. The Agreement also settles incurred interest and penalties on the amounts due through January 5, 2022, as well as future interest payments on amounts to be incurred in the first quarter of 2022 (collectively, the “Additional Costs”, and combined with the Accounts Payable Amount, the “Company Debt Obligations”). The Accounts Payable Amount is $500,000, the Additional Costs is $294,912.56 and the conversion price is $0.25. As a result, 3,179,650 Restricted Shares were authorized to be issued. The Company’s Board of Directors approved the Agreement on January 5, 2022. As of December 31, 2021, the Company had cash and cash equivalents of $1.2 million, current liabilities of $5.6 million, and has incurred a loss from operations. The Company’s principal operation is the development and deployment of software and systems for the healthcare marketplace. The Company intends to a) develop and own primary care clinics operated by nurse practitioners, b) develop and acquire telemedical technologies, and c) evaluate other healthcare related opportunities both domestically and on an international basis. The Company’s activities are subject to significant risks and uncertainties, including failing to secure additional funding to execute its business plan. As a result of these factors, there is substantial doubt about the ability of the Company to continue as a going concern for one year from the date the financial statements are issued. The Company’s continuance is dependent on raising capital and generating revenues sufficient to sustain operations. The Company believes that the necessary capital will be raised and has entered discussions to do so with certain individuals and companies. However, as of the date of these consolidated financial statements, no formal agreement exists. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts classified as liabilities that might be necessary should the Company be forced to take any such actions. PPP Loan During March 2020, in response to the COVID-19 crisis, the federal government announced plans to offer loans to small businesses in various forms, including the Payroll Protection Program, or "PPP", established as part of the Corona Virus Aid, Relief and Economic Security Act (“CARES Act”) and administered by the U.S. Small Business Administration. On April 25, 2020, the Company entered an unsecured Promissory Note (the “Note”) with Bank of America for a loan in the original principal amount of approximately $460,000, and the Company received the full amount of the loan proceeds on May 4, 2020. The current balance is $460,406 and the Company is currently in discussions for a) a partial forgiveness and b) the conversion of any remaining balance into a term note. COVID -19 Impact The Company has had some impact on its operations because of the effects of the COVID-19 pandemic, primarily with accessibility to staffing, consultants and in the capital markets, and it is adjusting as needed within its available resources. The Company will continue to assess the effect of the pandemic on its operations. The extent to which the COVID-19 pandemic will continue to impact the Company’s business and operations will depend on future developments that are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, the duration and effect of possible business disruptions and the short-term effects and ultimate effectiveness of the travel restrictions, quarantines, social distancing requirements and business closures in the United States and other countries to contain and treat the disease. While the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, a widespread pandemic could result in significant disruption of global financial markets, reducing the Company’s ability to access capital, which could in the future negatively affect the Company’s liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect the Company’s business and the value of its securities.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	Note 3 Summary of Significant Accounting Policies Principles of Consolidation Use of Estimates - Cash - Property, Plant, and Equipment - Years Office equipment 3 to 5 Furniture & fixtures 3 to 7 Machinery & equipment 3 to 10 Leasehold improvements Term of lease Revenue Recognition The Company applied the modified retrospective approach to all contracts when adopting ASC 606. As a result, at the adoption of ASC 606 what was previously classified as the provision for bad debts in the statement of operations is now reflected as implicit price concessions (as defined in ASC 606) and therefore included as a reduction to net operating revenues in 2018. For changes in credit issues not assessed at the date of service, the Company will prospectively recognize those amounts in other operating expenses on the statement of operations. For periods prior to the adoption of ASC 606, the provision for bad debts has been presented consistent with the previous revenue recognition standards that required it to be presented separately as a component of net operating revenues. Our revenues generally relate to net patient fees received from various payers and patients themselves under contracts in which our performance obligations are to provide services to the patients. Revenues are recorded during the period our obligations to provide services are satisfied. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates for services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals. Stock-Based Compensation - Equity instruments issued to those other than employees are recognized pursuant to FASB issued ASU 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. This ASU relates to the accounting for non-employee share-based payments. The amendment in this update expands the scope of Topic 718 to include all share-based payment transactions in which a grantor acquired goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The ASU excludes share-based payment awards that relate to: (1) financing to the issuer; or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts from Customers. The share-based payments are to be measured at grant-date fair value of the equity instruments that the entity is obligated to issue when the goods or service has been delivered or rendered and all other conditions necessary to earn the right to benefit from the equity instruments have been satisfied. This standard became effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. We adopted the provisions of this ASU on January 1, 2019. The adoption had no impact on our results of operations, cash flows, or financial condition. Convertible Instruments Common Stock Purchase Warrants- Stockholders Equity- Per Share Data- Financial Instruments and Fair Values- Level 1 – inputs include exchange quoted prices for identical instruments and are the most observable. Level 2 – inputs include brokered and/or quoted prices for similar assets and observable inputs such as interest rates. Level 3 – inputs include data not observable in the market and reflect management judgment about the assumptions market participants would use in pricing the asset or liability. The use of observable and unobservable inputs and their significance in measuring fair value are reflected in our hierarchy assessment. The carrying amount of cash, prepaid assets, accounts payable and accrued liabilities approximate fair value due to the short-term maturities of these instruments. Because cash and cash equivalents are readily liquidated, management classifies these values as Level 1. The fair value of the derivative liabilities approximates their book value as the instruments are short-term in nature and contain market rates of interest. Because there is no ready market or observable transactions, management classifies the derivative liabilities as Level 3. New Accounting Standards From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on its financial position or results of operations upon adoption. Recent Accounting Standards Not Yet Adopted In August 2020, the FASB issued ASU 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40)”. This ASU reduces the number of accounting models for convertible debt instruments and convertible Preferred Stock. As well as amend the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. In addition, this ASU improves and amends the related EPS guidance. This standard is effective for us on January 1, 2024, including interim periods within those fiscal years. Adoption is either a modified retrospective method or a fully retrospective method of transition. We are currently assessing the impact the new guidance will have on our condensed consolidated financial statements. There are various other updates recently issued, most of which represent technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s consolidated financial position, results of operations or cash flows.	Note 3 Summary of Significant Accounting Policies Basis of Accounting Principles of Consolidation Use of Estimates - Cash - Property, Plant, and Equipment - Years Office equipment 3 to 5 Furniture & fixtures 3 to 7 Machinery & equipment 3 to 10 Leasehold improvements Term of lease Construction in Progress - Revenue Recognition The Company applied the modified retrospective approach to all contracts when adopting ASC 606. As a result, at the adoption of ASC 606 what was previously classified as the provision for bad debts in the statement of operations is now reflected as implicit price concessions (as defined in ASC 606) and therefore included as a reduction to net operating revenues in 2018. For changes in credit issues not assessed at the date of service, the Company will prospectively recognize those amounts in other operating expenses on the statement of operations. For periods prior to the adoption of ASC 606, the provision for bad debts has been presented consistent with the previous revenue recognition standards that required it to be presented separately as a component of net operating revenues. Our revenues generally relate to net patient fees received from various payers and patients themselves under contracts in which our performance obligations are to provide services to the patients. Revenues are recorded during the period our obligations to provide services are satisfied. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates for services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals. Stock-Based Compensation - Equity instruments issued to those other than employees are recognized pursuant to FASB issued ASU 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. This ASU relates to the accounting for non-employee share-based payments. The amendment in this update expands the scope of Topic 718 to include all share-based payment transactions in which a grantor acquired goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The ASU excludes share-based payment awards that relate to: (1) financing to the issuer; or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts from Customers. The share-based payments are to be measured at grant-date fair value of the equity instruments that the entity is obligated to issue when the goods or service has been delivered or rendered and all other conditions necessary to earn the right to benefit from the equity instruments have been satisfied. This standard will be effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. We adopted the provisions of this ASU on January 1, 2019. The adoption had no impact on our results of operations, cash flows, or financial condition. Convertible Instruments Derivative Financial Instruments Common Stock Purchase Warrants- Stockholders Equity- Per Share Data- Income Taxes- Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all the deferred tax assets will not be realized. The Company has determined that a valuation allowance is needed due to recent taxable net operating losses and the limited taxable income in the carry back periods. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income or expense in the period that includes the enactment date. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and certain tax loss carryforwards, less any valuation allowance. The Company accounts for uncertain tax positions as required in that a position taken or expected to be taken in a tax return is recognized in the consolidated financial statements when it is more likely than not (i.e., a likelihood of more than 50%) that the position would be sustained upon examination by tax authorities. A recognized tax position is then measured at the largest amount of benefit that is greater than 50% of being realized upon ultimate settlement. The Company does not have any material unrecognized tax benefits. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as components of interest expense and other expense, respectively, in arriving at pretax income or loss. The Company does not have any interest and penalties accrued. The Company is no longer subject to U.S. federal, state, and local income tax examinations for the years before 2012. Business Combinations- ● future expected cash flows from product sales, support agreements, consulting contracts, other customer contracts, and acquired developed technologies and patents; and ● discount rates utilized in valuation estimates. Unanticipated events and circumstances may occur that may affect the accuracy or validity of such assumptions, estimates or actual results. Additionally, any change in the fair value of the acquisition-related contingent consideration subsequent to the acquisition date, including changes from events after the acquisition date, such as changes in our estimates of relevant revenue or other targets, will be recognized in earnings in the period of the estimated fair value change. A change in fair value of the acquisition-related contingent consideration or the occurrence of events that cause results to differ from our estimates or assumptions could have a material effect on the consolidated financial position, statements of operations or cash flows in the period of the change in the estimate. Impairment of Long-Lived Assets- Financial Instruments and Fair Values- Level 1 – inputs include exchange quoted prices for identical instruments and are the most observable. Level 2 – inputs include brokered and/or quoted prices for similar assets and observable inputs such as interest rates. Level 3 – inputs include data not observable in the market and reflect management judgment about the assumptions market participants would use in pricing the asset or liability. The use of observable and unobservable inputs and their significance in measuring fair value are reflected in our hierarchy assessment. The carrying amount of cash, prepaid assets, accounts payable and accrued liabilities approximate fair value due to the short-term maturities of these instruments. Because cash and cash equivalents are readily liquidated, management classifies these values as Level 1. The fair value of the derivative liabilities approximates their book value as the instruments are short-term in nature and contain market rates of interest. Because there is no ready market or observable transactions, management classifies the derivative liabilities as Level 3. Recently Issued Accounting Standards In June 2018, the FASB issued ASU 2018-07 "Improvements to Non-employee Share-Based Payment Accounting”, which simplifies the accounting for share-based payments granted to non-employees for goods and services. Under the ASU, most of the guidance on such payments to non-employees would be aligned with the requirements for share-based payments granted to employees. The amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. In December 2019, the FASB issued ASU No. 2019-12, "Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company has adopted ASU No. 2019-12, "Income Taxes (Topic 740) however giving the Company’s historical losses and full valuation allowance it did not have an impact on its condensed consolidated financial statements and related disclosures. Recent Accounting Standards Not Yet Adopted In August 2020, the FASB issued ASU 2020-06, "Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40)”. This ASU reduces the number of accounting models for convertible debt instruments and convertible Preferred Stock. As well as amend the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. In addition, this ASU improves and amends the related EPS guidance. This standard is effective for us on January 1, 2022, including interim periods within those fiscal years. Adoption is either a modified retrospective method or a fully retrospective method of transition. We are currently assessing the impact the new guidance will have on our consolidated financial statements. There are various other updates recently issued, most of which represent technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s consolidated financial position, results of operations or cash flows.

Net Loss Per Share Applicable t

Net Loss Per Share Applicable to Common Shareholders	3 Months Ended
	Mar. 31, 2022
Earnings Per Share Reconciliation [Abstract]
Earnings Per Share Reconciliation Disclosure	Note 4 – Net Loss Per Share Applicable to Common Shareholders Net Loss per Share Applicable to Common Stockholders Basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted loss per common share is computed similarly to basic loss per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock.  The following table sets forth the computation of loss per share for the three months ended March 31, 2022, and 2021, respectively:      For the Three Months Ended       March 31,       2022     2021   Numerator:                 Net loss applicable to common shareholders   $ (3,724,886 )   $ (2,754,952 )                   Denominator:                 Weighted average common shares outstanding     213,703,195       187,152,300                     Net loss per share:                 Basic and diluted   $ (0.02 )   $ (0.01 )  The Company excluded all common equivalent shares outstanding for warrants, options, and convertible instruments to purchase common stock from the calculation of diluted net loss per share because all such securities are antidilutive for the periods presented. As of March 31, 2022, and 2021, the following shares were issuable and excluded from the calculation of diluted loss:      For the Three Months Ended       March 31,       2022     2021   Common stock options     18,671,211       10,967,879   Common stock purchase warrants     31,405,000       12,600,000   Convertible Preferred Stock Series C     4,362,575       12,600,000   Convertible Preferred Stock Series D     13,020,000       -   Accrued interest on Preferred Stock     1,230,858       72,657   Potentially dilutive securities     68,689,644       36,240,536

Related Party Transactions

Related Party Transactions	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Note 5 Related Party Transactions For the three months ended March 31, 2022: Mitesco, Inc. (the “Company”) issued a 10% Promissory Note due August 14, 2022, dated February 14, 2022, to Lawrence Diamond (the “Lender”). Mr. Diamond is the Chief Executive Officer of the Company and a member of its Board of Directors. The principal amount of the Note is $175,000, carries a 10% interest rate per annum, payable in monthly installments, and has a maturity date that is the earlier of (i) six (6) months from the date of execution, or (ii) the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Note payable to the Company for the Note was $148,750 and was funded on February 14, 2022. The amount payable at maturity will be $175,000 plus 10% of that amount plus accrued and unpaid interest. Following an event of default, as defined in the Note, the principal amount shall bear interest for each day until paid, at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Note contains a “most favored nations” clause that provides that, so long as the Note is outstanding, if the Company issues any new security, which the Lender reasonably believes contains a term that is more favorable than those in the Note, the Company shall notify the Lender of such term, and such term, at the option of the Lender, shall become a part of the Note. In addition to the Note and Lender will be issued 367,500 5-year warrants that may be exercised at $.50 per share and 367,500 5-year warrants that may be exercised at $.75 per share. These warrants have all of the same terms as those previously issued in conjunction with the Company’s Series C Preferred shares and its Series D Preferred shares. Mitesco, Inc., issued a promissory notes to pay to the order of Lawrence Diamond (the “Lender” and collectively with the Borrower, the “Parties”) on the Termination Date (as defined below), the principal amount of $235,294 (the “Principal Amount”) plus an amount equal to ten percent of such Principal Amount. The purchase price for this promissory note (this “Note”) shall be $200,000 (the “Purchase Price”) and shall be payable by the Lender to the Borrower on the Issue Date. As further consideration for the Purchase Price payable hereunder, promptly following the Issue Date, the Borrower shall issue to the Lender a common stock purchase warrants, entitling the Lender to purchase 200,000 shares of the Borrower’s common stock on substantially the same terms as the Series A warrant issued in connection with the Borrower’s Series D Convertible Preferred Stock. (b) As further consideration for the Purchase Price payable hereunder, promptly following the Issue Date, the Borrower shall also issue to the Lender 192,000 restricted shares. The Company shall instruct its transfer agent to issue one (1) certificate or book entry statement representing 192,000 shares promptly following the execution hereof.	Note 5 Related Party Transactions For the year ended December 31, 2021: On July 21, 2021, the Company issued a total of 3,000,000 stock option awards to the Company’s executive officers: 1,500,000 to its Chief Executive Officer, 750,000 to its Chief Financial Officer and 750,000 to its Chief Legal Officer. The options will expire on the ten-year anniversary of the grant date and will vest following the Company’s achievement of a total of $30 million of revenues over four consecutive quarters, as recorded under accepted accounting principles of the United States of America. The options have a strike price of $0.25 the amount was based on the price of the lowest investment amount offered to outside investors in 2021 and is higher than the closing price on the date they were granted. On August 26, 2021, the Company issued 312,800 restricted shares of the Company’s common stock priced at $0.25, vesting immediately, in lieu of $78,200 of cash compensation owed to the Company’s Chief Executive Officer for services rendered to the Company prior to 2021. On December 30, 2021, the Company issued a 10% Promissory Note due June 30, 2022 to the Chief Executive Officer of the Good Clinic LLC, one of our subsidiaries. See Note 8. During the year ended December 31, 2021, the Company accrued dividends on its Series X Preferred Stock in the total amount of $61,818. Of this amount, a total of $7,890 was payable to officers and directors, $30,827 was payable to a related party shareholder, and $23,101 was payable to non-related parties. For the year ended December 31, 2020: On February 27, 2020, the Company agreed to issue 1,000,000 ten-year options to its two non-management directors (a total of 2,000,000 options). These options have a fair value at issuance of $39,162 per director (a total of $78,324), an exercise price of $0.05 per share, and vest over a three On March 2, 2020, the Company agreed to issue 1,500,000 ten On June 1, 2020, the Company agreed to issue 1,000,000 ten On August 1, 2020, the Company agreed to issue 1,000,000 ten-year options to a non-management director. These options have a fair value of $56,037, an exercise price of $0.05 per share, and vest over a three-year period. The Company valued these options using the Black-Scholes valuation model. On December 14, 2020, the exercise price of these options was changed to $0.03 per share reflecting the market price at the time (see note 10). During the year ended December 31, 2020, the amount of $56,067 was charged to operations in connection these options. On December 28, 2020, the Company agreed to issue 100,000 options with a fair value of $2,465 to each to its four non-management directors (a total of 400,000 options with a fair value of $9,860). These options have an exercise price of $0.03 per share and vested upon issuance. The Company valued these options using the Black-Scholes valuation model. During the year ended December 31, 2020, the amount of $2,465 was charged to operations in connection with each of these options grants (a total of $9,860 for 400,000 options). On December 28, 2020, the Company agreed to issue 1,000,000 options with a fair value of $24,645 to each to Chief Executive Officer and to a consultant (a total of 2,000,000 options with a fair value of $49,290). These options have an exercise price of $0.03 per share, and vested upon issuance. The Company valued these options using the Black-Scholes valuation model. During the year ended December 31, 2020, the amount of $24,645 was charged to operations in connection with each of these options grants (a total of $49,290 for 2,000,000 options). During the year ended December 31, 2020, the Company charged the amount of $67,623 to operations in connection with the vesting of restricted common stock as follows: $15,856 for shares issued to management; $32,614 for shares issued to Board members; and $7,135 related to shares issued to an employee. Julie R. Smith, our former President, Chief Operating Officer, and a Board member, resigned effective June 30, 2020; at the time of her resignation, a total of 1,000,000 shares of the Company’s common stock issued to Ms. Smith for compensation as a Board member were vested, and remain outstanding; an additional 250,000 shares of common stock issued to Ms. Smith for compensation as an officer were vested, and also remain outstanding; 750,000 shares of common stock to be issued to Ms. Smith for compensation as an officer had not vested, and these shares were cancelled. A total of $11,909 was charged to operations for the vesting of shares issued to Ms. Smith. During the year ended December 31, 2020, the Company accrued dividends on its Series X Preferred Stock in the total amount of $65,568. Of this amount, a total of $8,000 was payable to officers and directors, $31,258 was payable to a related party shareholder, and $26,310 was payable to non-related parties. On December 31, 2020, the Company issued 2,151,204 shares of common stock as payment for dividends accrued on its Series X Preferred Stock in the amount of $65,568. Of this amount, a total of 262,478 shares in the amount of $8,000 were issued to officers and directors; 1,025,514 shares in the amount of $31,528 were issued to a consultant; and 863,212 shares in the amount of $26,310 were issued to non-related parties. On December 31, 2019, the Company issued a total of 26,227 shares of Series X Preferred Stock in settlement of various liabilities. All of the entities who received these shares were related parties, either because they were officer and or directors, or because the voting rights attached to these shares created a related party relationship. As of December 31, 2021, the shares of Series X Preferred Stock issued and outstanding is as follows: Type of Name Liability # shares Ronald Riewold, Director Deferred Compensation 1,200 Larry Diamond, Director, and CEO Deferred Compensation 2,000 James Crone, ex-Officer, and Director Deferred Compensation 2,884 Louis Deluca, ex-Officer, and Director Deferred Compensation 2,400 Irish Italian Retirement Fund Consulting services, notes payable 12,503 Frank Lightmas Legal fees 3,240 Total 24,227

Accounts Payable and Accrued Li

Accounts Payable and Accrued Liabilities	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 6 Accounts Payable and Accrued Liabilities Accounts payable and accrued liabilities consisted of the following at March 31, 2022 and 2021: March 31, December 31, 2022 2021 Trade accounts payable 4,890,066 3,933,305 Accrued payroll and payroll taxes 96,641 23,554 Other 17,928 19,205 Total accounts payable and accrued liabilities 5,004,635 3,976,064	Note 6 Accounts Payable and Accrued Liabilities Accounts payable and accrued liabilities consisted of the following at December 31, 2021 and 2020: December 31, December 31, 2021 2020 Trade accounts payable 3,933,305 824,405 Accrued payroll and payroll taxes 23,554 244,926 Other 19,205 - Total accounts payable and accrued liabilities 3,976,064 1,069,331

Right to Use Assets and Lease L

Right to Use Assets and Lease Liabilities - Operating Leases	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Disclosure Text Block [Abstract]
Lessee, Operating Leases [Text Block]	Note 7 - Right to Use Assets and Lease Liabilities Operating Leases The Company has operating leases for its clinic with a remaining lease term of approximately 7.3 years. The Company’s lease expense was entirely comprised of operating leases. Lease expense for the three months ended March 31, 2022 and 2021 amounted to $230,973 and $10,642, respectively. The Company’s ROU asset amortization for the three months ended March 31, 2022 and 2021 was $267,463 and $4,318, respectively. The difference between the lease expense and the associated ROU asset amortization consists of interest at a rate of 12% per annum. As of March 31, 2022, the Company had total operating lease liabilities of approximately $4.1 million and right-of-use assets of approximately $3.6 million, which were included in the condensed consolidated balance sheet. Right to use assets – operating leases are summarized below: March 31, 2022 December 31, 2021 Right to use assets, net $ 3,619,403 $ 3,886,866 Operating lease liabilities are summarized below: March 31, 2022 December 31, 2021 Lease liability $ 4,146,960 $ 4,134,802 Less: current portion (276,639 ) (161,838 ) Lease liability, non-current $ 3,870,321 $ 3,972,964 Maturity analysis under these lease agreements are as follows: For the twelve months ended March 31, 2023 $ 763,580 For the twelve months ended March 31, 2024 874,687 For the twelve months ended March 31, 2025 827,773 For the twelve months ended March 31, 2026 846,523 For the twelve months ended March 31, 2027 865,517 Thereafter 2,251,381 Total $ 6,429,461 Less: Present value discount (2,282,501 ) Lease liability $ 4,146,960	Note 7 - Right to Use Assets and Lease Liabilities Operating Leases The Company has an operating lease for its clinic with a remaining lease term of approximately 7.5 years. The Company’s lease expense was entirely comprised of operating leases. Lease expense for the years ended December 31, 2021 and 2020 amounted to $351,854 and $10,642, respectively. The Company’s ROU asset amortization for the years ended December 31, 2021 and 2020 was $162,276 and $4,318, respectively. The difference between the lease expense and the associated ROU asset amortization consists of interest at a rate of 12% per annum. Right to use assets – operating leases are summarized below: December 31, 2021 December 31, 2020 Right to use assets, net $ 3,886,866 $ 310,361 Operating lease liabilities are summarized below: December 31, 2021 December 31, 2020 Lease liability $ 4,134,802 $ 321,004 Less: current portion (161,838 ) (8,905 ) Lease liability, non-current $ 3,972,964 $ 312,099 Maturity analysis under these lease agreements are as follows: For the period ended December 31, 2022 $ 652,653 For the period ended December 31, 2023 888,152 For the period ended December 31, 2024 821,296 For the period ended December 31, 2025 841,600 For the period ended December 31, 2026 860,551 Thereafter 2,478,412 Total $ 6,542,664 Less: Present value discount (2,407,862 ) Lease liability $ 4,134,802

Debt

Debt	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	Note 8 Debt Howe Note Mitesco, Inc. (the “Company”) issued a 10% Promissory Note due June 30, 2022, dated December 30, 2021, to the Michael C. Howe Living Trust (the “Lender”). Michael C. Howe is the Chief Executive Officer of the Good Clinic LLC, one of our subsidiaries. The principal amount of the Note is $1,000,000, carries a 10% interest rate per annum, payable in monthly installments, and has a maturity date that is the earlier of (i) six (6) months from the date of execution, or (ii) the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Note payable to the Company for the Note was $850,000 and was funded on December 30, 2021. An original issue discount in the amount of $150,000 was recorded. The amount payable at maturity will be $1,000,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default, as defined in the Note, the principal amount shall bear interest for each day until paid, at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Note contains a “most favored nations” clause that provides that, so long as the Note is outstanding, if the Company issues any new security, which the Lender reasonably believes contains a term that is more favorable than those in the Note, the Company shall notify the Lender of such term, and such term, at the option of the Lender, shall become a part of the Note. At March 31, 2022, the principal balance of this note was $1,000,000; $74,176 of the original issue discount was amortized to interest expense during the three months ended March 31, 2022, and the remaining original issue discount at March 31, 2022 was $75,824. Warrants. Diamond Note 1 The Company issued a 10% Promissory Note due August 14, 2022, dated February 14, 2022, to Lawrence Diamond (the “Lender”). Mr. Diamond is the Chief Executive Officer of the Company and a member of its Board of Directors. The principal amount of the Note is $175,000, carries a 10% interest rate per annum, payable in monthly installments, and has a maturity date that is the earlier of (i) six (6) months from the date of execution, or (ii) the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Note payable to the Company for the Note was $148,750 and was funded on February 14, 2022. The amount payable at maturity will be $175,000 plus 10% of that amount plus accrued and unpaid interest. Following an event of default, as defined in the Note, the principal amount shall bear interest for each day until paid, at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Note contains a “most favored nations” clause that provides that, so long as the Note is outstanding, if the Company issues any new security, which the Lender believes contains a term that is more favorable than those in the Note, the Company shall notify the Lender of such term, and such term, at the option of the Lender, shall become a part of the Note. In addition to the Note and Lender will be issued 367,500 5-year warrants that may be exercised at $.50 per share and 367,500 5-year warrants that may be exercised at $.75 per share. These warrants have all of the same terms as those previously issued in conjunction with the Company’s Series C Preferred shares and its Series D Preferred shares. The warrants have an aggregate commitment date fair value of $2,914. Diamond Note 2 The Company issued a 10% Promissory Note due June 18, 2022 (the “Diamond Note”), dated March 18, 2022, to Lawrence Diamond (the “Lender”), which was subsequently amended. Lawrence Diamond is the Chief Executive Officer of the Company. The principal amount of the Diamond Note is $235,294.00, carries a 10% interest rate per annum, payable in monthly installments, and has a maturity date that is the earlier of (i) April 4, 2022, (ii) the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE, or (iii) the date of receipt of the Company of the next round of debt or equity financing in an amount of at least $1,000,000. The purchase price of the Diamond Note payable to the Company for the Diamond Note was $200,000 and was funded on March 18, 2022. The amount payable at maturity will be $235,294 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default, as defined in the Diamond Note, the principal amount shall bear interest for each day until paid, at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Diamond Note contains a “most favored nations” clause that provides that, so long as the Note is outstanding, if the Company issues any new security, which the Lender reasonably believes contains a term that is more favorable than those in the Diamond Note, the Company shall notify the Lender of such term, and such term, at the option of the Lender, shall become a part of the Note. In addition, the Lender will be issued 200,000 5-year warrants that may be exercised on substantially the same terms as the Series A warrant issued in connection with the Company’s Series D Convertible Preferred Stock. The warrants have an aggregate commitment date fair value of $2,213. AJB Capital Note On March 18, 2022, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with AJB Capital Investments, LLC (the “Investor”) with respect to the sale and issuance to the Investor of: (i) an initial commitment fee in the amount of $430,000 in the form of 1,720,000 shares (the “Commitment Fee Shares”) of the Company’s common stock (the “Common Stock”), which Commitment Fee Shares can be decreased to 720,000 shares ($180,000) if the Company repays the Note on or prior its maturity (the “True-Up Provision”), (ii) a promissory note in the aggregate principal amount of $750,000, and (iii) Common Stock Purchase Warrants to purchase up to an aggregate of 750,000 shares of the Common Stock (the “Warrants”). The Note and Warrants were issued on March 17, 2022 (the “Original Issue Date”) and were held in escrow pending effectiveness of the Purchase Agreement. Pursuant to the terms of the Purchase Agreement, the initial Commitment Fee Shares were issued at a value of $430,000, the Note was issued in a principal amount of $750,000 for a purchase price of $675,000, resulting in an original issue discount of $75,000; and the Warrants were issued, with an initial exercise price of $0.50 per share, subject to adjustment as described herein. The aggregate cash subscription amount received by the Company from the Investor for the issuance of the Commitment Fee Shares, Note and Warrants was $616,250, due to a reduction in the $675,000 purchase price as a result of broker, legal, and transaction fees. The warrants have a commitment date fair value of $24,952. PPP Loan During March 2020, in response to the COVID-19 crisis, the federal government announced plans to offer loans to small businesses in various forms, including the Payroll Protection Program, or “PPP”, established as part of the Corona Virus Aid, Relief and Economic Security Act (“CARES Act”) and administered by the U.S. Small Business Administration. On April 25, 2020, the Company entered an unsecured Promissory Note with Bank of America for a loan in the original principal amount of approximately $460,000, and the Company received the full amount of the loan proceeds on May 4, 2020. The current balance is $460,406 and the Company is currently in discussions for a) a partial forgiveness and b) the conversion of any remaining balance into a term note. These amounts are reflected in the table below: Notes Payable Table 1: March 31, 2022 December 31, 2021 Notes Payable $ 2,160,294 $ 1,000,000 PPP Loan $ 460,406 $ 460,406 $ 2,620,700 $ 1,460,406 Less: Discount (671,973 ) (411,568 ) Notes payable - net of discount $ 1,948,727 $ 1,048,838 Current Portion, net of discount $ 1,948,727 $ 1,048,838 Long-term portion, net of discount $ - $ -	Note 8 Debt August 2014 Series C Convertible Debenture On March 30, 2021, the Company issued 272,837 shares of common stock and paid cash in the amount of $122,166 as settlement of principal and accrued interest in the amounts of $110,833 and $71,526, respectively, due under the Series C Debenture and principal and accrued interest in the amounts of $11,333 and $8,722 due under the Series C Debenture. The Company recognized a gain in the amount of $3,035 on this transaction. These obligations have been fully satisfied as of the date of this filing and the Company has no further requirements related to these matters. March 2016 Convertible Note A On March 24, 2021, the Company paid cash in the amount of $55,368 as settlement of principal and accrued interest in the amount of $41,000 and $13,167, respectively, due under the March 2016 Convertible Note A. The Company recognized a loss in the amount of $1,201 on this transaction. This obligation has been fully satisfied as of the date of this filing and the Company has no further requirements related to this matter. Eagle Equities Note 4 On January 4, 2021, the Company issued 4,123,750 shares of common stock at a price of $0.012 per share pursuant to the conversion of $45,000 of principal and $4,485 of accrued interest in Eagle Equities Note 4. On January 6, 2021, the Company issued 3,505,964 shares of common stock at a price of $0.01224 per share pursuant to the conversion of $39,000 of principal and $3,913 of accrued interest in Eagle Equities Note 4. This obligation has been fully satisfied as of the date of this filing and the Company has no further requirements related to this matter. Eagle Equities Note 5 On January 11, 2021, the Company issued 4,463,507 shares of common stock at a price of $0.01224 per share pursuant to the conversion of $50,000 of principal and $4,633 of accrued interest in Eagle Equities Note 5. On January 14, 2021, the Company issued 4,319,378 shares of common stock at a price of $0.01266 per share pursuant to the conversion of $50,000 of principal and $4,683 of accrued interest in Eagle Equities Note 5. This obligation has been fully satisfied as of the date of this filing and the Company has no further requirements related to this matter. Eagle Equities Note 6 On January 21, 2021, the Company issued 6,449,610 shares of common stock at a price of $0.0154 per share pursuant to the conversion of $93,000 of principal and $6,324 of accrued interest in Eagle Equities Note 6. On January 28, 2021, the Company issued 7,285,062 shares of common stock at a price of $0.01575 per share pursuant to the conversion of $107,200 of principal and $7,540 of accrued interest in Eagle Equities Note 6. This obligation has been fully satisfied as of the date of this filing and the Company has no further requirements related to this matter. Eagle Equities Note 7 On February 5, 2021, the Company entered into a settlement agreement with the holders of the Eagle Equities Note 7 whereby the Company issued 1,184,148 shares of common stock at a price of $0.24984 per share in satisfaction of $200,200 of principal and all accrued interest and prepayment penalties due under this note. This obligation has been fully satisfied as of the date of this filing and the Company has no further requirements related to this matter. Eagle Equities Note 8 On February 5, 2021, the Company entered into a settlement agreement with the holders of the Eagle Equities Note 8 whereby the Company issued 639,593 shares of common stock at a price of $0.23851 per share in satisfaction of $114,400 of principal and all accrued interest and prepayment penalties due under this note. This obligation has been fully satisfied as of the date of this filing and the Company has no further requirements related to this matter. Eagle Equities Note 9 On February 5, 2021, the Company entered into a settlement agreement with the holders of the Eagle Equities Note 9 whereby the Company issued 605,177 shares of common stock at a price of $0.24984 per share in satisfaction of $114,400 of principal and all accrued interest and prepayment penalties due under this note. This obligation has been fully satisfied as of the date of this filing and the Company has no further requirements related to this matter. Eagle Equities Note 10 On February 5, 2021, the Company entered into a settlement agreement with the holders of the Eagle Equities Note 10 whereby the Company issued 1,095,131 shares of common stock at a price of $0.23748 per share in satisfaction of $200,200 of principal and all accrued interest and prepayment penalties due under this note. This obligation has been fully satisfied as of the date of this filing and the Company has no further requirements related to this matter. PPP Loan During March 2020, in response to the COVID-19 crisis, the federal government announced plans to offer loans to small businesses in various forms, including the Payroll Protection Program, or "PPP", established as part of the Corona Virus Aid, Relief and Economic Security Act ("CARES Act”) and administered by the U.S. Small Business Administration. On April 25, 2020, the Company entered an unsecured Promissory Note (the "Note”) with Bank of America for a loan in the original principal amount of approximately $460,000, and the Company received the full amount of the loan proceeds on May 4, 2020. The current balance is $460,406 and the Company is currently in discussions for a) a partial forgiveness and b) the conversion of any remaining balance into a term note. Howe Note Mitesco, Inc. (the “Company”) issued a 10% Promissory Note due June 30, 2022 (the “Note”), dated December 30, 2021, to the Michael C. Howe Living Trust (the “Lender”). Michael C. Howe is the Chief Executive Officer of the Good Clinic LLC, one of our subsidiaries. The principal amount of the Note is $1,000,000, carries a 10% interest rate per annum, payable in monthly installments, and has a maturity date that is the earlier of (i) six (6) months from the date of execution, or (ii) the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Note payable to the Company for the Note was $850,000 and was funded on December 30, 2021. The amount payable at maturity will be $1,000,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default, as defined in the Note, the principal amount shall bear interest for each day until paid, at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Note contains a “most favored nations” clause that provides that, so long as the Note is outstanding, if the Company issues any new security, which the Lender reasonably believes contains a term that is more favorable than those in the Note, the Company shall notify the Lender of such term, and such term, at the option of the Lender, shall become a part of the Note. Warrants. These amounts are reflected in the table below: Notes Payable Table 1: December 31, 2021 December 31, 2020 Notes Payable $ 738,432 $ 1,196,366 PPP Loan $ 460,406 $ 460,406 $ 1,198,838 $ 1,656,772 Less: Discount (150,000 ) (756,795 ) Notes payable - net of discount $ 1,048,838 $ 899,977 Current Portion, net of discount $ 1,048,838 $ 899,977 Long-term portion, net of discount $ - $ -

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Note 9 Stockholders Equity (Deficit) Common Stock The Company has authorized 500,000,000 shares of common stock, par value $0.01; 219,756,894 shares were issued and outstanding on March 31, 2022. Common Stock Transactions During the Three Months Ended March 31, 2022 On January 12, 2022, the Company entered into a settlement agreement with an ex-employee. Pursuant to the terms of this agreement, the Company agreed to pay the amount of $19,032 for accrued salary, and the employee returned to the Company for cancellation 400,000 shares of common stock previously issued as compensation. These shares were valued at par value of $0.01 or a total value of $4,000; the Company recorded a gain on cancellation of these shares in the amount of $15,032. The Company entered into a debt-for-equity exchange agreement with Gardner Builders Holdings, LLC (“Gardner”) on January 7, 2022 (the “Debt for Equity Agreement”). Pursuant to the Debt for Equity Agreement, the Company issued shares of restricted common stock to Gardner in exchange for the Company Debt Obligations, as defined below. The Agreement settled for certain accounts payable amounts owed by the Company to the Creditor (the “Accounts Payable Amount”) as well as upcoming amounts that will become due between the date of the Agreement and April 1, 2022. The Agreement also settled accrued interest and penalties on the amounts due through January 5, 2022, as well as future interest payments on amounts to be accrued in the first quarter of 2022 (collectively, the “Additional Costs”, and combined with the Accounts Payable Amount, the “Company Debt Obligations”). The Accounts Payable Amount was $500,000, the Additional Costs were $294,912 and the conversion price was $0.25. As a result, 3,179,650 Restricted Shares were authorized to be issued. The Company’s Board of Directors approved the Agreement on January 5, 2022. On March 22, 2022 and March 31, 2022, the Company issued an aggregate 1,541,721 shares of common stock as waiver fees to holders of the Series C and Series D Preferred Stock for their waivers of certain covenants as set forth and defined in the Series C and Series D Certificates of Designations. The Company valued these shares at their contractual price of $0.25 per share and recorded the amount of $385,431 as waiver fees during the three months ended March 31, 2022. The Company recorded an aggregate gain upon issuance of these shares in the amount of $198,273 based on the market price of the Company’s common stock on the date of issuance. On March 31, 2022, the Company issued 1,720,000 Commitment Fee Shares to AJB Capital Investors, LLC; see note 8. A Monte Carlo model was used to value the warrants and call features, and a probability weighted expected return model was used to value the True-Up Provision. The contractual price of the common stock $0.25 per share; valuation purposes, the common stock was valued at the market price on the date of the transaction of $0.12695 per share. The derivative liability was valued at $106,608 on the date of the transaction, and was revalued at $26,771 on March 31, 2022. The discount on the notes due to the Commitment Fee Shares and warrants was valued at $349,914. The Company recorded the amount of $226,106 to additional paid-in capital pursuant to this transaction. On March 31, 2022, the Company issued 382,353 shares of common stock at a price of $0.25 per share which were previously subscribed for the conversion of accounts payable in the amount of $95,558. Common Stock Transactions During the Three Months Ended March 31, 2021 On January 4, 2021, the Company issued 4,123,750 shares of common stock at a price of $0.012 per share pursuant to the conversion of $45,000 of principal and $4,485 of accrued interest in Eagle Equities Note 4. On January 6, 2021, the Company issued 3,505,964 shares of common stock at a price of $0.01224 per share pursuant to the conversion of $39,000 of principal and $3,913 of accrued interest in Eagle Equities Note 4. On January 11, 2021, the Company issued 4,463,507 shares of common stock at a price of $0.01224 per share pursuant to the conversion of $50,000 of principal and $4,633 of accrued interest in Eagle Equities Note 5. On January 14, 2021, the Company issued 4,319,378 shares of common stock at a price of $0.01266 per share pursuant to the conversion of $50,000 of principal and $4,683 of accrued interest in Eagle Equities Note 5. On January 21, 2021, the Company issued 6,449,610 shares of common stock at a price of $0.0154 per share pursuant to the conversion of $93,000 of principal and $6,324 of accrued interest in Eagle Equities Note 6. On January 28, 2021, the Company issued 7,285,062 shares of common stock at a price of $0.01575 per share pursuant to the conversion of $107,200 of principal and $7,540 of accrued interest in Eagle Equities Note 6. On February 1, 2021, the Company issued 6,672,000 shares of common stock in a private placement (the “2021 Private Placement”) at a price of $0.25 per share for cash proceeds of $1,668,000. On February 5, 2021, the Company entered into a settlement agreement with the holders of the Eagle Equities Note 7 whereby the Company issued 1,184,148 shares of common stock at a price of $0.24984 per share in satisfaction of $200,200 of principal and all accrued interest and prepayment penalties due under this note. On February 5, 2021, the Company entered into a settlement agreement with the holders of the Eagle Equities Note 8 whereby the Company issued 639,593 shares of common stock at a price of $0.23851 per share in satisfaction of $114,400 of principal and all accrued interest and prepayment penalties due under this note. On February 5, 2021, the Company entered into a settlement agreement with the holders of the Eagle Equities Note 9 whereby the Company issued 605,177 shares of common stock at a price of $0.24984 per share in satisfaction of $114,400 of principal and all accrued interest and prepayment penalties due under this note. On February 5, 2021, the Company entered into a settlement agreement with the holders of the Eagle Equities Note 10 whereby the Company issued 1,095,131 shares of common stock at a price of $0.23748 per share in satisfaction of $200,200 of principal and all accrued interest and prepayment penalties due under this note. On February 22, 2021, the Company issued 336,000 shares of common stock for the exercise of options at a price of $0.03 per share. On March 11, 2021, the Company issued 600,000 shares of common stock to four officers of The Good Clinic in exchange for 4,800 shares of Series A Preferred Stock. The 4,800 shares of Series A Preferred Stock were cancelled. On March 17, 2021, the Company issued 300,000 shares of common stock at a price of $0.31 per share to a service provider. On March 23, 2021, the Company issued 461,358 shares of common stock at a price of $0.26 per share to the underwriters of the 2021 Private Placement. Preferred Stock We have authorized to issue 100,000,000 shares of Preferred Stock with such rights designations and preferences as determined by our Board of Directors. We have designated 500,000 shares of series A stock, 3,000,000 shares of Series C Preferred, 10,000,000 shares of Series D Preferred and we have designated 400,000 shares as Series X Preferred Stock. Series A Preferred Stock Transactions During the Three Months Ended March 31, 2022 None. Series A Preferred Stock Transactions During the Three Months Ended March 31, 2021 During the three months ended March 31, 2021, the Company accrued dividends in the amount of $1,000 on the Series A Preferred Stock. On March 11, 2021, the Company issued 600,000 shares of common stock to the four officers of The Good Clinic in exchange for the previously issued Series A Preferred Stock and accrued dividends. The Series A preferred stock was canceled. The Preferred Stock was valued at cost of $71,558, and the common stock was valued at the market price of $0.463 per share or a total value of $277,800. This transaction resulted in a deemed dividend to the Preferred A shareholders in the amount of $206,242. Series C Preferred Stock Series C Preferred Stock Transactions During the Three Months Ended March 31, 2022 None. Series C Preferred Stock Transactions During the Three Months Ended March 31, 2021 On March 25, 2021, the Company sold 3,000,000 shares of its Series C Preferred Stock along with (i) five-year warrants to purchase 6,300,000 shares of the Company’s common stock at a price of $0.50 per share, and (ii) five The Series C Preferred Stock has the following terms: Ranking Pari passu Voting Rights. Conversion. Dividends. Liquidation Rights. Pari passu Rights and Preferences. Redemption Rights. Price Adjustments Protection Preemptive or Similar Rights Fully Paid and Nonassessable Series X Preferred Stock The Company has 24,227 shares of its 10% Series X Cumulative Redeemable Perpetual Preferred Stock (the “Series X Preferred Stock”) outstanding as of March 31, 2022 and December 31, 2021. The Series X Preferred Stock has a par value of $0.01 per share, no stated maturity, a liquidation preference of $25.00 per share, and will not be subject to any sinking fund or mandatory redemption and will remain outstanding indefinitely unless the Company decides to redeem or otherwise repurchase the Series X Preferred Stock; the Series X Preferred Stock is not redeemable prior to November 4, 2020. The Series X Preferred Stock will rank senior to all classes of the Company’s common and preferred stock and accrues dividends at the rate of 10% on $25.00 per share. The Company reserves the right to pay the dividends in shares of the Company’s common stock at a price equal to the average closing price over the five days prior to the date of the dividend declaration. Each one share of the Series X Preferred Stock is entitled to 20,000 votes on all matters submitted to a vote of our shareholders. Series X Preferred Stock Transactions During the Three Month Ended March 31, 2022 During the three months ended March 31, 2022, the Company accrued dividends in the amount of approximately $97,675 on the Series X Preferred Stock. Series X Preferred Stock Transactions During the Three Months Ended March 31, 2021 During the three months ended March 31, 2021, the Company accrued dividends in the amount of approximately $16,392 on the Series X Preferred Stock. On March 31, 2021, dividend payable on the Series X Preferred Stock was $16,392. Stock Options The following table summarizes the options outstanding at March 31, 2022 and the related prices for the options to purchase shares of the Company’s common stock: Weighted Weighted Weighted average average average exercise exercise Range of Number of remaining price of Number of price of exercise options contractual outstanding options exercisable prices outstanding life (years) options exercisable options $ 0.03- 0.39 18,671,211 8.85 $ 0.20 6,636,628 $ 0.14 18,671,211 8.85 $ 0.20 6,636,628 $ 0.14 Transactions involving stock options are summarized as follows: Shares Weighted- Average Exercise Price ($) (A) Outstanding at December 31, 2021 18,746,211 $ 0.20 Granted - $ - Expired (75,000 ) 0.03 Outstanding at March 31, 2022 18,671,211 $ 0.20 Options vested and exercisable 6,636,628 $ 0.14 During the three months ended March 31, 2022 and 2021, the Company charged the amount of $167,015 and $5,942, respectively, for the vesting of stock options. At March 31, 2022, the total stock-based compensation cost related to unvested awards not yet recognized was $2,635,359. The Company did not value any stock options during the three months ended March 31, 2022. The Company valued stock options during the three months ended March 31, 2021 using the Black-Scholes valuation model utilizing the following variables: March 31, March 31, 2022 2021 Volatility - % 169.3% to 183.5 % Dividends $ - $ - Risk-free interest rates - % 0.82% to 1.69 % Term (years) - 2.50 to 10.00 Warrants The following table summarizes the warrants outstanding on March 31, 2022, and the related prices for the warrants to purchase shares of the Company’s common stock: Shares Weighted- Average Exercise Price ($) Outstanding on December 31, 2021 29,820,000 $ 0.625 Granted 1,585,000 $ 0.558 Exercised - $ - Outstanding on March 31, 2022 31,405,000 $ 0.622 The Company valued warrants options during the three months ended March 31, 2022 and 2021 using the Black-Scholes valuation model utilizing the following variables: March 31, March 31, 2022 2021 Volatility 147.8 to 150.7 % 171.6% to 183.5 % Dividends $ - $ - Risk-free interest rates 0.76% to 0.83 % 1.15% to 1.63 % Term (years) 0.25 5.00 to 6.50	Note 10 Stockholders Equity (Deficit) Common Stock The Company has authorized 500,000,000 shares of common stock, par value $0.01; 213,333,170 and 155,381,183 shares were issued and outstanding at December 31, 2021 and December 31, 2020, respectively. Common Stock Transactions During the Year Ended December 31, 2021 On January 4, 2021, the Company issued 4,123,750 shares of common stock at a price of $0.012 per share pursuant to the conversion of $45,000 of principal and $4,485 of accrued interest in Eagle Equities Note 4. On January 6, 2021, the Company issued 3,505,964 shares of common stock at a price of $0.01224 per share pursuant to the conversion of $39,000 of principal and $3,913 of accrued interest in Eagle Equities Note 4. On January 11, 2021, the Company issued 4,463,507 shares of common stock at a price of $0.01224 per share pursuant to the conversion of $50,000 of principal and $4,633 of accrued interest in Eagle Equities Note 5. On January 14, 2021, the Company issued 4,319,378 shares of common stock at a price of $0.01266 per share pursuant to the conversion of $50,000 of principal and $4,683 of accrued interest in Eagle Equities Note 5. On January 21, 2021, the Company issued 6,449,610 shares of common stock at a price of $0.0154 per share pursuant to the conversion of $93,000 of principal and $6,324 of accrued interest in Eagle Equities Note 6. On January 28, 2021, the Company issued 7,285,062 shares of common stock at a price of $0.01575 per share pursuant to the conversion of $107,200 of principal and $7,540 of accrued interest in Eagle Equities Note 6. On February 1, 2021, the Company issued 6,672,000 shares of common stock in a private placement (the "2021 Private Placement”) at a price of $0.25 per share for cash proceeds of $1,668,000. On February 5, 2021, the Company entered into a settlement agreement with the holders of the Eagle Equities Note 7 whereby the Company issued 1,184,148 shares of common stock at a price of $0.24984 per share in satisfaction of $200,200 of principal and all accrued interest and prepayment penalties due under this note. On February 5, 2021, the Company entered into a settlement agreement with the holders of the Eagle Equities Note 8 whereby the Company issued 639,593 shares of common stock at a price of $0.23851 per share in satisfaction of $114,400 of principal and all accrued interest and prepayment penalties due under this note. On February 5, 2021, the Company entered into a settlement agreement with the holders of the Eagle Equities Note 9 whereby the Company issued 605,177 shares of common stock at a price of $0.24984 per share in satisfaction of $114,400 of principal and all accrued interest and prepayment penalties due under this note. On February 5, 2021, the Company entered into a settlement agreement with the holders of the Eagle Equities Note 10 whereby the Company issued 1,095,131 shares of common stock at a price of $0.23748 per share in satisfaction of $200,200 of principal and all accrued interest and prepayment penalties due under this note. On February 22, 2021, the Company issued 336,000 shares of common stock for the exercise of options at a price of $0.03 per share. On March 11, 2021, the Company issued 600,000 shares of common stock to four officers of The Good Clinic in exchange for 4,800 shares of Series A Preferred Stock. The 4,800 shares of Series A Preferred Stock were cancelled. On March 17, 2021, the Company issued 300,000 shares of common stock at a price of $0.31 per share to a service provider. On March 23, 2021, the Company issued 461,358 shares of common stock at a price of $0.26 per share to the underwriters of the 2021 Private Placement. On April 19, 2021, the Company issued 1,962 shares of common stock for professional fees which had been performed in a prior period. The Company recorded these shares at the par value of $0.01 per share. On May 4 through May 26, 2021, the Company issued 4,237,424 shares of common stock for the conversion of 1,059,356 shares of Series C Preferred Stock at a price of $0.25 per share. On May 12, 2021, the Company issued 2,500,000 shares of common stock at a price of $0.03 per share for the exercise of stock options by an investor. On June 10 through June 29, 2021, the Company issued 5,116,668 shares of common stock at a price of $0.03 per share for the exercise of stock options by officers and directors. On June 23, 2021, the Company cancelled 2,000,000 shares of common stock held by an ex-officer in connection with a settlement agreement. The cancellation of these shares was recorded at the par value of $0.01 per share. Also, in connection with the settlement agreement, the Company issued 637,953 shares to the ex-officer at the market price of $.20 per share. On August 17, 2021, accrued liabilities in the amount of $156,441 were converted to 625,764 shares of common stock. 479,464 shares were issued during December 2021 and the remaining 146,300 shares was not issued and recorded in common stock subscribed as of December 31, 2021. Among the 625,764 shares, 312,800 restricted shares of the Company’s common stock were issued to settled $78,200 cash compensation owed to the Company’s Chief Executive Officer for services rendered to the Company prior to 2021. Between August 11, 2021 and September 2, 2021, the Company issued 4,000,001 shares of the Company common stock in connection with the conversion of Series C preferred stock issued in the first quarter. Also, during the year ended December 31, 2021, the Company charged the amount of $13,032 to operations in connection with the vesting of stock granted to its officers, employees, and board members; the Company also charged the amount of $676,423 to operations in connection with the vesting of options granted to its officers, employees, and board members. Common Stock Transactions During the Year Ended December 31, 2020 The Company entered into agreements with two note holders regarding the exercise price of warrants held by the note holders. These agreements resulted in the following: (i) on January 29, 2020, the Company issued 1,000,000 shares of common stock, and the note holders agreed to cancel 2,769,482 warrants; the Company recorded a gain in the amount of $77,652 on this transaction; (ii) on February 19, 2020, the Company issued 4,098,556 shares of common stock for the exercise of 4,480,938 warrants in a cashless transaction; the Company recorded a gain in the amount of $182,295 on this transaction, which is included in gain on derivative liabilities. On May 27, 2020, the Company issued 2,901,440 shares of common stock for the cashless exercise of warrants. These warrants were issued pursuant to a settlement agreement with a note holder regarding the effective price of warrants issued with regard to a variable conversion price feature which resulted in the issuance of 1,011,967 more shares than would have been issued prior to the settlement agreement. The Company recorded a loss in the amount of $24,894 on this transaction based upon the additional shares issued at the market price of the Company’s common stock. The Company issued, in nineteen transactions and at prices ranging from $0.0108 to $0.0120 per share, a total of 63,374,555 shares in connection with the conversion of principal and interest of convertible notes payable in the aggregate amounts of $813,000 and $70,658. No gain or loss was recognized on these transactions. See note 8. On January 2, 2020, the Company issued 200,000 restricted shares of the Company’s common stock at valued $7,680 in exchange for services conducted on behalf of the Company. The value of these shares was based on the closing market price on the respective date of grant. On August 27, 2020, the Company issued 386,985 shares of common stock at a price of $0.034 per share to an ex-employee for accrued compensation. A gain in the amount of $6,988 was recognized on this transaction. The Company charged the amount of $67,623 to operations in connection with the vesting of stock granted to its officers, Board members, and employees. The Company charged the amount of $421,502 to operations in connection with the vesting of stock options granted to its officers, Board members, consultants, and employees. On December 31, 2020, the Company issued 2,151,204 shares of common stock at a price of $0.0305 per share as payment of accrued dividends on the Series X Preferred Stock. Preferred Stock We have authorized to issue 100,000,000 shares of Preferred Stock with such rights designations and preferences as determined by our Board of Directors. We have designated 500,000 shares of series A stock, 3,000,000 shares of Series C Preferred, 10,000,000 shares of Series D Preferred and we have designated 27,324 shares as Series X Preferred Stock. Series A Preferred Stock Transactions During the Year Ended December 31, 2021 During the year ended December 31, 2021, the Company accrued dividends in the amount of $1,000 on the Series A Preferred Stock. On March 11, 2021, the Company issued 600,000 shares of common stock to the four officers of The Good Clinic in exchange for the previously issued Series A Preferred Stock and accrued dividends. The Series A preferred stock was canceled and there are no Series A Preferred shares outstanding at December 31, 2021. Series A Preferred Stock Transactions During the Year Ended December 31, 2020 On March 2, 2020, the Company issued 4,800 shares of its Series A Preferred Stock to four individuals with certain skills and know-how to assist the Company in the development of its newly-formed subsidiary The Good Clinic, LLC. The Company has valued these shares at $71,558 or approximately $14.91 per share based upon an analysis performed by an independent valuation consultant. During the year ended December 31, 2020, the Company accrued dividends in the amount of $9,967 on the Series A Preferred Stock. At December 31, 2020, dividend payable on the Series A Preferred Stock was $9,967. At December 31, 2020, if management determined to pay these dividends in shares of the Company’s common stock, this would result in the issuance of 755,076 shares of common stock based upon the average price of $0.0132 per share for the five-day period ended December 31, 2020. Subsequent to year end the Company cancelled these shares and instead issued a total of 600,000 shares of restricted common stock to the holders. Series C Preferred Stock On March 25, 2021, the Company entered into Securities Purchase Agreements with four institutional investors (the “Investors” and each an “Investor”) pursuant to which the Company sold to the Investors in a private placement an aggregate of 3,000,000 units (the “Units” and each a “Unit”) with a purchase price of $1.00 per Unit, with each Unit consisting of (a) one share of a newly formed Series C Convertible Preferred Stock, par value $0.01 per share (the “Series C Preferred Stock”), (b) one warrant (the “Series A Warrants”) to purchase 2.1 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”) at a purchase price of $0.50 per whole share of Common Stock, and (c) one warrant (the “Series B Warrants” and together with the Series A Warrants, the “Warrants”) to purchase 2.1 shares of Common Stock at a purchase price of $0.75 per whole share. The aggregate gross proceeds to the Company were $3,000,000 and the number of shares of Common Stock initially issuable upon conversion of the Series C Preferred Stock is 12,600,000 shares of Common stock and the aggregate number of shares of Common Stock initially issuable upon exercise of the Warrants is 12,600,000 shares of Common Stock. The Series C Preferred Stock has the following terms: Ranking Pari passu Voting Rights. Conversion. Dividends. Liquidation Rights. Pari passu Rights and Preferences. Redemption Rights. Price Adjustments Protection Preemptive or Similar Rights Fully Paid and Nonassessable Series C Preferred Stock Transactions During the Year Ended December 31, 2021 On March 25, 2021, the Company sold 3,000,000 shares of its Series C Preferred Stock along with (i) five-year warrants to purchase 6,300,000 shares of the Company’s common stock at a price of $0.50 per share, and (ii) five On May 4 through May 26, 2021, 1,059,356 shares of Series C Preferred Stock were converted at a price of $0.25 per share to 4,237,424 shares of common stock. Between August 11,2021 through September 2, 2021, 1,000,000 shares of Series C Preferred Stock were converted at a price of $0.25 per share to 4,000,001 shares of common stock. During the year ended December 31, 2021, the Company accrued dividends on the Series C Preferred Stock in the amount of $87,059. Series C Preferred Stock Transactions During the Year Ended December 31, 2020 None. Series D Preferred Stock On November 19, 2021, the Company closed a bridge financing round totaling $3,100,000 of Series D preferred stock sold to investors in a private placement. Each Series D Unit will had a purchase price of $1.00 per Unit, with each Unit consisting of (a) one share of a newly formed Series D Convertible Preferred Stock, par value $0.01 per share (the “Series D Preferred Stock”), (b) one warrant (the “Series A Warrants”) to purchase 2.1 shares of the Company’s Common Stock at a purchase price of $0.50 per whole share of Common Stock, and (c) one warrant (the “Series B Warrants” and together with the Series A Warrants, the “Warrants”) to purchase 2.1 shares of Common Stock at a purchase price of $0.75 per whole share. The Series D Preferred Stock has the following terms: Ranking Pari passu Voting Rights. Conversion. Dividends. Liquidation Rights. Pari passu Rights and Preferences. Redemption Rights. Price Adjustments Protection Preemptive or Similar Rights Series D Preferred Stock Transactions During the Year Ended December 31, 2021 On October 18, 2021, the Company sold 2,050,000 shares of Series D Preferred Stock and (i) five-year warrants to acquire 4,252,500 shares of the Company’s common stock at a price of $0.50 per shares, and (ii) five On November 10, 2021, the Company sold 1,075,000 shares of Series D Preferred Stock and (i) five-year warrants to acquire 2,257,500 shares of the Company’s common stock at a price of $0.50 per shares, and (ii) five-year warrants to acquire 2,257,500 shares of the Company’s common stock at a price of $0.75 per share for proceeds of $999,250, net of costs in the amount of $75,750. During the year ended December 31, 2021, the Company accrued dividends on the Series D Preferred Stock in the amount of $35,327. Series D Preferred Stock Transactions During the Year Ended December 31, 2020 None. Series X Preferred Stock The Company has 24,227 and 26,227 shares of its 10% Series X Cumulative Redeemable Perpetual Preferred Stock (the “Series X Preferred Stock”) outstanding as of December 31, 2021 and December 31, 2020, respectively. The Series X Preferred Stock has a par value of $0.01 per share, no stated maturity, a liquidation preference of $25.00 per share, and will not be subject to any sinking fund or mandatory redemption and will remain outstanding indefinitely unless the Company decides to redeem or otherwise repurchase the Series X Preferred Stock; the Series X Preferred Stock is not redeemable prior to November 4, 2020. The Series X Preferred Stock will rank senior to all classes of the Company’s common and preferred stock and accrues dividends at the rate of 10% on $25.00 per share. The Company reserves the right to pay the dividends in shares of the Company’s common stock at a price equal to the average closing price over the five days prior to the date of the dividend declaration. Each one share of the Series X Preferred Stock is entitled to 20,000 votes on all matters submitted to a vote of our shareholders. Series X Preferred Stock Transactions During the Year Ended December 31, 2021 On June 23, 2021, 2,000 shares of Series X Preferred Stock were cancelled pursuant to a settlement agreement with an ex-officer. Series X Preferred Stock Transactions During the Year Ended December 31, 2020 During the year ended December 31, 2020, the Company accrued dividends in the amount of $65,568 on the Series X Preferred Stock. On December 31, 2020, the Company issued 2,151,204 shares of common stock at a price of $0.0305 per share in satisfaction of the accrued dividends on the Series X Preferred Stock. The price of the common stock issued was equal to the average closing price over the five days prior the date of conversion. At December 31, 2020, dividend payable on the Series X Preferred Stock was $0. Stock Options The following table summarizes the options outstanding at December 31, 2021 and the related prices for the options to purchase shares of the Company’s common stock: Weighted Weighted Weighted average average average exercise exercise Range of Number of remaining price of Number of price of exercise options contractual outstanding options exercisable prices outstanding life (years) options exercisable options $ 0.03- 0.39 18,746,211 9.10 $ 0.20 5,502,877 $ 0.11 18,746,211 9.10 $ 0.20 5,502,877 $ 0.11 Transactions involving stock options are summarized as follows: Shares Weighted- Average Exercise Price ($) (A) Outstanding at January 1, 2020 67,879 $ 0.03 Granted 14,886,000 0.03 Cancelled/Expired (1,500,000 ) 0.03 Outstanding at December 31, 2020 13,453,879 $ 0.03 Granted 14,295,000 $ 0.26 Cancelled/Expired (350,000 ) $ 0.03 Exercised (8,652,668 ) 0.03 Outstanding at December 31, 2021 18,746,211 $ 0.20 Options vested and exercisable 5,502,877 $ 0.11 (A) On December 14, 2020, the Company reset the exercise price of all the options then outstanding options to $0.03 per share. This included 150,000 options previously priced at $0.04 per share; 7,450,000 options previously priced at $0.05 per share; 1,000,000 options previously priced at $0.06 per share; and 67,879 options previously prices at $21.40 per share. The Company valued these options as of December 14, 2020, at the original exercise price and at the new price of $0.03 per share and charged the increase in value in the amount of $4,113 to operations during the year ended December 31, 2020. The exercise prices of all options are shown at the restated price of $0.03 per share. (B) On December 28, 2020, the Company accelerated the vesting of certain of its options issued to Board members, management, and consultants, resulting in a charge to operations in the amount of $164,647 during the year ended December 31, 2020. At December 31, 2021, the total stock-based compensation cost related to unvested awards not yet recognized was $3,154,383. The Company valued stock options during the years ended December 31, 2021 and 2020 using the Black-Scholes valuation model utilizing the following variables: December 31, December 31, 2021 2020 Volatility 153.5% to 183.5 % 149.4% to 209.6 % Dividends $ - $ - Risk-free interest rates 0.820% to 1.69 % 0.55% to 1.30 % Term (years) 5.00-6.5 5.00 Warrants The following table summarizes the warrants outstanding at December 30, 2021 and the related prices for the warrants to purchase shares of the Company’s common stock: Shares Weighted- Average Exercise Price ($) Outstanding at December 31, 2019 1,800,000 $ 0.00858 Granted 6,582,382 $ 0.00858 Exercised (8,382,382 ) $ 0.0561 Outstanding at December 31, 2020 - $ - Granted 29,820,000 $ 0.625 Exercised - $ - Outstanding at December 31, 2021 29,820,000 $ 0.625

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Note 10 Commitments and Contingencies Legal There are no pending or anticipated legal actions at this time. PPP Loan During March 2020, in response to the COVID-19 crisis, the federal government announced plans to offer loans to small businesses in various forms, including the Payroll Protection Program, or “PPP”, established as part of the Corona Virus Aid, Relief and Economic Security Act (“CARES Act”) and administered by the U.S. Small Business Administration. On April 25, 2020, the Company entered an unsecured Promissory Note with Bank of America for a loan in the original principal amount of approximately $460,000, and the Company received the full amount of the loan proceeds on May 4, 2020. The current balance is $460,406 and the Company is currently in discussions for a) a partial forgiveness and b) the conversion of any remaining balance into a term note.	Note 13 Commitments and Contingencies Legal There is no pending or anticipated legal actions at this time except as noted below in “Other.” PPP Loan During March 2020, in response to the COVID-19 crisis, the federal government announced plans to offer loans to small businesses in various forms, including the Payroll Protection Program, or "PPP", established as part of the Corona Virus Aid, Relief and Economic Security Act ("CARES Act”) and administered by the U.S. Small Business Administration. On April 25, 2020, the Company entered an unsecured Promissory Note (the "Note”) with Bank of America for a loan in the original principal amount of approximately $460,000, and the Company received the full amount of the loan proceeds on May 4, 2020. The current balance is $460,406 and the Company is currently in discussions for a) a partial forgiveness and b) the conversion of any remaining balance into a term note. As of December 31, 2021, based on communication with Bank of America, it is expected that approximately $25,000 of the PPP loan will be forgiven and we have received conditional approval to pay the loan off over sixty months.

Subsequent Events

Subsequent Events	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Note 11 Subsequent Events On April 1, 2022, the Company issued 168,221 shares of common stock to Larry Diamonds, it’s Chief Executive Officer, as compensation for the waiver of certain covenants as set forth and defined in Diamond Note 1. On April 18, 2022, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with GS Capital Partners (the “Investor”) with respect to the sale and issuance to the Investor of: (i) an initial commitment fee in the amount of $159,259 in the form of 637,036 shares (the “Commitment Fee Shares”) of the Company’s common stock (the “Common Stock”), which Commitment Fee Shares can be decreased to 266,280 shares ($66,570) if the Company repays the Note on or prior to their maturity, (ii) promissory note in the principal amount of $277,777, and (iii) Common Stock Purchase Warrants to purchase up to 277,777 shares of the Common Stock (the “Warrants”). The Note and Warrants were issued on April 18, 2022 (the “Original Issue Date”) and were held in escrow pending effectiveness of the Purchase Agreement. Pursuant to the terms of the Purchase Agreement, the initial Commitment Fee Shares were issued at a value of $159,259, the Note was issued in the principal amount of $277,777 for a purchase price of $250,000, resulting in the original issue discount of $27,777; and the Warrants were issued, with an initial exercise price of $0.50 per share, subject to adjustment. On April 6, 2022, the Company entered into separate Securities Purchase Agreement with each of Anson East Master Fund LP and Anson Investments Master Fund LP with respect to the sale and issuance to AEMF and AIMF of: (i) an aggregate initial commitment fee in the amount of $430,000 in the form of 1,720,000 shares (the “Commitment Fee Shares”) of the Company’s common stock (the “Common Stock”), which Commitment Fee Shares can be decreased to 722,400 shares ($180,000) if the Company repays the Notes on or prior their maturity, (ii) promissory notes in the aggregate principal amount of $750,000 (the “Notes”), and (iii) Common Stock Purchase Warrants to purchase up to an aggregate of 750,000 shares of the Common Stock (the “Warrants”). The Notes and Warrants were issued on April 6, 2022 (the “Original Issue Date”) and were held in escrow pending effectiveness of the Purchase Agreements. On April 27, 2022, the Company issued 720,000 shares of stock to Cavalry Fund 1 LP as compensation for the waiver of certain covenants as set forth in the Series C Certificate of Designation. On April 27, 2022, the Company issued 96,471 shares of common stock to Larry Diamonds, it’s Chief Executive Officer, as compensation for the waiver of certain covenants as set forth and defined in Diamond Note 2. The Company also issued five year warrants to purchase 92,471 shares of common stock at a price of $0.50 to Mr. Diamond pursuant to a promissory note. On April 27, 2022, the Company issued a 10% Promissory Note due June 30, 2022 (the “Diamond Note”) to Lawrence Diamond (the “Lender”). Lawrence Diamond is the Chief Executive Officer of the Company. The principal amount of the Diamond Note is $235,294.00, carries a 10% interest rate per annum, payable in monthly installments, and has a maturity date that is the earlier of (i) April 4, 2022, (ii) the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE, or (iii) the date of receipt of the Company of the next round of debt or equity financing in an amount of at least $1,000,000. The purchase price of the Diamond Note payable to the Company for the Diamond Note was $200,000 and was funded on April 27, 2022. The amount payable at maturity will be $235,294 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default, as defined in the Diamond Note, the principal amount shall bear interest for each day until paid, at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Diamond Note contains a “most favored nations” clause that provides that, so long as the Note is outstanding, if the Company issues any new security, which the Lender reasonably believes contains a term that is more favorable than those in the Diamond Note, the Company shall notify the Lender of such term, and such term, at the option of the Lender, shall become a part of the Note. On May 10, 2022, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Kishon Investments, LLC (the “Investor”) with respect to the sale and issuance to the Investor of: (i) an initial commitment fee in the amount of $159,259 in the form of 637,036 shares (the “Commitment Fee Shares”) of the Company’s common stock (the “Common Stock”), (ii) promissory note in the principal amount of $277,777 due on November 10, 2022, and (iii) Common Stock Purchase Warrants to purchase up to 277,777 shares of the Common Stock (the “Warrants”). The Note and Warrants were issued on May 10, 2022 (the “Original Issue Date”) and were held in escrow pending effectiveness of the Purchase Agreement. Pursuant to the terms of the Purchase Agreement, the initial Commitment Fee Shares were issued at a value of $159,259, the Note was issued in the principal amount of $277,777 for a purchase price of $250,000, resulting in the original issue discount of $27,777; and the Warrants were issued, with an initial exercise price of $0.50 per share, subject to adjustment.	Note 14 Subsequent Events The Company entered into a debt-for-equity exchange agreement with Gardner Builders Holdings, LLC (the “Creditor”) on January 7, 2022 (the “Agreement”). Pursuant to the Agreement, the Company issued shares of restricted common stock, par value $0.01 per share, of MITI (the “Restricted Shares”) to the Creditor in exchange for the Company Debt Obligations, as defined below. The Agreement settles for certain accounts payable amounts owed by the Company to the Creditor (the “Accounts Payable Amount”) as well as upcoming amounts that will become due between the date of the Agreement and April 1, 2022. The Agreement also settles incurred interest and penalties on the amounts due through January 5, 2022, as well as future interest payments on amounts to be incurred in the first quarter of 2022 (collectively, the “Additional Costs”, and combined with the Accounts Payable Amount, the “Company Debt Obligations”). The Accounts Payable Amount is $500,000, the Additional Costs is $294,912.56 and the conversion price is $0.25. As a result, 3,179,650 Restricted Shares were authorized to be issued. The Company’s Board of Directors approved the Agreement on January 5, 2022. The Company issued a 10% Promissory Note due August 14, 2022 (the “Note”), dated February 14, 2022, to Lawrence Diamond (the “Lender”). Mr. Diamond is the Chief Executive Officer of the Company and a member of its Board of Directors. The principal amount of the Note is $175,000, carries a 10% interest rate per annum, payable in monthly installments, and has a maturity date that is the earlier of (i) six (6) months from the date of execution, or (ii) the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Note payable to the Company for the Note was $148,750 and was funded on February 14, 2022. The amount payable at maturity will be $175,000 plus 10% of that amount plus accrued and unpaid interest. Following an event of default, as defined in the Note, the principal amount shall bear interest for each day until paid, at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Note contains a “most favored nations” clause that provides that, so long as the Note is outstanding, if the Company issues any new security, which the Lender believes contains a term that is more favorable than those in the Note, the Company shall notify the Lender of such term, and such term, at the option of the Lender, shall become a part of the Note. In addition to the Note and Lender will be issued 367,500 5-year warrants that may be exercised at $.50 per share and 367,500 5-year warrants that may be exercised at $.75 per share. These warrants have all of the same terms as those previously issued in conjunction with the Company’s Series C Preferred shares and its Series D Preferred shares. The Company issued a 10% Promissory Note due June 18, 2022 (the “Diamond Note”), dated March 18, 2022, to Lawrence Diamond (the “Lender”), which was subsequently amended. Lawrence Diamond is the Chief Executive Officer of the Company. The principal amount of the Diamond Note is $235,294.00, carries a 10% interest rate per annum, payable in monthly installments, and has a maturity date that is the earlier of (i) April 4, 2022, (ii) the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE, or (iii) the date of receipt of the Company of the next round of debt or equity financing in an amount of at least $1,000,000. The purchase price of the Diamond Note payable to the Company for the Diamond Note was $200,000 and was funded on March 18, 2022. The amount payable at maturity will be $235,294 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default, as defined in the Diamond Note, the principal amount shall bear interest for each day until paid, at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Diamond Note contains a “most favored nations” clause that provides that, so long as the Note is outstanding, if the Company issues any new security, which the Lender reasonably believes contains a term that is more favorable than those in the Diamond Note, the Company shall notify the Lender of such term, and such term, at the option of the Lender, shall become a part of the Note. In addition, the Lender will be issued 200,000 5-year warrants that may be exercised on substantially the same terms as the Series A warrant issued in connection with the Company’s Series D Convertible Preferred Stock. On March 18, 2022, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with AJB Capital Investments, LLC (the “Investor”) with respect to the sale and issuance to the Investor of: (i) an initial commitment fee in the amount of $430,000 in the form of 1,720,000 shares (the “Commitment Fee Shares”) of the Company’s common stock (the “Common Stock”), which Commitment Fee Shares can be decreased to 720,000 shares ($180,000) if the Company repays the Note on or prior its maturity, (ii) a promissory note in the aggregate principal amount of $750,000 (the “Note”), and (iii) Common Stock Purchase Warrants to purchase up to an aggregate of 750,000 shares of the Common Stock (the “Warrants”). The Note and Warrants were issued on March 17, 2022 (the “Original Issue Date”) and were held in escrow pending effectiveness of the Purchase Agreement. Pursuant to the terms of the Purchase Agreement, the initial Commitment Fee Shares were issued at a value of $430,000, the Note was issued in a principal amount of $750,000 for a purchase price of $675,000, resulting in an original issue discount of $75,000; and the Warrants were issued, with an initial exercise price of $0.50 per share, subject to adjustment as described herein. The aggregate cash subscription amount received by the Company from the Investor for the issuance of the Commitment Fee Shares, Note and Warrants was $616,250.00, due to a reduction in the $675,000 purchase price as a result of broker, legal, and transaction fees. As previously disclosed on the Company’s form 8-K filed on March 26, 2021 and October 22, 2021, the Company issued the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock to the investors named therein (the “Series C Investors” and “Series D Investors”). The Company obtained consents and waivers (the “Consents”) from the Series D and Series D Investors to allow the Company to enter into the Purchase Agreement. The Company issued 411,000 shares of Common Stock to the Series C Investors 1,271,000 shares of Common Stock to the Series D Investors in connection with obtaining the Consents.

Net Loss Per Share Applicable_2

Net Loss Per Share Applicable to Common Shareholders	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	Note 4 Net Loss Per Share Applicable to Common Shareholders Net Loss per Share Applicable to Common Stockholders Basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted loss per common share is computed similarly to basic loss per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock. The following table sets forth the computation of loss per share for the years ended December 31, 2021 and 2020, respectively: For the Years Ended December 31, 2021 2020 Numerator: Net loss applicable to common shareholders $ (11,226,366 ) $ (2,936,129 ) Denominator: Weighted average common shares outstanding 203,000,201 105,177,272 Net loss per share: Basic and diluted $ (0.06 ) $ (0.03 ) The Company excluded all common equivalent shares for warrants, options, and convertible instruments from the calculation of diluted net loss per share because all such securities are antidilutive for the periods presented. As of December 31, 2021 and 2020, the following shares were issuable and excluded from the calculation of diluted loss: December 31, 2021 2020 Convertible Notes - 79,475,904 Options 18,746,211 13,453,879 Warrants 29,820,000 - Preferred Stock 17,382,575 - Accrued Interest 872,160 92,253 Total 66,820,946 93,022,036

Derivative Liabilities

Derivative Liabilities	12 Months Ended
	Dec. 31, 2021
Disclosure Text Block [Abstract]
Derivatives and Fair Value [Text Block]	Note 9 Derivative Liabilities Certain of the Company’s convertible notes and warrants contain features that create derivative liabilities. The pricing model the Company uses for determining fair value of its derivatives is the Lattice Model. Valuations derived from this model are subject to ongoing internal and external verification and review. The model uses market-sourced inputs such as interest rates and stock price volatilities. Selection of these inputs involves management’s judgment and may impact net income. The derivative components of these notes are valued at issuance, at conversion, at restructure, and at each period end. Derivative liability activity for the year ended December 31, 2021 was $0. Derivative liability activity for the years ended December 31, 2020 is summarized in the table below: Conversion features issued 1,273,463 Settled upon conversion or exercise (1,296,416 ) Settled upon payment of note (148,949 ) Gain on revaluation (508,839 ) December 31, 2020 $ 807,682

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Note 11 Income Taxes Deferred income taxes result from the temporary differences primarily attributable to amortization of intangible assets and debt discount and an accumulation of net operating loss carryforwards for income tax purposes with a valuation allowance against the carryforwards for book purposes. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. Included in deferred tax assets are Federal and State net operating loss carryforwards of approximately $8.1 million, which will expire through 2040. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Due to significant changes in the Company’s ownership, the Company’s future use of its existing net operating losses may be limited. The provision (benefit) for income taxes for the years ended December 31, 2021 and 2020 consist of the following: 2021 2020 Current $ - $ - Deferred - - Total $ - $ - For the years ended December 31, 2021 and 2020, the expected tax expense (benefit) based on the U. S. federal statutory rate is reconciled with the actual tax provision (benefit) as follows: For the Years Ended December 31, 2021 2020 Expected tax at statutory rates $ (2,351,000 ) 21 % $ (617,000 ) 21 % Permanent Differences 692,000 6 % (42,000 ) 1 % State Income Tax, Net of Federal benefit (612,000 ) 5 % - 0 % Current Year Change in Valuation Allowance 2,291,000 20 % 659,000 22 % Prior Year True-Ups (20,000 ) 0 % - 0 % Income tax expense $ - 0 % $ - 0 % Deferred income taxes reflect the tax impact of temporary differences between the amounts of assets and liabilities for financial reporting purposes and such amounts as measured by tax laws and regulations. Deferred income taxes include the net tax effects of net operating loss (NOL) carryforwards and the temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. As of December 31, 2021, and 2020 significant components of the Company’s deferred tax assets are as follows: For the Years Ended December 31, 2021 2020 Deferred Tax Assets (Liabilities): Accrued payroll $ 22,000 $ 41,000 ASC842-ROU Asset (1,117,000 ) 65,000 ASC842-ROU (Liability) 1,189,000 (67,000 ) Gain from derivatives (4,000 ) (107,000 ) Stock based compensation 398,000 119,000 Depreciation (764,000 ) (1,000 ) Net operating loss 8,478,000 5,861,000 Net deferred tax assets (liabilities) 8,202,000 5,911,000 Valuation allowance (8,202,000 ) (5,911,000 ) Net deferred tax assets (liabilities) $ - $ -

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	Note 12 Fair Value of Financial Instruments The following summarizes the Company’s derivative financial liabilities that are recorded at fair value on a recurring basis at December 31, 2021 and 2020. December 31, 2021 Level 1 Level 2 Level 3 Total Liabilities Derivative liabilities $ - $ - $ - $ - December 31, 2020 Level 1 Level 2 Level 3 Total Liabilities Derivative liabilities $ - $ - $ 807,682 $ 807,682

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation	Principles of Consolidation
Use of Estimates, Policy [Policy Text Block]	Use of Estimates -	Use of Estimates -
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash -	Cash -
Property, Plant and Equipment, Policy [Policy Text Block]	Property, Plant, and Equipment - Years Office equipment 3 to 5 Furniture & fixtures 3 to 7 Machinery & equipment 3 to 10 Leasehold improvements Term of lease	Property, Plant, and Equipment - Years Office equipment 3 to 5 Furniture & fixtures 3 to 7 Machinery & equipment 3 to 10 Leasehold improvements Term of lease Construction in Progress -
Revenue [Policy Text Block]	Revenue Recognition The Company applied the modified retrospective approach to all contracts when adopting ASC 606. As a result, at the adoption of ASC 606 what was previously classified as the provision for bad debts in the statement of operations is now reflected as implicit price concessions (as defined in ASC 606) and therefore included as a reduction to net operating revenues in 2018. For changes in credit issues not assessed at the date of service, the Company will prospectively recognize those amounts in other operating expenses on the statement of operations. For periods prior to the adoption of ASC 606, the provision for bad debts has been presented consistent with the previous revenue recognition standards that required it to be presented separately as a component of net operating revenues. Our revenues generally relate to net patient fees received from various payers and patients themselves under contracts in which our performance obligations are to provide services to the patients. Revenues are recorded during the period our obligations to provide services are satisfied. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates for services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.	Revenue Recognition The Company applied the modified retrospective approach to all contracts when adopting ASC 606. As a result, at the adoption of ASC 606 what was previously classified as the provision for bad debts in the statement of operations is now reflected as implicit price concessions (as defined in ASC 606) and therefore included as a reduction to net operating revenues in 2018. For changes in credit issues not assessed at the date of service, the Company will prospectively recognize those amounts in other operating expenses on the statement of operations. For periods prior to the adoption of ASC 606, the provision for bad debts has been presented consistent with the previous revenue recognition standards that required it to be presented separately as a component of net operating revenues. Our revenues generally relate to net patient fees received from various payers and patients themselves under contracts in which our performance obligations are to provide services to the patients. Revenues are recorded during the period our obligations to provide services are satisfied. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates for services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.
Share-Based Payment Arrangement [Policy Text Block]	Stock-Based Compensation - Equity instruments issued to those other than employees are recognized pursuant to FASB issued ASU 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. This ASU relates to the accounting for non-employee share-based payments. The amendment in this update expands the scope of Topic 718 to include all share-based payment transactions in which a grantor acquired goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The ASU excludes share-based payment awards that relate to: (1) financing to the issuer; or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts from Customers. The share-based payments are to be measured at grant-date fair value of the equity instruments that the entity is obligated to issue when the goods or service has been delivered or rendered and all other conditions necessary to earn the right to benefit from the equity instruments have been satisfied. This standard became effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. We adopted the provisions of this ASU on January 1, 2019. The adoption had no impact on our results of operations, cash flows, or financial condition.	Stock-Based Compensation - Equity instruments issued to those other than employees are recognized pursuant to FASB issued ASU 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. This ASU relates to the accounting for non-employee share-based payments. The amendment in this update expands the scope of Topic 718 to include all share-based payment transactions in which a grantor acquired goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The ASU excludes share-based payment awards that relate to: (1) financing to the issuer; or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts from Customers. The share-based payments are to be measured at grant-date fair value of the equity instruments that the entity is obligated to issue when the goods or service has been delivered or rendered and all other conditions necessary to earn the right to benefit from the equity instruments have been satisfied. This standard will be effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. We adopted the provisions of this ASU on January 1, 2019. The adoption had no impact on our results of operations, cash flows, or financial condition.
Convertible Instruments, Policy [Policy Text Block]	Convertible Instruments	Convertible Instruments
Warrants, Policy [Policy Text Block]	Common Stock Purchase Warrants-	Common Stock Purchase Warrants-
Stockholders' Equity, Policy [Policy Text Block]	Stockholders Equity-	Stockholders Equity-
Earnings Per Share, Policy [Policy Text Block]	Per Share Data-	Per Share Data-
Fair Value of Financial Instruments, Policy [Policy Text Block]	Financial Instruments and Fair Values- Level 1 – inputs include exchange quoted prices for identical instruments and are the most observable. Level 2 – inputs include brokered and/or quoted prices for similar assets and observable inputs such as interest rates. Level 3 – inputs include data not observable in the market and reflect management judgment about the assumptions market participants would use in pricing the asset or liability. The use of observable and unobservable inputs and their significance in measuring fair value are reflected in our hierarchy assessment. The carrying amount of cash, prepaid assets, accounts payable and accrued liabilities approximate fair value due to the short-term maturities of these instruments. Because cash and cash equivalents are readily liquidated, management classifies these values as Level 1. The fair value of the derivative liabilities approximates their book value as the instruments are short-term in nature and contain market rates of interest. Because there is no ready market or observable transactions, management classifies the derivative liabilities as Level 3.	Financial Instruments and Fair Values- Level 1 – inputs include exchange quoted prices for identical instruments and are the most observable. Level 2 – inputs include brokered and/or quoted prices for similar assets and observable inputs such as interest rates. Level 3 – inputs include data not observable in the market and reflect management judgment about the assumptions market participants would use in pricing the asset or liability. The use of observable and unobservable inputs and their significance in measuring fair value are reflected in our hierarchy assessment. The carrying amount of cash, prepaid assets, accounts payable and accrued liabilities approximate fair value due to the short-term maturities of these instruments. Because cash and cash equivalents are readily liquidated, management classifies these values as Level 1. The fair value of the derivative liabilities approximates their book value as the instruments are short-term in nature and contain market rates of interest. Because there is no ready market or observable transactions, management classifies the derivative liabilities as Level 3.
New Accounting Pronouncements, Policy [Policy Text Block]	New Accounting Standards From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on its financial position or results of operations upon adoption. Recent Accounting Standards Not Yet Adopted In August 2020, the FASB issued ASU 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40)”. This ASU reduces the number of accounting models for convertible debt instruments and convertible Preferred Stock. As well as amend the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. In addition, this ASU improves and amends the related EPS guidance. This standard is effective for us on January 1, 2024, including interim periods within those fiscal years. Adoption is either a modified retrospective method or a fully retrospective method of transition. We are currently assessing the impact the new guidance will have on our condensed consolidated financial statements. There are various other updates recently issued, most of which represent technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s consolidated financial position, results of operations or cash flows.	Recently Issued Accounting Standards In June 2018, the FASB issued ASU 2018-07 "Improvements to Non-employee Share-Based Payment Accounting”, which simplifies the accounting for share-based payments granted to non-employees for goods and services. Under the ASU, most of the guidance on such payments to non-employees would be aligned with the requirements for share-based payments granted to employees. The amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. In December 2019, the FASB issued ASU No. 2019-12, "Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company has adopted ASU No. 2019-12, "Income Taxes (Topic 740) however giving the Company’s historical losses and full valuation allowance it did not have an impact on its condensed consolidated financial statements and related disclosures. Recent Accounting Standards Not Yet Adopted In August 2020, the FASB issued ASU 2020-06, "Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40)”. This ASU reduces the number of accounting models for convertible debt instruments and convertible Preferred Stock. As well as amend the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. In addition, this ASU improves and amends the related EPS guidance. This standard is effective for us on January 1, 2022, including interim periods within those fiscal years. Adoption is either a modified retrospective method or a fully retrospective method of transition. We are currently assessing the impact the new guidance will have on our consolidated financial statements. There are various other updates recently issued, most of which represent technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s consolidated financial position, results of operations or cash flows.
Basis of Accounting, Policy [Policy Text Block]		Basis of Accounting
Derivatives, Policy [Policy Text Block]		Derivative Financial Instruments
Income Tax, Policy [Policy Text Block]		Income Taxes- Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all the deferred tax assets will not be realized. The Company has determined that a valuation allowance is needed due to recent taxable net operating losses and the limited taxable income in the carry back periods. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income or expense in the period that includes the enactment date. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and certain tax loss carryforwards, less any valuation allowance. The Company accounts for uncertain tax positions as required in that a position taken or expected to be taken in a tax return is recognized in the consolidated financial statements when it is more likely than not (i.e., a likelihood of more than 50%) that the position would be sustained upon examination by tax authorities. A recognized tax position is then measured at the largest amount of benefit that is greater than 50% of being realized upon ultimate settlement. The Company does not have any material unrecognized tax benefits. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as components of interest expense and other expense, respectively, in arriving at pretax income or loss. The Company does not have any interest and penalties accrued. The Company is no longer subject to U.S. federal, state, and local income tax examinations for the years before 2012.
Business Combinations Policy [Policy Text Block]		Business Combinations- ● future expected cash flows from product sales, support agreements, consulting contracts, other customer contracts, and acquired developed technologies and patents; and ● discount rates utilized in valuation estimates. Unanticipated events and circumstances may occur that may affect the accuracy or validity of such assumptions, estimates or actual results. Additionally, any change in the fair value of the acquisition-related contingent consideration subsequent to the acquisition date, including changes from events after the acquisition date, such as changes in our estimates of relevant revenue or other targets, will be recognized in earnings in the period of the estimated fair value change. A change in fair value of the acquisition-related contingent consideration or the occurrence of events that cause results to differ from our estimates or assumptions could have a material effect on the consolidated financial position, statements of operations or cash flows in the period of the change in the estimate.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]		Impairment of Long-Lived Assets-

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Property, Plant and Equipment [Table Text Block]	Years Office equipment 3 to 5 Furniture & fixtures 3 to 7 Machinery & equipment 3 to 10 Leasehold improvements Term of lease	Property, plant, and equipment are depreciated using the straight-line method based on the lesser of the estimated useful lives of the assets or the lease term based upon the following life expectancy: Years Office equipment 3 to 5 Furniture & fixtures 3 to 7 Machinery & equipment 3 to 10 Leasehold improvements Term of lease

Net Loss Per Share Applicable_3

Net Loss Per Share Applicable to Common Shareholders (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Earnings Per Share Reconciliation [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	The following table sets forth the computation of loss per share for the three months ended March 31, 2022, and 2021, respectively: For the Three Months Ended March 31, 2022 2021 Numerator: Net loss applicable to common shareholders $ (3,724,886 ) $ (2,754,952 ) Denominator: Weighted average common shares outstanding 213,703,195 187,152,300 Net loss per share: Basic and diluted $ (0.02 ) $ (0.01 )	The following table sets forth the computation of loss per share for the years ended December 31, 2021 and 2020, respectively: For the Years Ended December 31, 2021 2020 Numerator: Net loss applicable to common shareholders $ (11,226,366 ) $ (2,936,129 ) Denominator: Weighted average common shares outstanding 203,000,201 105,177,272 Net loss per share: Basic and diluted $ (0.06 ) $ (0.03 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The Company excluded all common equivalent shares outstanding for warrants, options, and convertible instruments to purchase common stock from the calculation of diluted net loss per share because all such securities are antidilutive for the periods presented. As of March 31, 2022, and 2021, the following shares were issuable and excluded from the calculation of diluted loss: For the Three Months Ended March 31, 2022 2021 Common stock options 18,671,211 10,967,879 Common stock purchase warrants 31,405,000 12,600,000 Convertible Preferred Stock Series C 4,362,575 12,600,000 Convertible Preferred Stock Series D 13,020,000 - Accrued interest on Preferred Stock 1,230,858 72,657 Potentially dilutive securities 68,689,644 36,240,536	As of December 31, 2021 and 2020, the following shares were issuable and excluded from the calculation of diluted loss: December 31, 2021 2020 Convertible Notes - 79,475,904 Options 18,746,211 13,453,879 Warrants 29,820,000 - Preferred Stock 17,382,575 - Accrued Interest 872,160 92,253 Total 66,820,946 93,022,036

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
Schedule of Stock by Class [Table Text Block]	As of December 31, 2021, the shares of Series X Preferred Stock issued and outstanding is as follows: Type of Name Liability # shares Ronald Riewold, Director Deferred Compensation 1,200 Larry Diamond, Director, and CEO Deferred Compensation 2,000 James Crone, ex-Officer, and Director Deferred Compensation 2,884 Louis Deluca, ex-Officer, and Director Deferred Compensation 2,400 Irish Italian Retirement Fund Consulting services, notes payable 12,503 Frank Lightmas Legal fees 3,240 Total 24,227

Accounts Payable and Accrued _2

Accounts Payable and Accrued Liabilities (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	Accounts payable and accrued liabilities consisted of the following at March 31, 2022 and 2021: March 31, December 31, 2022 2021 Trade accounts payable 4,890,066 3,933,305 Accrued payroll and payroll taxes 96,641 23,554 Other 17,928 19,205 Total accounts payable and accrued liabilities 5,004,635 3,976,064	Accounts payable and accrued liabilities consisted of the following at December 31, 2021 and 2020: December 31, December 31, 2021 2020 Trade accounts payable 3,933,305 824,405 Accrued payroll and payroll taxes 23,554 244,926 Other 19,205 - Total accounts payable and accrued liabilities 3,976,064 1,069,331

Right to Use Assets and Lease_2

Right to Use Assets and Lease Liabilities - Operating Leases (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Disclosure Text Block [Abstract]
Lease, Cost [Table Text Block]	Right to use assets – operating leases are summarized below: March 31, 2022 December 31, 2021 Right to use assets, net $ 3,619,403 $ 3,886,866 Operating lease liabilities are summarized below: March 31, 2022 December 31, 2021 Lease liability $ 4,146,960 $ 4,134,802 Less: current portion (276,639 ) (161,838 ) Lease liability, non-current $ 3,870,321 $ 3,972,964	Right to use assets – operating leases are summarized below: December 31, 2021 December 31, 2020 Right to use assets, net $ 3,886,866 $ 310,361 December 31, 2021 December 31, 2020 Lease liability $ 4,134,802 $ 321,004 Less: current portion (161,838 ) (8,905 ) Lease liability, non-current $ 3,972,964 $ 312,099
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Maturity analysis under these lease agreements are as follows: For the twelve months ended March 31, 2023 $ 763,580 For the twelve months ended March 31, 2024 874,687 For the twelve months ended March 31, 2025 827,773 For the twelve months ended March 31, 2026 846,523 For the twelve months ended March 31, 2027 865,517 Thereafter 2,251,381 Total $ 6,429,461 Less: Present value discount (2,282,501 ) Lease liability $ 4,146,960	Maturity analysis under these lease agreements are as follows: For the period ended December 31, 2022 $ 652,653 For the period ended December 31, 2023 888,152 For the period ended December 31, 2024 821,296 For the period ended December 31, 2025 841,600 For the period ended December 31, 2026 860,551 Thereafter 2,478,412 Total $ 6,542,664 Less: Present value discount (2,407,862 ) Lease liability $ 4,134,802

Debt (Tables)

Debt (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Debt Disclosure [Abstract]
Schedule of Debt [Table Text Block]	Notes Payable Table 1: March 31, 2022 December 31, 2021 Notes Payable $ 2,160,294 $ 1,000,000 PPP Loan $ 460,406 $ 460,406 $ 2,620,700 $ 1,460,406 Less: Discount (671,973 ) (411,568 ) Notes payable - net of discount $ 1,948,727 $ 1,048,838 Current Portion, net of discount $ 1,948,727 $ 1,048,838 Long-term portion, net of discount $ - $ -	Notes Payable Table 1: December 31, 2021 December 31, 2020 Notes Payable $ 738,432 $ 1,196,366 PPP Loan $ 460,406 $ 460,406 $ 1,198,838 $ 1,656,772 Less: Discount (150,000 ) (756,795 ) Notes payable - net of discount $ 1,048,838 $ 899,977 Current Portion, net of discount $ 1,048,838 $ 899,977 Long-term portion, net of discount $ - $ -

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit) (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Stockholders' Equity Note [Abstract]
Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	The following table summarizes the options outstanding at March 31, 2022 and the related prices for the options to purchase shares of the Company’s common stock: Weighted Weighted Weighted average average average exercise exercise Range of Number of remaining price of Number of price of exercise options contractual outstanding options exercisable prices outstanding life (years) options exercisable options $ 0.03- 0.39 18,671,211 8.85 $ 0.20 6,636,628 $ 0.14 18,671,211 8.85 $ 0.20 6,636,628 $ 0.14	The following table summarizes the options outstanding at December 31, 2021 and the related prices for the options to purchase shares of the Company’s common stock: Weighted Weighted Weighted average average average exercise exercise Range of Number of remaining price of Number of price of exercise options contractual outstanding options exercisable prices outstanding life (years) options exercisable options $ 0.03- 0.39 18,746,211 9.10 $ 0.20 5,502,877 $ 0.11 18,746,211 9.10 $ 0.20 5,502,877 $ 0.11
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Transactions involving stock options are summarized as follows: Shares Weighted- Average Exercise Price ($) (A) Outstanding at December 31, 2021 18,746,211 $ 0.20 Granted - $ - Expired (75,000 ) 0.03 Outstanding at March 31, 2022 18,671,211 $ 0.20 Options vested and exercisable 6,636,628 $ 0.14	Transactions involving stock options are summarized as follows: Shares Weighted- Average Exercise Price ($) (A) Outstanding at January 1, 2020 67,879 $ 0.03 Granted 14,886,000 0.03 Cancelled/Expired (1,500,000 ) 0.03 Outstanding at December 31, 2020 13,453,879 $ 0.03 Granted 14,295,000 $ 0.26 Cancelled/Expired (350,000 ) $ 0.03 Exercised (8,652,668 ) 0.03 Outstanding at December 31, 2021 18,746,211 $ 0.20 Options vested and exercisable 5,502,877 $ 0.11 (A) On December 14, 2020, the Company reset the exercise price of all the options then outstanding options to $0.03 per share. This included 150,000 options previously priced at $0.04 per share; 7,450,000 options previously priced at $0.05 per share; 1,000,000 options previously priced at $0.06 per share; and 67,879 options previously prices at $21.40 per share. The Company valued these options as of December 14, 2020, at the original exercise price and at the new price of $0.03 per share and charged the increase in value in the amount of $4,113 to operations during the year ended December 31, 2020. The exercise prices of all options are shown at the restated price of $0.03 per share. (B) On December 28, 2020, the Company accelerated the vesting of certain of its options issued to Board members, management, and consultants, resulting in a charge to operations in the amount of $164,647 during the year ended December 31, 2020.
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The Company did not value any stock options during the three months ended March 31, 2022. The Company valued stock options during the three months ended March 31, 2021 using the Black-Scholes valuation model utilizing the following variables: March 31, March 31, 2022 2021 Volatility - % 169.3% to 183.5 % Dividends $ - $ - Risk-free interest rates - % 0.82% to 1.69 % Term (years) - 2.50 to 10.00	The Company valued stock options during the years ended December 31, 2021 and 2020 using the Black-Scholes valuation model utilizing the following variables: December 31, December 31, 2021 2020 Volatility 153.5% to 183.5 % 149.4% to 209.6 % Dividends $ - $ - Risk-free interest rates 0.820% to 1.69 % 0.55% to 1.30 % Term (years) 5.00-6.5 5.00
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	The following table summarizes the warrants outstanding on March 31, 2022, and the related prices for the warrants to purchase shares of the Company’s common stock: Shares Weighted- Average Exercise Price ($) Outstanding on December 31, 2021 29,820,000 $ 0.625 Granted 1,585,000 $ 0.558 Exercised - $ - Outstanding on March 31, 2022 31,405,000 $ 0.622	The following table summarizes the warrants outstanding at December 30, 2021 and the related prices for the warrants to purchase shares of the Company’s common stock: Shares Weighted- Average Exercise Price ($) Outstanding at December 31, 2019 1,800,000 $ 0.00858 Granted 6,582,382 $ 0.00858 Exercised (8,382,382 ) $ 0.0561 Outstanding at December 31, 2020 - $ - Granted 29,820,000 $ 0.625 Exercised - $ - Outstanding at December 31, 2021 29,820,000 $ 0.625
Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]	The Company valued warrants options during the three months ended March 31, 2022 and 2021 using the Black-Scholes valuation model utilizing the following variables: March 31, March 31, 2022 2021 Volatility 147.8 to 150.7 % 171.6% to 183.5 % Dividends $ - $ - Risk-free interest rates 0.76% to 0.83 % 1.15% to 1.63 % Term (years) 0.25 5.00 to 6.50

Net Loss Per Share Applicable_4

Net Loss Per Share Applicable to Common Shareholders (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	The following table sets forth the computation of loss per share for the three months ended March 31, 2022, and 2021, respectively: For the Three Months Ended March 31, 2022 2021 Numerator: Net loss applicable to common shareholders $ (3,724,886 ) $ (2,754,952 ) Denominator: Weighted average common shares outstanding 213,703,195 187,152,300 Net loss per share: Basic and diluted $ (0.02 ) $ (0.01 )	The following table sets forth the computation of loss per share for the years ended December 31, 2021 and 2020, respectively: For the Years Ended December 31, 2021 2020 Numerator: Net loss applicable to common shareholders $ (11,226,366 ) $ (2,936,129 ) Denominator: Weighted average common shares outstanding 203,000,201 105,177,272 Net loss per share: Basic and diluted $ (0.06 ) $ (0.03 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The Company excluded all common equivalent shares outstanding for warrants, options, and convertible instruments to purchase common stock from the calculation of diluted net loss per share because all such securities are antidilutive for the periods presented. As of March 31, 2022, and 2021, the following shares were issuable and excluded from the calculation of diluted loss: For the Three Months Ended March 31, 2022 2021 Common stock options 18,671,211 10,967,879 Common stock purchase warrants 31,405,000 12,600,000 Convertible Preferred Stock Series C 4,362,575 12,600,000 Convertible Preferred Stock Series D 13,020,000 - Accrued interest on Preferred Stock 1,230,858 72,657 Potentially dilutive securities 68,689,644 36,240,536	As of December 31, 2021 and 2020, the following shares were issuable and excluded from the calculation of diluted loss: December 31, 2021 2020 Convertible Notes - 79,475,904 Options 18,746,211 13,453,879 Warrants 29,820,000 - Preferred Stock 17,382,575 - Accrued Interest 872,160 92,253 Total 66,820,946 93,022,036

Derivative Liabilities (Tables)

Derivative Liabilities (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure Text Block [Abstract]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Derivative liability activity for the years ended December 31, 2020 is summarized in the table below: Conversion features issued 1,273,463 Settled upon conversion or exercise (1,296,416 ) Settled upon payment of note (148,949 ) Gain on revaluation (508,839 ) December 31, 2020 $ 807,682

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	The provision (benefit) for income taxes for the years ended December 31, 2021 and 2020 consist of the following: 2021 2020 Current $ - $ - Deferred - - Total $ - $ -
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	For the years ended December 31, 2021 and 2020, the expected tax expense (benefit) based on the U. S. federal statutory rate is reconciled with the actual tax provision (benefit) as follows: For the Years Ended December 31, 2021 2020 Expected tax at statutory rates $ (2,351,000 ) 21 % $ (617,000 ) 21 % Permanent Differences 692,000 6 % (42,000 ) 1 % State Income Tax, Net of Federal benefit (612,000 ) 5 % - 0 % Current Year Change in Valuation Allowance 2,291,000 20 % 659,000 22 % Prior Year True-Ups (20,000 ) 0 % - 0 % Income tax expense $ - 0 % $ - 0 %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	As of December 31, 2021, and 2020 significant components of the Company’s deferred tax assets are as follows: For the Years Ended December 31, 2021 2020 Deferred Tax Assets (Liabilities): Accrued payroll $ 22,000 $ 41,000 ASC842-ROU Asset (1,117,000 ) 65,000 ASC842-ROU (Liability) 1,189,000 (67,000 ) Gain from derivatives (4,000 ) (107,000 ) Stock based compensation 398,000 119,000 Depreciation (764,000 ) (1,000 ) Net operating loss 8,478,000 5,861,000 Net deferred tax assets (liabilities) 8,202,000 5,911,000 Valuation allowance (8,202,000 ) (5,911,000 ) Net deferred tax assets (liabilities) $ - $ -

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Schedule of Derivative Liabilities at Fair Value [Table Text Block]	The following summarizes the Company’s derivative financial liabilities that are recorded at fair value on a recurring basis at December 31, 2021 and 2020. December 31, 2021 Level 1 Level 2 Level 3 Total Liabilities Derivative liabilities $ - $ - $ - $ - December 31, 2020 Level 1 Level 2 Level 3 Total Liabilities Derivative liabilities $ - $ - $ 807,682 $ 807,682

Financial Condition, Going Co_2

Financial Condition, Going Concern and Management Plans (Details) - USD ($)								3 Months Ended		6 Months Ended	12 Months Ended
	Jun. 30, 2022	Jan. 07, 2022	Jan. 05, 2022	Dec. 30, 2021	Nov. 19, 2021	Mar. 25, 2021	Jul. 21, 2020	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2020	Apr. 25, 2022	Oct. 18, 2021	Jun. 23, 2021	May 04, 2020	Apr. 25, 2020
Financial Condition, Going Concern and Management Plans (Details) [Line Items]
Unit Price Per Unit (in Dollars per share)						$ 1
Preferred Stock, Shares Authorized (in Shares)								100,000,000			100,000,000	100,000,000		10,000,000
Debt Instrument, Face Amount				$ 1,000,000													$ 460,000
Debt Instrument, Interest Rate, Stated Percentage				10%
Proceeds from Issuance of Debt				$ 850,000				$ 675,000	$ 0		$ 0	$ 1,673,406
Debt, Default Interest Rate				18%
Common Stock, Par or Stated Value Per Share (in Dollars per share)	$ 0.01							$ 0.01		$ 0.01	$ 0.01	$ 0.01			$ 0.01
Debt Conversion, Converted Instrument, Amount			$ 500,000
Other Accrued Liabilities, Current		$ 294,912.56	$ 294,912					$ 17,928			$ 19,205	$ 0
Debt Instrument, Convertible, Conversion Price (in Dollars per share)		$ 0.25	$ 0.25
Debt Conversion, Converted Instrument, Shares Issued (in Shares)		3,179,650										63,374,555
Cash and Cash Equivalents, at Carrying Value								263,148			1,164,483	$ 64,789
Liabilities, Current								7,740,426			5,558,988	3,028,640
Proceeds from Loans							$ 460,406
Unit Description					(a) one share of a newly formed Series D Convertible Preferred Stock, par value $0.01 per share (the “Series D Preferred Stock”), (b) one warrant (the “Series A Warrants”) to purchase 2.1 shares of the Company’s Common Stock at a purchase price of $0.50 per whole share of Common Stock, and (c) one warrant (the “Series B Warrants” and together with the Series A Warrants, the “Warrants”) to purchase 2.1 shares of Common Stock at a purchase price of $0.75 per whole share	each Unit consisting of (a) one share of a newly formed Series C Convertible Preferred Stock, par value $0.01 per share (the “Series C Preferred Stock”), (b) one warrant (the “Series A Warrants”) to purchase 2.1 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”) at a purchase price of $0.50 per whole share of Common Stock, and (c) one warrant (the “Series B Warrants” and together with the Series A Warrants, the “Warrants”) to purchase 2.1 shares of Common Stock at a purchase price of $0.75 per whole share
Debt Instrument, Term				6 months						6 months
Notes Payable, Current				$ 1,000,000				$ 1,488,321			$ 588,432	$ 0
Debt Instrument, Interest Rate, Increase (Decrease)	18%
Series D Preferred Stock [Member]
Financial Condition, Going Concern and Management Plans (Details) [Line Items]
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants					$ 3,100,000
Unit Price Per Unit (in Dollars per share)					$ 1
Preferred Stock, Shares Authorized (in Shares)								10,000,000			10,000,000			10,000,000
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)					$ 0.01			$ 0.01			$ 0.01	$ 0.01		$ 1.05
Preferred Stock, Convertible, Conversion Price (in Dollars per share)														$ 0.25
Preferred Stock Offering								$ 3,100,000			$ 3,100,000
Unit Description					each Unit consisting of (a) one share of a newly formed Series D Convertible Preferred Stock, par value $0.01 per share (the “Series D Preferred Stock”), (b) one warrant (the “Series A Warrants”) to purchase 2.1 shares of the Company’s Common Stock at a purchase price of $0.50 per whole share of Common Stock, and (c) one warrant (the “Series B Warrants” and together with the Series A Warrants, the “Warrants”) to purchase 2.1 shares of Common Stock at a purchase price of $0.75 per whole share
Restricted Stock [Member]
Financial Condition, Going Concern and Management Plans (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued (in Shares)		3,179,650	3,179,650
Accounts Payable [Member]
Financial Condition, Going Concern and Management Plans (Details) [Line Items]
Debt Conversion, Converted Instrument, Amount		$ 500,000
PPP Loan [Member]
Financial Condition, Going Concern and Management Plans (Details) [Line Items]
Debt Instrument, Face Amount													$ 460,000			$ 460,000	$ 460,000
Proceeds from Loans								$ 460,406
Debt Instrument, Term											60 months

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Cash and Cash Equivalents, at Carrying Value	$ 263,148	$ 1,164,483	$ 64,789

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Property, Plant, and Equipment - Property and equipment is recorded at the lower of cost or estimate	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2020
Office Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years	3 years
Office Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years	5 years
Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years	3 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	7 years	7 years
Machinery and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years	3 years
Machinery and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years	10 years
Leasehold Improvements [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	Term of lease
Leasehold Improvements [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	Term of lease

Net Loss Per Share Applicable_5

Net Loss Per Share Applicable to Common Shareholders (Details) - Schedule of Earnings Per Share, Basic and Diluted - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Numerator:
Net loss applicable to common shareholders	$ (3,724,886)	$ (2,754,952)	$ (11,226,366)	$ (2,936,129)
Denominator:
Weighted average common shares outstanding	213,703,195	187,152,300	203,000,201	105,177,272
Net loss per share:
Basic and diluted	$ (0.02)	$ (0.01)	$ (0.06)	$ (0.03)

Net Loss Per Share Applicable_6

Net Loss Per Share Applicable to Common Shareholders (Details) - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share - shares	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	68,689,644	36,240,536	66,820,946	93,022,036
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	18,671,211	10,967,879	18,746,211	13,453,879
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	31,405,000	12,600,000	29,820,000	0
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities			0	79,475,904
Series C Preferred Stock [Member] | Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	4,362,575	12,600,000
Series D Preferred Stock [Member] | Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	13,020,000	0
Accrued Interest [Member] | Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	1,230,858	72,657	872,160	92,253

Related Party Transactions (Det

Related Party Transactions (Details)

3 Months Ended

12 Months Ended

Jun. 30, 2022

Mar. 18, 2022 USD ($) shares

Feb. 14, 2022 USD ($) $ / shares shares

Jan. 12, 2022 shares

Dec. 30, 2021 USD ($)

Aug. 26, 2021 USD ($) $ / shares shares

Jul. 21, 2021 $ / shares shares

Jun. 23, 2021 shares

Apr. 19, 2021 $ / shares shares

Mar. 25, 2021 $ / shares shares

Mar. 17, 2021 $ / shares shares

Dec. 31, 2020 USD ($) $ / shares shares

Dec. 28, 2020 USD ($) $ / shares shares

Dec. 14, 2020 $ / shares

Aug. 27, 2020 shares

Aug. 01, 2020 USD ($) $ / shares shares

Jun. 30, 2020 USD ($) shares

Jun. 01, 2020 USD ($) $ / shares shares

May 27, 2020 shares

Mar. 02, 2020 USD ($) $ / shares shares

Feb. 27, 2020 USD ($) $ / shares shares

Dec. 31, 2019 $ / shares shares

Mar. 31, 2022 USD ($) $ / shares shares

Mar. 31, 2021 USD ($)

Dec. 31, 2021 USD ($) $ / shares shares

Dec. 31, 2020 USD ($) $ / shares shares

Nov. 10, 2021 $ / shares

Oct. 18, 2021 $ / shares

May 26, 2021 $ / shares

Mar. 23, 2021 $ / shares

Feb. 01, 2021 $ / shares

Apr. 25, 2020 USD ($)

Related Party Transactions (Details) [Line Items]

Debt Instrument, Face Amount | $

$ 1,000,000

$ 460,000

Debt Instrument, Interest Rate, Stated Percentage

10%

Proceeds from Related Party Debt | $

$ 348,750

$ 0

Debt, Default Interest Rate

18%

Class of Warrant or Rights, Granted (in Shares) | shares

6,300,000

1,585,000

29,820,000

6,582,382

Warrants and Rights Outstanding, Term

5 years

5 years

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares

$ 0.75

$ 0.75

$ 0.75

Stock Issued During Period, Shares, Other (in Shares) | shares

637,953

1,720,000

2,151,204

Debt Instrument, Maturity Date, Description

maturity date that is the earlier of (i) six (6) months from the date of execution, or (ii) the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in Shares) | shares

0

14,295,000

14,886,000

Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share) | $ / shares

$ 0.03

$ 0.05

$ 0

$ 0.26

[1]

$ 0.03

[1]

Stock Issued During Period, Shares, Issued for Services (in Shares) | shares

312,800

1,962

300,000

386,985

2,901,440

Shares Issued, Price Per Share (in Dollars per share) | $ / shares

$ 0.25

$ 0.01

$ 0.31

$ 0.0305

$ 0.034

$ 0.25

$ 0.0305

$ 0.25

$ 0.26

$ 0.25

Stock Issued During Period, Value, Issued for Services | $

$ 78,200

222,480

$ 222,480

$ 7,680

Debt Instrument, Maturity Date

Jun. 30, 2022

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures (in Shares) | shares

4,500,000

Share-Based Payment Arrangement, Expense | $

$ 49,290

$ 176,229

24,645

(in Dollars per share) | $ / shares

$ 0.03

Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture (in Shares) | shares

312,800

Share-Based Payment Arrangement, Noncash Expense | $

$ 168,527

232,430

1,039,843

568,363

Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited (in Shares) | shares

400,000

Dividends, Preferred Stock | $

79,692

20,499

185,202

75,535

Series X Preferred Stock [Member]

Related Party Transactions (Details) [Line Items]

Dividends Payable | $

$ 0

61,818

0

Dividends, Preferred Stock | $

$ 16,392

0

65,568

Common Stock Dividends, Shares (in Shares) | shares

2,151,204

Dividends, Preferred Stock, Stock | $

$ 65,568

Chief Executive Officer [Member]

Related Party Transactions (Details) [Line Items]

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures (in Shares) | shares

1,500,000

Officer [Member]

Related Party Transactions (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

10%

Officer [Member] | Series X Preferred Stock [Member]

Related Party Transactions (Details) [Line Items]

Dividends Payable | $

7,890

Majority Shareholder [Member] | Series X Preferred Stock [Member]

Related Party Transactions (Details) [Line Items]

Dividends Payable | $

30,827

Investor [Member] | Series X Preferred Stock [Member]

Related Party Transactions (Details) [Line Items]

Dividends Payable | $

$ 23,101

Issued to Each Related Party [Member]

Related Party Transactions (Details) [Line Items]

Share-Based Payment Arrangement, Expense | $

$ 24,645

49,290

Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period

10 years

(in Dollars per share) | $ / shares

0.03

President [Member]

Related Party Transactions (Details) [Line Items]

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures (in Shares) | shares

1,500,000

Share-Based Payment Arrangement, Noncash Expense | $

11,909

Director [Member]

Related Party Transactions (Details) [Line Items]

Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share) | $ / shares

0.03

$ 0.05

Share-Based Payment Arrangement, Expense | $

$ 56,037

56,067

Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture (in Shares) | shares

1,000,000

Director [Member] | June 1, 2020 [Member]

Related Party Transactions (Details) [Line Items]

Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share) | $ / shares

$ 0.03

Share-Based Payment Arrangement, Expense | $

$ 28,460

Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period

10 years

Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture (in Shares) | shares

1,000,000

Related Party [Member] | Series X Preferred Stock [Member]

Related Party Transactions (Details) [Line Items]

Stock Issued During Period, Shares, Other (in Shares) | shares

26,227

Common Stock Dividends, Shares (in Shares) | shares

1,025,514

Dividends, Preferred Stock, Stock | $

$ 31,528

Restricted Stock [Member]

Related Party Transactions (Details) [Line Items]

Share-Based Payment Arrangement, Noncash Expense | $

67,623

Restricted Stock [Member] | Board Member [Member]

Related Party Transactions (Details) [Line Items]

Share-Based Payment Arrangement, Noncash Expense | $

32,614

Share-Based Payment Arrangement, Option [Member]

Related Party Transactions (Details) [Line Items]

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in Shares) | shares

3,000,000

Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share) | $ / shares

$ 0.25

Share-Based Payment Arrangement, Noncash Expense | $

$ 167,015

Share-Based Payment Arrangement, Option [Member] | Chief Executive Officer [Member]

Related Party Transactions (Details) [Line Items]

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in Shares) | shares

1,500,000

Share-Based Payment Arrangement, Option [Member] | Chief Financial Officer [Member]

Related Party Transactions (Details) [Line Items]

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in Shares) | shares

750,000

Share-Based Payment Arrangement, Option [Member] | Chief Legal Officer [Member]

Related Party Transactions (Details) [Line Items]

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in Shares) | shares

750,000

Chief Executive Officer [Member]

Related Party Transactions (Details) [Line Items]

Debt Instrument, Face Amount | $

$ 235,294

$ 175,000

Debt Instrument, Interest Rate, Stated Percentage

10%

10%

Proceeds from Related Party Debt | $

$ 200,000

$ 148,750

Debt, Default Interest Rate

18%

Class of Warrant or Rights, Granted (in Shares) | shares

200,000

Debt Instrument, Maturity Date, Description

maturity date that is the earlier of (i) six (6) months from the date of execution, or (ii) the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE

Chief Executive Officer [Member] | Warrants at $0.50 [Member]

Related Party Transactions (Details) [Line Items]

Class of Warrant or Rights, Granted (in Shares) | shares

367,500

Warrants and Rights Outstanding, Term

5 years

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares

$ 0.50

Chief Executive Officer [Member] | Warrants at $0.75 [Member]

Related Party Transactions (Details) [Line Items]

Class of Warrant or Rights, Granted (in Shares) | shares

367,500

Warrants and Rights Outstanding, Term

5 years

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares

$ 0.75

Chief Executive Officer [Member] | Issued to Each Related Party [Member]

Related Party Transactions (Details) [Line Items]

Share-Based Payment Arrangement, Expense | $

$ 58,743

Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture (in Shares) | shares

1,000,000

Chief Executive Officer [Member] | Restricted Stock [Member]

Related Party Transactions (Details) [Line Items]

Stock Issued During Period, Shares, Other (in Shares) | shares

192,000

Director [Member]

Related Party Transactions (Details) [Line Items]

Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share) | $ / shares

$ 0.03

$ 0.05

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures (in Shares) | shares

2,000,000

Number of Directors

2

Share-Based Payment Arrangement, Expense | $

$ 9,860

$ 78,324

9,860

Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period

3 years

Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture (in Shares) | shares

400,000

Director [Member] | Issued to Each Related Party [Member]

Related Party Transactions (Details) [Line Items]

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures (in Shares) | shares

1,000,000

Share-Based Payment Arrangement, Expense | $

$ 2,465

$ 39,162

2,465

Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture (in Shares) | shares

100,000

Each Consultant [Member] | Issued to Each Related Party [Member]

Related Party Transactions (Details) [Line Items]

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures (in Shares) | shares

1,500,000

Share-Based Payment Arrangement, Expense | $

$ 58,743

Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture (in Shares) | shares

2,000,000

President [Member]

Related Party Transactions (Details) [Line Items]

Share-Based Payment Arrangement, Expense | $

$ (1,632)

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period (in Shares) | shares

1,500,000

President [Member] | Issued to Each Related Party [Member]

Related Party Transactions (Details) [Line Items]

Share-Based Payment Arrangement, Expense | $

$ 58,743

Investor [Member] | Series X Preferred Stock [Member]

Related Party Transactions (Details) [Line Items]

Dividends Payable | $

$ 26,310

26,310

Common Stock Dividends, Shares (in Shares) | shares

863,212

Dividends, Preferred Stock, Stock | $

$ 26,310

Investor [Member] | Director [Member] | Accounts Payable [Member]

Related Party Transactions (Details) [Line Items]

Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share) | $ / shares

$ 0.03

Management [Member] | Restricted Stock [Member]

Related Party Transactions (Details) [Line Items]

Share-Based Payment Arrangement, Noncash Expense | $

15,856

Board Member [Member]

Related Party Transactions (Details) [Line Items]

Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture (in Shares) | shares

1,000,000

Board Member [Member] | Restricted Stock [Member] | Issued to Each Related Party [Member]

Related Party Transactions (Details) [Line Items]

Share-Based Payment Arrangement, Noncash Expense | $

7,135

Former President [Member]

Related Party Transactions (Details) [Line Items]

Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture (in Shares) | shares

250,000

Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited (in Shares) | shares

750,000

Officers and Directors [Member] | Series X Preferred Stock [Member]

Related Party Transactions (Details) [Line Items]

Dividends Payable | $

8,000

8,000

Majority Shareholder [Member] | Series X Preferred Stock [Member]

Related Party Transactions (Details) [Line Items]

Dividends Payable | $

$ 31,258

$ 31,258

Officer [Member] | Series X Preferred Stock [Member]

Related Party Transactions (Details) [Line Items]

Common Stock Dividends, Shares (in Shares) | shares

262,478

Dividends, Preferred Stock, Stock | $

$ 8,000

[1]On December 14, 2020, the Company reset the exercise price of all the options then outstanding options to $0.03 per share. This included 150,000 options previously priced at $0.04 per share; 7,450,000 options previously priced at $0.05 per share; 1,000,000 options previously priced at $0.06 per share; and 67,879 options previously prices at $21.40 per share. The Company valued these options as of December 14, 2020, at the original exercise price and at the new price of $0.03 per share and charged the increase in value in the amount of $4,113 to operations during the year ended December 31, 2020. The exercise prices of all options are shown at the restated price of $0.03 per share.

Accounts Payable and Accrued _3

Accounts Payable and Accrued Liabilities (Details) - Schedule of Accounts Payable and Accrued Liabilities - USD ($)	Mar. 31, 2022	Jan. 07, 2022	Jan. 05, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of Accounts Payable and Accrued Liabilities [Abstract]
Trade accounts payable	$ 4,890,066			$ 3,933,305	$ 824,405
Accrued payroll and payroll taxes	96,641			23,554	244,926
Other	17,928	$ 294,912.56	$ 294,912	19,205	0
Total accounts payable and accrued liabilities	$ 5,004,635			$ 3,976,064	$ 1,069,331

Right to Use Assets and Lease_3

Right to Use Assets and Lease Liabilities - Operating Leases (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Disclosure Text Block [Abstract]
Operating Lease, Weighted Average Remaining Lease Term	7 years 3 months 18 days		7 years 6 months
Operating Lease, Expense	$ 230,973	$ 10,642	$ 351,854	$ 10,642
Operating Lease, Right-of-Use Asset, Amortization Expense	$ 267,463	$ 4,318	$ 162,276	4,318
Lessee, Operating Lease, Discount Rate	12%		12%
Operating Lease, Liability	$ 4,146,960		$ 4,134,802	321,004
Operating Lease, Right-of-Use Asset	$ 3,619,403		$ 3,886,866	$ 310,361

Right to Use Assets and Lease_4

Right to Use Assets and Lease Liabilities - Operating Leases (Details) - Lease, Cost - USD ($)	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Lease, Cost [Abstract]
Right to use assets, net	$ 3,619,403	$ 3,886,866	$ 310,361
Lease liability	4,146,960	4,134,802	321,004
Less: current portion	(276,639)	(161,838)	(8,905)
Lease liability, non-current	$ 3,870,321	$ 3,972,964	$ 312,099

Right to Use Assets and Lease_5

Right to Use Assets and Lease Liabilities - Operating Leases (Details) - Lessee, Operating Lease, Liability, Maturity - USD ($)	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Lessee, Operating Lease, Liability, Maturity [Abstract]
For the twelve months ended March 31, 2023	$ 763,580	$ 652,653
For the twelve months ended March 31, 2024	874,687	888,152
For the twelve months ended March 31, 2025	827,773	821,296
For the twelve months ended March 31, 2026	846,523	841,600
For the twelve months ended March 31, 2027	865,517	860,551
Thereafter	2,251,381	2,478,412
Total	6,429,461	6,542,664
Less: Present value discount	(2,282,501)	(2,407,862)
Lease liability	$ 4,146,960	$ 4,134,802	$ 321,004

Debt (Details)

Debt (Details) - USD ($)

3 Months Ended

12 Months Ended

Mar. 18, 2022

Feb. 14, 2022

Jan. 07, 2022

Dec. 30, 2021

Jun. 23, 2021

Mar. 30, 2021

Mar. 25, 2021

Mar. 24, 2021

Feb. 05, 2021

Jan. 28, 2021

Jan. 21, 2021

Jan. 14, 2021

Jan. 11, 2021

Jan. 06, 2021

Jan. 04, 2021

Oct. 15, 2020

Mar. 31, 2022

Mar. 31, 2021

Dec. 31, 2021

Dec. 31, 2020

Apr. 25, 2022

Jan. 05, 2022

Nov. 10, 2021

Oct. 18, 2021

May 04, 2020

Apr. 25, 2020

Debt (Details) [Line Items]

Debt Instrument, Face Amount

$ 1,000,000

$ 460,000

Debt Instrument, Interest Rate, Stated Percentage

10%

Debt Instrument, Maturity Date, Description

maturity date that is the earlier of (i) six (6) months from the date of execution, or (ii) the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE

Proceeds from Issuance of Debt

$ 850,000

$ 675,000

$ 0

$ 0

$ 1,673,406

Debt Instrument, Unamortized Discount

150,000

756,795

Debt, Default Interest Rate

18%

Notes Payable

1,048,838

899,977

Amortization of Debt Discount (Premium)

$ 231,180

756,795

$ 756,795

$ 1,128,885

Class of Warrant or Rights, Granted (in Shares)

6,300,000

1,585,000

29,820,000

6,582,382

Warrant or Right, Reason for Issuance, Description

entitling the Lender to purchase (i) 2,100,000 shares of the Borrower’s common stock on substantially the same terms as the Series A warrant issued in connection with the Borrower’s Series D Convertible Preferred Stock, and (ii) 2,100,000 shares of the Borrower’s common stock on substantially the same terms as the Series B warrant issued in connection with the Borrower’s Series D Convertible Preferred Stock. one warrant (the “Series A Warrants”) to purchase 2.1 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”) at a purchase price of $0.50 per whole share of Common Stock, and one warrant (the “Series B Warrants” and together with the Series A Warrants, the “Warrants”) to purchase 2.1 shares of Common Stock at a purchase price of $0.75 per whole share

Adjustments to Additional Paid in Capital, Warrant Issued

$ 2,914

$ 261,568

Warrants and Rights Outstanding, Term

5 years

5 years

Stock Issued During Period, Shares, Other (in Shares)

637,953

1,720,000

2,151,204

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 0.75

$ 0.75

$ 0.75

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

3,179,650

63,374,555

Debt Conversion, Original Debt, Amount

$ 0

2,653,795

0

$ 1,633,406

Gain (Loss) on Extinguishment of Debt

0

$ 1,836

1,836

$ 35,236

Debt Instrument, Convertible, Conversion Price (in Dollars per share)

$ 0.25

$ 0.25

Commitments [Member]

Debt (Details) [Line Items]

Stock Issued During Period, Value, Other

243,306

Howe Note [Member]

Debt (Details) [Line Items]

Debt Instrument, Face Amount

$ 1,000,000

Debt Instrument, Interest Rate, Stated Percentage

10%

Debt Instrument, Maturity Date, Description

maturity date that is the earlier of (i) six (6) months from the date of execution, or (ii) the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE

Proceeds from Issuance of Debt

$ 850,000

Debt Instrument, Unamortized Discount

$ 261,568

75,824

Debt, Default Interest Rate

18%

Notes Payable

1,000,000

Amortization of Debt Discount (Premium)

74,176

Class of Warrant or Rights, Granted (in Shares)

2

Warrant or Right, Reason for Issuance, Description

entitling the Lender to purchase (i) 2,100,000 shares of the Borrower’s common stock on substantially the same terms as the Series A warrant issued in connection with the Borrower’s Series D Convertible Preferred Stock, and (ii) 2,100,000 shares of the Borrower’s common stock on substantially the same terms as the Series B warrant issued in connection with the Borrower’s Series D Convertible Preferred Stock. one warrant (the “Series A Warrants”) to purchase 2.1 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”) at a purchase price of $0.50 per whole share of Common Stock, and  one warrant (the “Series B Warrants” and together with the Series A Warrants, the “Warrants”) to purchase 2.1 shares of Common Stock at a purchase price of $0.75 per whole share

Debt Original Issue Discount Rate

18%

Howe Note [Member] | Original Issue Discount [Member]

Debt (Details) [Line Items]

Debt Instrument, Unamortized Discount

$ 150,000

Diamond Note [Member]

Debt (Details) [Line Items]

Debt Instrument, Face Amount

$ 175,000

Debt Instrument, Interest Rate, Stated Percentage

10%

Proceeds from Issuance of Debt

$ 148,750

Debt, Default Interest Rate

18%

Warrant or Right, Reason for Issuance, Description

Lender will be issued 367,500 5-year warrants that may be exercised at $.50 per share and 367,500 5-year warrants that may be exercised at $.75 per share

Adjustments to Additional Paid in Capital, Warrant Issued

$ 2,914

Diamond Note 2 [Member]

Debt (Details) [Line Items]

Debt Instrument, Face Amount

$ 235,294

Debt Instrument, Interest Rate, Stated Percentage

10%

Debt Instrument, Maturity Date, Description

maturity date that is the earlier of (i) April 4, 2022, (ii) the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE, or (iii) the date of receipt of the Company of the next round of debt or equity financing in an amount of at least $1,000,000

Proceeds from Issuance of Debt

$ 200,000

Debt, Default Interest Rate

18%

Class of Warrant or Rights, Granted (in Shares)

200,000

Adjustments to Additional Paid in Capital, Warrant Issued

$ 2,213

2,213

Warrants and Rights Outstanding, Term

5 years

AJB Capital Note [Member]

Debt (Details) [Line Items]

Debt Instrument, Face Amount

$ 750,000

Proceeds from Issuance of Debt

675,000

Debt Instrument, Unamortized Discount

$ 75,000

349,914

Class of Warrant or Rights, Granted (in Shares)

750,000

Adjustments to Additional Paid in Capital, Warrant Issued

$ 24,952

Debt Instrument, Fee

Commitment Fee Shares can be decreased to 720,000 shares ($180,000) if the Company repays the Note on or prior its maturity

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 0.5

Proceeds from Debt, Net of Issuance Costs

$ 616,250

AJB Capital Note [Member] | Commitments [Member]

Debt (Details) [Line Items]

Stock Issued During Period, Value, Other

$ 430,000

Stock Issued During Period, Shares, Other (in Shares)

1,720,000

PPP Loan [Member]

Debt (Details) [Line Items]

Debt Instrument, Face Amount

$ 460,000

$ 460,000

$ 460,000

Notes Payable

$ 460,406

$ 460,406

Series C Debenture [Member]

Debt (Details) [Line Items]

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

272,837

Debt Conversion, Original Debt, Amount

$ 122,166

Gain (Loss) on Extinguishment of Debt

3,035

Series C Debenture [Member] | Principal [Member]

Debt (Details) [Line Items]

Debt Conversion, Original Debt, Amount

110,833

Series C Debenture [Member] | Accrued Interest [Member]

Debt (Details) [Line Items]

Debt Conversion, Original Debt, Amount

71,526

Series D Debenture [Member] | Principal [Member]

Debt (Details) [Line Items]

Debt Conversion, Original Debt, Amount

11,333

Series D Debenture [Member] | Accrued Interest [Member]

Debt (Details) [Line Items]

Debt Conversion, Original Debt, Amount

$ 8,722

Convertible Note A [Member]

Debt (Details) [Line Items]

Gain (Loss) on Extinguishment of Debt

$ 1,201

Repayments of Debt

55,368

Convertible Note A [Member] | Principal [Member]

Debt (Details) [Line Items]

Repayments of Debt

41,000

Convertible Note A [Member] | Accrued Interest [Member]

Debt (Details) [Line Items]

Repayments of Debt

$ 13,167

Eagle Equities Note 4 [Member]

Debt (Details) [Line Items]

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

3,505,964

4,123,750

Debt Instrument, Convertible, Conversion Price (in Dollars per share)

$ 0.01224

$ 0.012

Eagle Equities Note 4 [Member] | Principal [Member]

Debt (Details) [Line Items]

Debt Conversion, Original Debt, Amount

$ 39,000

$ 45,000

Eagle Equities Note 4 [Member] | Accrued Interest [Member]

Debt (Details) [Line Items]

Debt Conversion, Original Debt, Amount

$ 3,913

$ 4,485

Eagle Equities Note 5 [Member]

Debt (Details) [Line Items]

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

4,319,378

4,463,507

Debt Instrument, Convertible, Conversion Price (in Dollars per share)

$ 0.01266

$ 0.01224

Eagle Equities Note 5 [Member] | Principal [Member]

Debt (Details) [Line Items]

Debt Conversion, Original Debt, Amount

$ 50,000

$ 50,000

Eagle Equities Note 5 [Member] | Accrued Interest [Member]

Debt (Details) [Line Items]

Debt Conversion, Original Debt, Amount

$ 4,683

$ 4,633

Eagle Equities Note 6 [Member]

Debt (Details) [Line Items]

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

7,285,062

6,449,610

Debt Instrument, Convertible, Conversion Price (in Dollars per share)

$ 0.01575

$ 0.0154

Eagle Equities Note 6 [Member] | Principal [Member]

Debt (Details) [Line Items]

Debt Conversion, Original Debt, Amount

$ 107,200

$ 93,000

Eagle Equities Note 6 [Member] | Accrued Interest [Member]

Debt (Details) [Line Items]

Debt Conversion, Original Debt, Amount

$ 7,540

$ 6,324

Eagle Equities Note 7 [Member]

Debt (Details) [Line Items]

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

1,184,148

Debt Conversion, Original Debt, Amount

$ 200,200

Debt Instrument, Convertible, Conversion Price (in Dollars per share)

$ 0.24984

Eagle Equities Note 7 [Member] | Principal [Member]

Debt (Details) [Line Items]

Debt Conversion, Original Debt, Amount

$ 200,200

Eagle Equities Note 8 [Member]

Debt (Details) [Line Items]

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

639,593

Debt Conversion, Original Debt, Amount

$ 114,400

Debt Instrument, Convertible, Conversion Price (in Dollars per share)

$ 0.23851

Eagle Equities Note 8 [Member] | Principal [Member]

Debt (Details) [Line Items]

Debt Conversion, Original Debt, Amount

$ 114,400

Eagle Equities Note 9 [Member]

Debt (Details) [Line Items]

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

605,177

Debt Conversion, Original Debt, Amount

$ 114,400

Debt Instrument, Convertible, Conversion Price (in Dollars per share)

$ 0.24984

Eagle Equities Note 9 [Member] | Principal [Member]

Debt (Details) [Line Items]

Debt Conversion, Original Debt, Amount

$ 114,400

Eagle Equities Note 10 [Member]

Debt (Details) [Line Items]

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

1,095,131

Debt Conversion, Original Debt, Amount

$ 200,200

Debt Instrument, Convertible, Conversion Price (in Dollars per share)

$ 0.23748

Eagle Equities Note 10 [Member] | Principal [Member]

Debt (Details) [Line Items]

Debt Conversion, Original Debt, Amount

$ 200,200

Debt (Details) - Schedule of De

Debt (Details) - Schedule of Debt - Notes Payable, Other Payables [Member] - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Debt (Details) - Schedule of Debt [Line Items]
Notes Payable, Gross	$ 2,160,294	$ 1,000,000
	2,620,700	1,460,406
Less: Discount	(671,973)	(411,568)
Notes payable - net of discount	1,948,727	1,048,838
Current Portion, net of discount	1,948,727	1,048,838
Long-term portion, net of discount	0	0
PPP Loan [Member]
Debt (Details) - Schedule of Debt [Line Items]
Notes Payable, Gross	$ 460,406	$ 460,406

Stockholders' Equity (Deficit_2

Stockholders' Equity (Deficit) (Details)																																									1 Months Ended			3 Months Ended		12 Months Ended
	May 10, 2022 USD ($) $ / shares shares	Apr. 27, 2022 shares	Apr. 18, 2022 USD ($) $ / shares shares	Apr. 06, 2022 shares	Apr. 01, 2022 shares	Mar. 31, 2022 USD ($) $ / shares shares	Mar. 18, 2022 USD ($) $ / shares shares	Mar. 17, 2022 shares	Jan. 12, 2022 USD ($) shares	Jan. 07, 2022 USD ($) $ / shares shares	Jan. 05, 2022 USD ($) $ / shares shares	Nov. 19, 2021 USD ($) $ / shares	Nov. 10, 2021 USD ($) $ / shares shares	Oct. 18, 2021 USD ($) $ / shares shares	Aug. 26, 2021 USD ($) $ / shares shares	Aug. 17, 2021 USD ($) shares	Jun. 23, 2021 $ / shares shares	May 12, 2021 $ / shares shares	Apr. 19, 2021 $ / shares shares	Mar. 25, 2021 USD ($) $ / shares shares	Mar. 23, 2021 $ / shares shares	Mar. 17, 2021 $ / shares shares	Mar. 11, 2021 USD ($) $ / shares shares	Feb. 22, 2021 $ / shares shares	Feb. 05, 2021 USD ($) $ / shares shares	Feb. 01, 2021 USD ($) $ / shares shares	Jan. 28, 2021 USD ($) $ / shares shares	Jan. 21, 2021 USD ($) $ / shares shares	Jan. 14, 2021 USD ($) $ / shares shares	Jan. 11, 2021 USD ($) $ / shares shares	Jan. 06, 2021 USD ($) $ / shares shares	Jan. 04, 2021 USD ($) $ / shares shares	Dec. 31, 2020 USD ($) $ / shares shares	Dec. 14, 2020 USD ($) $ / shares shares	Aug. 27, 2020 USD ($) shares	May 27, 2020 USD ($) shares	Mar. 02, 2020 USD ($) $ / shares shares	Feb. 19, 2020 USD ($) shares	Jan. 29, 2020 USD ($) shares	Jan. 02, 2020 USD ($) shares	Sep. 02, 2021 $ / shares shares	Jun. 29, 2021 $ / shares shares	May 26, 2021 $ / shares shares	Mar. 31, 2022 USD ($) $ / shares shares	Mar. 31, 2021 USD ($) shares	Dec. 31, 2021 USD ($) $ / shares shares		Dec. 31, 2020 USD ($) $ / shares shares	Jun. 30, 2022 $ / shares	Dec. 31, 2019 $ / shares
Stockholders' Equity (Deficit) (Details) [Line Items]
Common Stock, Shares Authorized						500,000,000																											500,000,000											500,000,000		500,000,000		500,000,000
Common Stock, Par or Stated Value Per Share (in Dollars per share) | $ / shares						$ 0.01											$ 0.01																$ 0.01											$ 0.01		$ 0.01		$ 0.01	$ 0.01
Common Stock, Shares, Issued						219,756,894																											155,381,183											219,756,894		213,333,170		155,381,183
Accrued Salaries, Current (in Dollars) | $									$ 19,032
Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited									400,000
Shares Issued, Value, Share-Based Payment Arrangement, Forfeited (in Dollars) | $									$ 4,000
Gains (Losses) on Restructuring of Debt (in Dollars) | $									$ 15,032																											$ 24,894								$ 15,032	$ 0	$ 0		$ 6,988
Debt Conversion, Converted Instrument, Amount (in Dollars) | $											$ 500,000
Other Accrued Liabilities, Current (in Dollars) | $						$ 17,928				$ 294,912.56	$ 294,912																						$ 0											$ 17,928		19,205		$ 0
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares										$ 0.25	$ 0.25
Debt Conversion, Converted Instrument, Shares Issued										3,179,650																																						63,374,555
Stock Issued During Period, Shares, Other																	637,953																											1,720,000				2,151,204
Shares Issued, Price Per Share (in Dollars per share) | $ / shares						$ 0.25									$ 0.25				$ 0.01		$ 0.26	$ 0.31				$ 0.25							$ 0.0305										$ 0.25	$ 0.25				$ 0.0305		$ 0.034
Other Nonoperating Income (in Dollars) | $																																												$ 198,273		0		$ 3,000
Share Price (in Dollars per share) | $ / shares						$ 0.25																																						$ 0.25
Derivative Liability (in Dollars) | $						$ 26,771					$ 106,608																																	$ 26,771
Debt Instrument, Unamortized Discount (in Dollars) | $																																	$ 756,795													150,000		756,795
Adjustments to Additional Paid in Capital, Other (in Dollars) | $																																												226,106
Debt Conversion, Original Debt, Amount (in Dollars) | $																																												$ 0	2,653,795	0		$ 1,633,406
Stock Issued During Period, Shares, New Issues																					461,358					6,672,000
Stock Issued During Period, Value, New Issues (in Dollars) | $																										$ 1,668,000																			1,668,000	$ 1,668,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period																		2,500,000						336,000	336,000																	5,116,668				8,652,668
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (in Dollars per share) | $ / shares																		$ 0.03						$ 0.03	$ 0.03																	$ 0.03				$ 0.03	[1]
Conversion of Stock, Shares Issued																							600,000																		4,000,001		4,237,424
Number of Individuals																							4
Conversion of Stock, Shares Converted																							4,800																				1,059,356
Stock Issued During Period, Shares, Issued for Services															312,800				1,962			300,000													386,985	2,901,440
Preferred Stock, Shares Authorized						100,000,000								10,000,000																			100,000,000											100,000,000		100,000,000		100,000,000
Dividends, Preferred Stock (in Dollars) | $																																												$ 79,692	20,499	$ 185,202		$ 75,535
Stock Issued During Period, Value, Conversion of Convertible Securities (in Dollars) | $																																														$ 2,653,795		$ 21,656
Class of Warrant or Right, Number of Securities Called by Warrants or Rights													2,257,500	4,252,500						12,600,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares													$ 0.75	$ 0.75						$ 0.75
Warrants and Rights Outstanding, Term														5 years						5 years
Class of Warrant or Rights, Granted																				6,300,000																								1,585,000		29,820,000		6,582,382
Proceeds from Issuance or Sale of Equity (in Dollars) | $																				$ 3,000,000
Share-Based Payment Arrangement, Noncash Expense (in Dollars) | $																																												$ 168,527	232,430	$ 1,039,843		$ 568,363
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount (in Dollars) | $																																	$ 3,154,383															$ 3,154,383
Common Stock, Shares, Outstanding						219,756,894																											155,381,183											219,756,894		213,333,170		155,381,183
Stock Repurchased and Retired During Period, Shares																	2,000,000
Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture															312,800
Shares Issued, Value, Share-Based Payment Arrangement, before Forfeiture (in Dollars) | $															$ 78,200
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition (in Dollars) | $																																														$ 13,032
APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition (in Dollars) | $																																												$ 167,015	5,942	$ 676,423		$ 421,502
Class of Warrants, Exercised																																												0		0		(8,382,382)
Other Nonoperating Gains (Losses) (in Dollars) | $																																												$ 198,273	0
Number of Transactions																																																19
Stock Issued During Period, Value, Issued for Services (in Dollars) | $															$ 78,200																														222,480	$ 222,480		$ 7,680
Gain on Settlement of Accounts Payable and Accrued Liabilities (in Dollars) | $																																			$ 6,988									$ (78,235)	$ 0	$ 0		399,761
APIC, Share-Based Payment Arrangement, Other, Increase for Cost Recognition (in Dollars) | $																																																$ (421,502)
Preferred Stock Dividends, Shares																																	2,151,204
Units Sold																				3,000,000
Unit Price Per Unit (in Dollars per share) | $ / shares																				$ 1
Unit Description												(a) one share of a newly formed Series D Convertible Preferred Stock, par value $0.01 per share (the “Series D Preferred Stock”), (b) one warrant (the “Series A Warrants”) to purchase 2.1 shares of the Company’s Common Stock at a purchase price of $0.50 per whole share of Common Stock, and (c) one warrant (the “Series B Warrants” and together with the Series A Warrants, the “Warrants”) to purchase 2.1 shares of Common Stock at a purchase price of $0.75 per whole share								each Unit consisting of (a) one share of a newly formed Series C Convertible Preferred Stock, par value $0.01 per share (the “Series C Preferred Stock”), (b) one warrant (the “Series A Warrants”) to purchase 2.1 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”) at a purchase price of $0.50 per whole share of Common Stock, and (c) one warrant (the “Series B Warrants” and together with the Series A Warrants, the “Warrants”) to purchase 2.1 shares of Common Stock at a purchase price of $0.75 per whole share
(in Dollars per share) | $ / shares																																		$ 0.03
Loss on modification of options (in Dollars) | $																																		$ 4,113
Stock Subscribed [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Stock Issued During Period, Shares, Other																																												382,353
Common Stock [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited																																												(400,000)
Stock Issued During Period, Shares, Other																																												382,353		479,464		7,999,996
Stock Issued During Period, Shares, New Issues																																													6,672,000	6,672,000
Stock Issued During Period, Value, New Issues (in Dollars) | $																																													$ 66,750	$ 66,750
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period																																														8,281,668
Stock Issued During Period, Shares, Issued for Services																																													1,097,358	1,099,320		200,000
Stock Issued During Period, Value, Conversion of Convertible Securities (in Dollars) | $																																														$ 339,442		$ 3,869
Stock Issued During Period, Shares, Conversion of Convertible Securities																																														33,944,157		386,985
Stock Issued During Period, Value, Issued for Services (in Dollars) | $																																													$ 10,961	$ 10,963		$ 2,000
Gain on Settlement of Accounts Payable and Accrued Liabilities (in Dollars) | $																																												$ (4,000)
Minimum [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares																																	$ 0.0108															$ 0.0108
Maximum [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares																																	$ 0.012															$ 0.012
Options Exercise Price $0.04 [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
(in Dollars per share) | $ / shares																																		$ 0.04
Options Modified																																		150,000
Options Exercise Price $0.05 [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
(in Dollars per share) | $ / shares																																		$ 0.05
Options Modified																																		7,450,000
Options Exercise Price $0.06 [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
(in Dollars per share) | $ / shares																																		$ 0.06
Options Modified																																		1,000,000
Options Exercise Price $12.40 [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
(in Dollars per share) | $ / shares																																		$ 21.4
Options Modified																																		67,879
Principal [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Debt Conversion, Original Debt, Amount (in Dollars) | $																																																$ 813,000
Accrued Interest [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Debt Conversion, Original Debt, Amount (in Dollars) | $																																																70,658
Agreement with Investors Regarding Exercise Price of Warrants [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities																																							1,000,000
Class of Warrants, Exercised																																							2,769,482
Other Nonoperating Gains (Losses) (in Dollars) | $																																							$ 77,652
Cashless Exercise of Warrants [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities																																						4,098,556
Class of Warrants, Exercised																																						4,480,938
Other Nonoperating Gains (Losses) (in Dollars) | $																																						$ 182,295
Additional Shares for Variable Conversion Feature on Warrants [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Stock Issued During Period, Shares, New Issues																																				1,011,967
AJB Capital Note [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Debt Instrument, Unamortized Discount (in Dollars) | $						$ 349,914	$ 75,000																																					349,914
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares							$ 0.5
Class of Warrant or Rights, Granted							750,000
Accounts Payable [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Debt Conversion, Original Debt, Amount (in Dollars) | $																																												$ 95,558
Eagle Equities Note 4 [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares																															$ 0.01224	$ 0.012
Debt Conversion, Converted Instrument, Shares Issued																															3,505,964	4,123,750
Eagle Equities Note 4 [Member] | Principal [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Debt Conversion, Original Debt, Amount (in Dollars) | $																															$ 39,000	$ 45,000
Eagle Equities Note 4 [Member] | Accrued Interest [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Debt Conversion, Original Debt, Amount (in Dollars) | $																															$ 3,913	$ 4,485
Eagle Equities Note 5 [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares																													$ 0.01266	$ 0.01224
Debt Conversion, Converted Instrument, Shares Issued																													4,319,378	4,463,507
Eagle Equities Note 5 [Member] | Principal [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Debt Conversion, Original Debt, Amount (in Dollars) | $																													$ 50,000	$ 50,000
Eagle Equities Note 5 [Member] | Accrued Interest [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Debt Conversion, Original Debt, Amount (in Dollars) | $																													$ 4,683	4,633
Eagle Equities Note 6 [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares																											$ 0.01575	$ 0.0154
Debt Conversion, Converted Instrument, Shares Issued																											7,285,062	6,449,610
Eagle Equities Note 6 [Member] | Principal [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Debt Conversion, Original Debt, Amount (in Dollars) | $																											$ 107,200	$ 93,000		93,000
Eagle Equities Note 6 [Member] | Accrued Interest [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Debt Conversion, Original Debt, Amount (in Dollars) | $																											$ 7,540	$ 6,324		$ 6,324
Eagle Equities Note 7 [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares																									$ 0.24984
Debt Conversion, Converted Instrument, Shares Issued																									1,184,148
Debt Conversion, Original Debt, Amount (in Dollars) | $																									$ 200,200
Stock Issued During Period, Shares, New Issues																									0.24984
Eagle Equities Note 8 [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares																									$ 0.23851
Debt Conversion, Converted Instrument, Shares Issued																									639,593
Debt Conversion, Original Debt, Amount (in Dollars) | $																									$ 114,400
Stock Issued During Period, Shares, New Issues																									0.23851
Eagle Equities Note 9 [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares																									$ 0.24984
Debt Conversion, Converted Instrument, Shares Issued																									605,177
Debt Conversion, Original Debt, Amount (in Dollars) | $																									$ 114,400
Stock Issued During Period, Shares, New Issues																									0.24984
Eagle Equities Note 10 [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares																									$ 0.23748
Debt Conversion, Converted Instrument, Shares Issued																									1,095,131
Debt Conversion, Original Debt, Amount (in Dollars) | $																									$ 200,200
Stock Issued During Period, Shares, New Issues																									0.23748
Valuation, Market Approach [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Share Price (in Dollars per share) | $ / shares						$ 0.12695																																						$ 0.12695
Restricted Stock [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued										3,179,650	3,179,650
Conversion of Stock, Shares Issued																							600,000
Series A Preferred Stock [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Shares Issued, Price Per Share (in Dollars per share) | $ / shares																																					$ 14.91
Adjustments to Additional Paid in Capital, Other (in Dollars) | $																							$ 206,242
Conversion of Stock, Shares Issued																							600,000
Number of Individuals																																					4
Stock Issued During Period, Shares, Issued for Services																																					4,800
Preferred Stock, Shares Authorized						500,000																																						500,000		500,000
Dividends, Preferred Stock (in Dollars) | $																																													1,000	$ 1,000
Conversion of Stock, Amount Converted (in Dollars) | $																							$ 71,558																					$ 0	$ 6,000	$ 6,000		$ 0
Preferred Stock, Convertible, Conversion Price (in Dollars per share) | $ / shares																							$ 0.463
Stock Issued During Period, Value, Conversion of Convertible Securities (in Dollars) | $																							$ 277,800
Preferred Stock, Shares Outstanding						0																											4,800											0		0		4,800
Preferred Stock, Par or Stated Value Per Share (in Dollars per share) | $ / shares						$ 0.01																											$ 0.01											$ 0.01		$ 0.01		$ 0.01
Preferred Stock, Dividend Payment Terms																																					issuance of 755,076 shares of common stock based upon the average price of $0.0132 per share for the five-day period ended December 31, 2020
Dividends Payable, Current (in Dollars) | $																																					$ 9,967
Stock Issued During Period, Value, Issued for Services (in Dollars) | $																																					$ 71,558											$ 71,558
Series A Preferred Stock [Member] | Common Stock [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Conversion of Stock, Shares Issued																																													600,000	600,000
Series C Preferred Stock [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Stock Issued During Period, Shares, New Issues																				3,000,000
Stock Issued During Period, Value, New Issues (in Dollars) | $																																													$ 1,491,283	$ 1,491,283
Conversion of Stock, Shares Issued																																									4,000,001		4,237,424
Conversion of Stock, Shares Converted																																									1,000,000		1,059,356
Preferred Stock, Shares Authorized						3,000,000																																						3,000,000		3,000,000
Dividends, Preferred Stock (in Dollars) | $																																														$ 87,059
Conversion of Stock, Amount Converted (in Dollars) | $																																														$ 61,781		$ 0
Preferred Stock, Convertible, Conversion Price (in Dollars per share) | $ / shares																																									$ 0.25		$ 0.25
Class of Warrant or Right, Number of Securities Called by Warrants or Rights													2,257,500							6,300,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares																				$ 0.5
Warrants and Rights Outstanding, Term																				5 years
Proceeds from Issuance or Sale of Equity (in Dollars) | $																				$ 3,000,000
Preferred Stock, Voting Rights																																												Voting Rights. Holders of the Series C Preferred Stock have the right to vote on any matter presented to holders of our Common Stock for their action or consideration at any meeting of the stockholders (or by written consent of stockholders in lieu of meeting), each holder of our Series C Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Series C preferred Stock held by such holder, as described below, are convertible as of the record date for determining stockholders entitled to vote on (or consent to) such matter, voting with the Common Stock as a single class.		Holders of the Series C Preferred Stock have the right to vote on any matter presented to holders of our Common Stock for their action or consideration at any meeting of the stockholders (or by written consent of stockholders in lieu of meeting), each holder of our Series C Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Series C preferred Stock held by such holder, as described below, are convertible as of the record date for determining stockholders entitled to vote on (or consent to) such matter, voting with the Common Stock as a single class.
Preferred Stock, Conversion Basis																																												Conversion. Each holder of our Series C Preferred Stock is entitled to convert their shares of Series C Preferred Stock, in whole or in part, at the Conversion Rate, which is determined by dividing the Conversion Amount (the Stated Value of $1.05, plus any accrued but unpaid dividends) by the Conversion Price ($0.25 per share). In addition, upon certain triggering events, the holders of our Series C Preferred Stock have the right to convert their Series C Preferred Stock at the lesser of the Conversion Price or 75% of the average VWAP for the five trading days prior to the date of the notice of conversion. The Conversion Price is subject to adjustment upon certain stock splits and recapitalization as well as upon the sale of Common Stock or Common Stock Equivalents. Each share of the Series C Preferred Stock is convertible at the option of the holder thereof, or automatically or upon the closing of an underwritten offering of at least $10 million of the Company’s securities or upon listing of the Company’s Common Stock on a national securities exchange.
Preferred Stock, Dividend Rate, Percentage																																												6%		6%
Preferred Stock, Redemption Terms																																												Redemption Rights. Upon receipt of a conversion notice, we have the right (but not the obligation) to redeem all or part of the Series C Preferred Stock (which the applicable holder of the Series C Preferred Stock is seeking to convert) at a price per share equal to the product of 125% of the (1) Stated Value plus (2) the Additional Amount (the “Redemption Price”). If we decide to exercise the redemption right, within one trading day, we shall deliver written notice to such holder(s) of Series C Preferred Stock that the Series C Preferred Stock will be redeemed (the “Redemption Notice”) on the date that is three trading days following the date of the Redemption Notice (such date, the “Redemption Date”). On the Redemption Date, we shall redeem the shares of Series C Preferred Stock specified in such request by paying in cash therefor a sum per share equal to the Redemption Price. In no event shall a Redemption Notice be given if we may not lawfully redeem our capital stock. On or before the Redemption Date, the Redemption Price for such shares shall be paid by wire transfer of immediately available funds to an account designated in writing by the applicable holder.		Upon receipt of a conversion notice, we have the right (but not the obligation) to redeem all or part of the Series C Preferred Stock (which the applicable holder of the Series C Preferred Stock is seeking to convert) at a price per share equal to the product of 125% of the (1) Stated Value plus (2) the Additional Amount (the “Redemption Price”). If we decide to exercise the redemption right, within one trading day, we shall deliver written notice to such holder(s) of Series C Preferred Stock that the Series C Preferred Stock will be redeemed (the “Redemption Notice”) on the date that is three trading days following the date of the Redemption Notice (such date, the “Redemption Date”). On the Redemption Date, we shall redeem the shares of Series C Preferred Stock specified in such request by paying in cash therefor a sum per share equal to the Redemption Price. In no event shall a Redemption Notice be given if we may not lawfully redeem our capital stock. On or before the Redemption Date, the Redemption Price for such shares shall be paid by wire transfer of immediately available funds to an account designated in writing by the applicable holder.
Preferred Stock, Shares Outstanding						940,644																											0											940,644		940,644		0
Preferred Stock, Par or Stated Value Per Share (in Dollars per share) | $ / shares						$ 0.01																											$ 0.01											$ 0.01		$ 0.01		$ 0.01
Preferred Stock, Dividend Payment Terms																																														Each share of Series C Preferred Stock accrues dividends on a quarterly basis in arrears, at the rate of 6% per annum of the Stated Value ($1.05 per share plus any accrued but unpaid dividends) and is to be paid within 15 days after the end of each of our fiscal quarters. Each holder of the Series C Preferred Stock is entitled to receive dividends or distributions on each share of the Series C Preferred Stock on an as converted into Common Stock basis when and if dividends are declared on the Common Stock by our Board of Directors.
Convertible Preferred Stock, Shares Issued upon Conversion																				12,600,000
Preferred Stock, Convertible, Terms																																														Each holder of our Series C Preferred Stock is entitled to convert their shares of Series C Preferred Stock, in whole or in part, at the Conversion Rate, which is determined by dividing the Conversion Amount (the Stated Value of $1.05, plus any accrued but unpaid dividends) by the Conversion Price ($0.25 per share). In addition, upon certain triggering events, the holders of our Series C Preferred Stock have the right to convert their Series C Preferred Stock at the lesser of the Conversion Price or 75% of the average VWAP for the five trading days prior to the date of the notice of conversion. The Conversion Price is subject to adjustment upon certain stock splits and recapitalization as well as upon the sale of Common Stock or Common Stock Equivalents. Each share of the Series C Preferred Stock is convertible at the option of the holder thereof, or automatically or upon the closing of an underwritten offering of at least $10 million of the Company’s securities or upon listing of the Company’s Common Stock on a national securities exchange
Preferred Stock, Preemptive Rights																																														Preemptive or Similar Rights Additionally, except for a public offering or certain exempt issuances of our securities, holders of the Series C Preferred Stock shall have the right to participate in any offering of our Common Stock or Common Stock Equivalents (as defined in the COD) in a transaction exempt from registration under the Securities Act in an amount equal to an aggregate of 30% of the financing on the same terms, conditions and price provided to investors in such an offering, such right shall expire on the 15 month anniversary of the issuance date of the Series C Preferred Stock. Further, until the earlier of 18 months from the issuance date of the Series C Preferred Stock and the date that there are less than 20% of the shares of Series C Preferred Stock outstanding, the Investors have most favored nations protection in the event we issue or sell Common Stock or Common Stock Equivalents that the Investors believe are more favorable than the terms and conditions under the Private Placement.
Series C Preferred Stock [Member] | Common Stock [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Conversion of Stock, Shares Issued																																														8,237,425
Series D Preferred Stock [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Stock Issued During Period, Shares, New Issues													1,075,000	2,050,000
Stock Issued During Period, Value, New Issues (in Dollars) | $																																														$ 1,719,018
Preferred Stock, Shares Authorized						10,000,000								10,000,000																														10,000,000		10,000,000
Dividends, Preferred Stock (in Dollars) | $																																														$ 35,327
Preferred Stock, Convertible, Conversion Price (in Dollars per share) | $ / shares														$ 0.25
Class of Warrant or Right, Number of Securities Called by Warrants or Rights														4,252,500
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares													$ 0.5	$ 0.5
Proceeds from Issuance or Sale of Equity (in Dollars) | $													$ 999,250	$ 1,874,450
Preferred Stock, Voting Rights																																														Holders of the Series D Preferred Stock have the right to vote on any matter presented to holders of our Common Stock for their action or consideration at any meeting of the stockholders (or by written consent of stockholders in lieu of meeting), each holder of our Series C Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Series D preferred Stock held by such holder, as described below, are convertible as of the record date for determining stockholders entitled to vote on (or consent to) such matter, voting with the Common Stock as a single class
Preferred Stock, Dividend Rate, Percentage																																														6%
Preferred Stock, Redemption Terms																																														Upon receipt of a conversion notice, we have the right (but not the obligation) to redeem all or part of the Series D Preferred Stock (which the applicable holder of the Series D Preferred Stock is seeking to convert) at a price per share equal to the product of 125% of the (1) Stated Value plus (2) the Additional Amount (the “Redemption Price”). If we decide to exercise the redemption right, within one trading day, we shall deliver written notice to such holder(s) of Series D Preferred Stock that the Series D Preferred Stock will be redeemed (the “Redemption Notice”) on the date that is three trading days following the date of the Redemption Notice (such date, the “Redemption Date”). On the Redemption Date, we shall redeem the shares of Series D Preferred Stock specified in such request by paying in cash therefor a sum per share equal to the Redemption Price. In no event shall a Redemption Notice be given if we may not lawfully redeem our capital stock. On or before the Redemption Date, the Redemption Price for such shares shall be paid by wire transfer of immediately available funds to an account designated in writing by the applicable holder.
Preferred Stock, Shares Outstanding						3,100,000																											0											3,100,000		3,100,000		0
Preferred Stock, Par or Stated Value Per Share (in Dollars per share) | $ / shares						$ 0.01						$ 0.01		$ 1.05																			$ 0.01											$ 0.01		$ 0.01		$ 0.01
Preferred Stock, Dividend Payment Terms																																														Dividends. Each share of Series D Preferred Stock accrues dividends on a quarterly basis in arrears, at the rate of 6% per annum of the Stated Value ($1.05 per share plus any accrued but unpaid dividends) and is to be paid within 15 days after the end of each of our fiscal quarters. Each holder of the Series C Preferred Stock is entitled to receive dividends or distributions on each share of the Series D Preferred Stock on an as converted into Common Stock basis when and if dividends are declared on the Common Stock by our Board of Directors.
Unit Price Per Unit (in Dollars per share) | $ / shares												$ 1
Unit Description												each Unit consisting of (a) one share of a newly formed Series D Convertible Preferred Stock, par value $0.01 per share (the “Series D Preferred Stock”), (b) one warrant (the “Series A Warrants”) to purchase 2.1 shares of the Company’s Common Stock at a purchase price of $0.50 per whole share of Common Stock, and (c) one warrant (the “Series B Warrants” and together with the Series A Warrants, the “Warrants”) to purchase 2.1 shares of Common Stock at a purchase price of $0.75 per whole share
Preferred Stock, Convertible, Terms																																														Conversion. Each holder of our Series D Preferred Stock is entitled to convert their shares of Series D Preferred Stock, in whole or in part, at the Conversion Rate, which is determined by dividing the Conversion Amount (the Stated Value of $1.05, plus any accrued but unpaid dividends) by the Conversion Price ($0.25 per share). In addition, upon certain triggering events, the holders of our Series C Preferred Stock have the right to convert their Series D Preferred Stock at the lesser of the Conversion Price or 75% of the average VWAP for the five trading days prior to the date of the notice of conversion. The Conversion Price is subject to adjustment upon certain stock splits and recapitalization as well as upon the sale of Common Stock or Common Stock Equivalents. Each share of the Series D Preferred Stock is convertible at the option of the holder thereof, or automatically or upon the closing of an underwritten offering of at least $10 million of the Company’s securities or upon listing of the Company’s Common Stock on a national securities exchange.
Preferred Stock, Preemptive Rights																																														Preemptive or Similar Rights Additionally, except for a public offering or certain exempt issuances of our securities, holders of the Series D Preferred Stock shall have the right to participate in any offering of our Common Stock or Common Stock Equivalents (as defined in the COD) in a transaction exempt from registration under the Securities Act in an amount equal to an aggregate of 30% of the financing on the same terms, conditions and price provided to investors in such an offering, such right shall expire on the 15 month anniversary of the issuance date of the Series D Preferred Stock. Further, until the earlier of 18 months from the issuance date of the Series D Preferred Stock and the date that there are less than 20% of the shares of Series D Preferred Stock outstanding, the Investors have most favored nations protection in the event we issue or sell Common Stock or Common Stock equivalents that the Investors believe are more favorable than the terms and conditions under the Private Placement.
Proceeds from Issuance of Private Placement (in Dollars) | $												$ 3,100,000
Preferred Stock, No Par Value (in Dollars per share) | $ / shares												$ 0.01
Payments of Stock Issuance Costs (in Dollars) | $													$ 75,750	$ 125,500
Series X Preferred Stock [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Stock Issued During Period, Shares, New Issues																	2,000																													24,227
Preferred Stock, Shares Authorized						400,000																																						400,000		27,324
Dividends, Preferred Stock (in Dollars) | $																																													16,392	$ 0		$ 65,568
Stock Issued During Period, Value, Conversion of Convertible Securities (in Dollars) | $																																																$ 65,568
Preferred Stock, Voting Rights																																												Each one share of the Series X Preferred Stock is entitled to 20,000 votes on all matters submitted to a vote of our shareholders.				Each one share of the Series X Preferred Stock is entitled to 20,000 votes
Preferred Stock, Dividend Rate, Percentage																																												10%		10%
Preferred Stock, Shares Outstanding						24,227																											26,227											24,227		24,227		26,227
Preferred Stock, Par or Stated Value Per Share (in Dollars per share) | $ / shares						$ 0.01																											$ 0.01											$ 0.01		$ 0.01		$ 0.01
Preferred Stock, Liquidation Preference Per Share (in Dollars per share) | $ / shares						$ 25																																						$ 25		$ 25
Preferred Stock, Dividend Payment Terms																																												The Company reserves the right to pay the dividends in shares of the Company’s common stock at a price equal to the average closing price over the five days prior to the date of the dividend declaration.		The Company reserves the right to pay the dividends in shares of the Company’s common stock at a price equal to the average closing price over the five days prior to the date of the dividend declaration.
Dividends Payable, Current (in Dollars) | $						$ 97,675																																						$ 97,675	16,392	$ 61,818
Number of Note Holders																																																2
Dividends Payable (in Dollars) | $																																	$ 0													$ 61,818		$ 0
Series X Preferred Stock [Member] | Common Stock [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Stock Issued During Period, Value, Conversion of Convertible Securities (in Dollars) | $																																																$ 21,511
Stock Issued During Period, Shares, Conversion of Convertible Securities																																																2,151,204
Share-Based Payment Arrangement, Option [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Share-Based Payment Arrangement, Noncash Expense (in Dollars) | $																																													$ 5,942
Subsequent Event [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Common Stock, Par or Stated Value Per Share (in Dollars per share) | $ / shares										$ 0.01
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares										$ 0.25
Debt Conversion, Converted Instrument, Shares Issued										3,179,650
Stock Issued During Period, Shares, Other	637,036		637,036		168,221		1,720,000
Debt Instrument, Unamortized Discount (in Dollars) | $	$ 27,777		$ 27,777				$ 75,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares	$ 0.5		$ 0.5				$ 0.5
Warrants and Rights Outstanding, Term		5 years
Class of Warrant or Rights, Granted	277,777	92,471	277,777	750,000			750,000
Restricted Stock, Shares Issued Net of Shares for Tax Withholdings																																												600,000
Subsequent Event [Member] | Series C Preferred Stock [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Stock Issued During Period, Shares, Other		720,000
Stock Issued During Period, Shares, New Issues								411,000
Subsequent Event [Member] | Series D Preferred Stock [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Stock Issued During Period, Shares, New Issues								1,271,000
Waiver Fee [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Stock Issued During Period, Shares, Other						1,541,721
Other Noncash Expense (in Dollars) | $																																												$ 385,431
Waiver Fee [Member] | Common Stock [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Stock Issued During Period, Shares, Other																																												1,541,721
Accrued Liabilities [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Debt Conversion, Converted Instrument, Amount (in Dollars) | $																$ 156,441
Debt Conversion, Converted Instrument, Shares Issued																625,764																														479,464
Accrued Liabilities [Member] | Stock Subscribed [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued																																														146,300
Services [Member] | Common Stock [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services																																								200,000
Stock Issued During Period, Value, Issued for Services (in Dollars) | $																																								$ 7,680
Share-Based Payment Arrangement, Option [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Share-Based Payment Arrangement, Noncash Expense (in Dollars) | $																																												$ 167,015
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount (in Dollars) | $						$ 2,635,359																																						$ 2,635,359
APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition (in Dollars) | $																																																$ 164,647
Share-Based Payment Arrangement [Member]
Stockholders' Equity (Deficit) (Details) [Line Items]
Share-Based Payment Arrangement, Noncash Expense (in Dollars) | $																																																$ 67,623
[1]On December 14, 2020, the Company reset the exercise price of all the options then outstanding options to $0.03 per share. This included 150,000 options previously priced at $0.04 per share; 7,450,000 options previously priced at $0.05 per share; 1,000,000 options previously priced at $0.06 per share; and 67,879 options previously prices at $21.40 per share. The Company valued these options as of December 14, 2020, at the original exercise price and at the new price of $0.03 per share and charged the increase in value in the amount of $4,113 to operations during the year ended December 31, 2020. The exercise prices of all options are shown at the restated price of $0.03 per share.

Stockholders' Equity (Deficit_3

Stockholders' Equity (Deficit) (Details) - Share-Based Payment Arrangement, Option, Exercise Price Range - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021		Dec. 31, 2020		Dec. 31, 2019
Share-Based Payment Arrangement, Option, Exercise Price Range [Abstract]
Range of exercise prices	$ 0.03	$ 0.03
Range of exercise prices	$ 0.39	$ 0.39
Number of options outstanding (in Shares)	18,671,211	18,746,211		13,453,879		67,879
Weighted average remaining contractual life (years)	8 years 10 months 6 days	9 years 1 month 6 days
Weighted average exercise price of outstanding options	$ 0.2	$ 0.2	[1]	$ 0.03	[1]	$ 0.03	[1]
Number of options exercisable (in Shares)	6,636,628	5,502,877	[2]
Weighted average exercise price of exercisable options	$ 0.14	$ 0.11	[1]
[1]On December 14, 2020, the Company reset the exercise price of all the options then outstanding options to $0.03 per share. This included 150,000 options previously priced at $0.04 per share; 7,450,000 options previously priced at $0.05 per share; 1,000,000 options previously priced at $0.06 per share; and 67,879 options previously prices at $21.40 per share. The Company valued these options as of December 14, 2020, at the original exercise price and at the new price of $0.03 per share and charged the increase in value in the amount of $4,113 to operations during the year ended December 31, 2020. The exercise prices of all options are shown at the restated price of $0.03 per share.[2]On December 28, 2020, the Company accelerated the vesting of certain of its options issued to board members, management, and consultants, resulting in a charge to operations in the amount of $164,647 during the year ended December 31, 2020.

Stockholders' Equity (Deficit_4

Stockholders' Equity (Deficit) (Details) - Share-Based Payment Arrangement, Option, Activity - $ / shares			3 Months Ended	12 Months Ended
	Dec. 28, 2020	Mar. 02, 2020	Mar. 31, 2022	Dec. 31, 2021		Dec. 31, 2020		Dec. 31, 2019
Share-Based Payment Arrangement, Option, Activity [Abstract]
Outstanding, Shares			18,671,211	18,746,211		13,453,879		67,879
Outstanding, Weighted-average exercise price			$ 0.2	$ 0.2	[1]	$ 0.03	[1]	$ 0.03	[1]
Options vested and exercisable, Shares			6,636,628	5,502,877	[2]
Options vested and exercisable, Weighted-average exercise price			$ 0.14	$ 0.11	[1]
Granted, Shares			0	14,295,000		14,886,000
Granted, Weighted-average exercise price	$ 0.03	$ 0.05	$ 0	$ 0.26	[1]	$ 0.03	[1]
Expired, Shares			(75,000)	(350,000)		(1,500,000)
Expired, Weighted-average exercise price			$ 0.03	$ 0.03	[1]	$ 0.03	[1]
[1]On December 14, 2020, the Company reset the exercise price of all the options then outstanding options to $0.03 per share. This included 150,000 options previously priced at $0.04 per share; 7,450,000 options previously priced at $0.05 per share; 1,000,000 options previously priced at $0.06 per share; and 67,879 options previously prices at $21.40 per share. The Company valued these options as of December 14, 2020, at the original exercise price and at the new price of $0.03 per share and charged the increase in value in the amount of $4,113 to operations during the year ended December 31, 2020. The exercise prices of all options are shown at the restated price of $0.03 per share.[2]On December 28, 2020, the Company accelerated the vesting of certain of its options issued to board members, management, and consultants, resulting in a charge to operations in the amount of $164,647 during the year ended December 31, 2020.

Stockholders' Equity (Deficit_5

Stockholders' Equity (Deficit) (Details) - Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions - Share-Based Payment Arrangement, Option [Member]	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Stockholders' Equity (Deficit) (Details) - Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Volatility	0%
Dividends	0%
Risk-free interest rates	0%
Term (years)	0 years
Minimum [Member]
Stockholders' Equity (Deficit) (Details) - Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Volatility		169.30%
Dividends		0%
Risk-free interest rates		0.82%
Term (years)		2 years 6 months
Maximum [Member]
Stockholders' Equity (Deficit) (Details) - Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Volatility		183.50%
Dividends		0%
Risk-free interest rates		1.69%
Term (years)		10 years

Stockholders' Equity (Deficit_6

Stockholders' Equity (Deficit) (Details) - Schedule of Stockholders' Equity Note, Warrants or Rights - $ / shares		3 Months Ended	12 Months Ended
	Mar. 25, 2021	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of Stockholders' Equity Note, Warrants or Rights [Abstract]
Outstanding, Shares		31,405,000	29,820,000	0	1,800,000
Outstanding, Weighted-average exercise price		$ 0.622	$ 0.625	$ 0	$ 0.00858
Granted, Shares	6,300,000	1,585,000	29,820,000	6,582,382
Granted, Weighted-average exercise price		$ 0.558	$ 0.625	$ 0.00858
Exercised, Shares		0	0	(8,382,382)
Exercised, Weighted-average exercise price		$ 0	$ 0	$ 0.0561

Stockholders' Equity (Deficit_7

Stockholders' Equity (Deficit) (Details) - Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award - Warrant [Member]	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Volatility	147.80%	171.60%
Risk-free interest rates	0.76%	1.15%
Term (years)	3 months	5 years
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Volatility	150.70%	183.50%
Risk-free interest rates	0.83%	1.63%
Term (years)	3 months	6 years 6 months

Commitments and Contingencies (

Commitments and Contingencies (Details) - PPP Loan [Member] - USD ($)	12 Months Ended
	Dec. 31, 2021	Apr. 25, 2022	Mar. 31, 2022	May 04, 2020	Apr. 25, 2020
Commitments and Contingencies (Details) [Line Items]
Debt Instrument, Face Amount		$ 460,000		$ 460,000	$ 460,000
Notes Payable	$ 460,406		$ 460,406
Debt Instrument, Decrease, Forgiveness	$ 25,000
Debt Instrument, Term	60 months

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)																	3 Months Ended		6 Months Ended	12 Months Ended
	May 10, 2022	Apr. 27, 2022	Apr. 18, 2022	Apr. 06, 2022	Apr. 01, 2022	Mar. 18, 2022	Mar. 17, 2022	Feb. 14, 2022	Jan. 07, 2022	Dec. 30, 2021	Nov. 10, 2021	Oct. 18, 2021	Jun. 23, 2021	Mar. 25, 2021	Mar. 23, 2021	Feb. 01, 2021	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2020	Jan. 05, 2022	Apr. 25, 2020
Subsequent Events (Details) [Line Items]
Stock Issued During Period, Shares, Other (in Shares)													637,953				1,720,000				2,151,204
Debt Instrument, Face Amount										$ 1,000,000													$ 460,000
Class of Warrant or Rights, Granted (in Shares)														6,300,000			1,585,000			29,820,000	6,582,382
Proceeds from Issuance of Debt										$ 850,000							$ 675,000	$ 0		$ 0	$ 1,673,406
Debt Instrument, Unamortized Discount																				$ 150,000	$ 756,795
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)											$ 0.75	$ 0.75		$ 0.75
Subsequent Event, Effect of Change in Tax Status			$ 430,000
Warrants and Rights Outstanding, Term												5 years		5 years
(in Dollars per share)																	$ 0.558			$ 0.625	$ 0.00858
Debt Instrument, Interest Rate, Stated Percentage										10%
Debt Instrument, Maturity Date, Description								maturity date that is the earlier of (i) six (6) months from the date of execution, or (ii) the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE
Debt, Default Interest Rate										18%
Common Stock, Par or Stated Value Per Share (in Dollars per share)													$ 0.01				$ 0.01		$ 0.01	$ 0.01	$ 0.01
Debt Conversion, Original Debt, Amount																	$ 0	$ 2,653,795		$ 0	$ 1,633,406
Debt Instrument, Convertible, Conversion Price (in Dollars per share)									$ 0.25													$ 0.25
Debt Conversion, Converted Instrument, Shares Issued (in Shares)									3,179,650												63,374,555
Debt Instrument, Term										6 months									6 months
Stock Issued During Period, Shares, New Issues (in Shares)															461,358	6,672,000
Series C Preferred Stock [Member]
Subsequent Events (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)														$ 0.5
Warrants and Rights Outstanding, Term														5 years
Stock Issued During Period, Shares, New Issues (in Shares)														3,000,000
Series D Preferred Stock [Member]
Subsequent Events (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)											$ 0.5	$ 0.5
Stock Issued During Period, Shares, New Issues (in Shares)											1,075,000	2,050,000
Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Stock Issued During Period, Shares, Other (in Shares)	637,036		637,036		168,221	1,720,000
Stock Issued During Period, Value, Other	$ 159,259		$ 159,259			$ 430,000
Debt Instrument, Fee			Commitment Fee Shares can be decreased to 266,280 shares ($66,570) if the Company repays the Note on or prior to their maturity	an aggregate initial commitment fee in the amount of $430,000 in the form of 1,720,000 shares (the “Commitment Fee Shares”) of the Company’s common stock (the “Common Stock”), which Commitment Fee Shares can be decreased to 722,400 shares ($180,000) if the Company repays the Notes on or prior their maturity		Commitment Fee Shares can be decreased to 720,000 shares ($180,000) if the Company repays the Note on or prior its maturity
Debt Instrument, Face Amount	$ 277,777		$ 277,777	$ 750,000		$ 750,000		$ 175,000
Class of Warrant or Rights, Granted (in Shares)	277,777	92,471	277,777	750,000		750,000
Proceeds from Issuance of Debt	$ 250,000		$ 250,000
Debt Instrument, Unamortized Discount	$ 27,777		$ 27,777			$ 75,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$ 0.5		$ 0.5			$ 0.5
Warrants and Rights Outstanding, Term		5 years
Proceeds from Notes Payable						$ 675,000	$ 616,250
Common Stock, Par or Stated Value Per Share (in Dollars per share)									$ 0.01
Debt Instrument, Convertible, Conversion Price (in Dollars per share)									$ 0.25
Debt Conversion, Converted Instrument, Shares Issued (in Shares)									3,179,650
Subsequent Event [Member] | Series C Preferred Stock [Member]
Subsequent Events (Details) [Line Items]
Stock Issued During Period, Shares, Other (in Shares)		720,000
Stock Issued During Period, Shares, New Issues (in Shares)							411,000
Subsequent Event [Member] | Series D Preferred Stock [Member]
Subsequent Events (Details) [Line Items]
Stock Issued During Period, Shares, New Issues (in Shares)							1,271,000
Accounts Payable [Member] | Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Debt Conversion, Original Debt, Amount									$ 500,000
Interest and Penalties [Member] | Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Debt Conversion, Original Debt, Amount									$ 294,912.56
Diamond Note 2 [Member]
Subsequent Events (Details) [Line Items]
Debt Instrument, Face Amount						$ 235,294
Class of Warrant or Rights, Granted (in Shares)						200,000
Proceeds from Issuance of Debt						$ 200,000
Warrants and Rights Outstanding, Term						5 years
Debt Instrument, Interest Rate, Stated Percentage						10%
Debt Instrument, Maturity Date, Description						maturity date that is the earlier of (i) April 4, 2022, (ii) the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE, or (iii) the date of receipt of the Company of the next round of debt or equity financing in an amount of at least $1,000,000
Debt, Default Interest Rate						18%
Diamond Note 2 [Member] | Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Stock Issued During Period, Shares, Other (in Shares)		96,471
(in Dollars per share)			$ 0.5
Diamond Note [Member]
Subsequent Events (Details) [Line Items]
Debt Instrument, Face Amount								175,000
Proceeds from Issuance of Debt								$ 148,750
Debt Instrument, Interest Rate, Stated Percentage								10%
Debt, Default Interest Rate								18%
Diamond Note [Member] | Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Debt Instrument, Face Amount		$ 235,294				$ 235,294
Class of Warrant or Rights, Granted (in Shares)						200,000
Warrants and Rights Outstanding, Term						5 years
Debt Instrument, Interest Rate, Stated Percentage		10%				10%
Debt Instrument, Maturity Date, Description		maturity date that is the earlier of (i) April 4, 2022, (ii) the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE, or (iii) the date of receipt of the Company of the next round of debt or equity financing in an amount of at least $1,000,000				maturity date that is the earlier of (i) April 4, 2022, (ii) the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE, or (iii) the date of receipt of the Company of the next round of debt or equity financing in an amount of at least $1,000,000
Proceeds from Notes Payable		$ 200,000				$ 200,000
Debt, Default Interest Rate		18%
Short-Term Debt, Interest Rate Increase						18%
Note Dated February 14, 2022 [Member] | Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage								10%
Proceeds from Notes Payable								$ 148,750
Debt, Default Interest Rate								18%
Debt Instrument, Term								6 months
Note Dated February 14, 2022 [Member] | Warrants at $0.50 [Member] | Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Class of Warrant or Rights, Granted (in Shares)								367,500
Warrants and Rights Outstanding, Term								5 years
Note Dated February 14, 2022 [Member] | Warrants at $0.75 [Member] | Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Class of Warrant or Rights, Granted (in Shares)								367,500
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)								$ 0.75
Warrants and Rights Outstanding, Term								5 years

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details) - Property, Plant and Equipment	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2020
Office Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years	3 years
Office Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years	5 years
Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years	3 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	7 years	7 years
Machinery and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years	3 years
Machinery and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years	10 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives		Term of lease
Leasehold Improvements [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	Term of lease
Leasehold Improvements [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	Term of lease

Net Loss Per Share Applicable_7

Net Loss Per Share Applicable to Common Shareholders (Details) - Schedule of Earnings Per Share, Basic and Diluted - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Numerator:
Net loss applicable to common shareholders	$ (3,724,886)	$ (2,754,952)	$ (11,226,366)	$ (2,936,129)
Denominator:
Weighted average common shares outstanding	213,703,195	187,152,300	203,000,201	105,177,272
Net loss per share:
Basic and diluted	$ (0.02)	$ (0.01)	$ (0.06)	$ (0.03)

Net Loss Per Share Applicable_8

Net Loss Per Share Applicable to Common Shareholders (Details) - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share - shares	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	68,689,644	36,240,536	66,820,946	93,022,036
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount			0	79,475,904
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	18,671,211	10,967,879	18,746,211	13,453,879
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	31,405,000	12,600,000	29,820,000	0
Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount			17,382,575	0
Accrued Interest [Member] | Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,230,858	72,657	872,160	92,253

Related Party Transactions (D_2

Related Party Transactions (Details) - Schedule of Stock by Class - Series X Preferred Stock [Member] - shares		12 Months Ended
	Jun. 23, 2021	Dec. 31, 2021
Class of Stock [Line Items]
# shares	2,000	24,227
Director [Member]
Class of Stock [Line Items]
# shares		1,200
Chief Executive Officer [Member]
Class of Stock [Line Items]
# shares		2,000
Director #2 [Member]
Class of Stock [Line Items]
# shares		2,884
Director #3 [Member]
Class of Stock [Line Items]
# shares		2,400
Irish Italian Retirement Fund [Member]
Class of Stock [Line Items]
# shares		12,503
Frank Lightmas [Member]
Class of Stock [Line Items]
# shares		3,240

Accounts Payable and Accrued _4

Accounts Payable and Accrued Liabilities (Details) - Schedule of Accounts Payable and Accrued Liabilities - USD ($)	Mar. 31, 2022	Jan. 07, 2022	Jan. 05, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of Accounts Payable and Accrued Liabilities [Abstract]
Trade accounts payable	$ 4,890,066			$ 3,933,305	$ 824,405
Accrued payroll and payroll taxes	96,641			23,554	244,926
Other	17,928	$ 294,912.56	$ 294,912	19,205	0
Total	$ 5,004,635			$ 3,976,064	$ 1,069,331

Right to Use Assets and Lease_6

Right to Use Assets and Lease Liabilities - Operating Leases (Details) - Lease, Cost - USD ($)	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Lease, Cost [Abstract]
Right to use assets, net	$ 3,619,403	$ 3,886,866	$ 310,361
Lease liability	4,146,960	4,134,802	321,004
Less: current portion	(276,639)	(161,838)	(8,905)
Lease liability, non-current	$ 3,870,321	$ 3,972,964	$ 312,099

Right to Use Assets and Lease_7

Right to Use Assets and Lease Liabilities - Operating Leases (Details) - Lessee, Operating Lease, Liability, Maturity - USD ($)	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Lessee, Operating Lease, Liability, Maturity [Abstract]
For the period ended December 31, 2022	$ 763,580	$ 652,653
For the period ended December 31, 2023	874,687	888,152
For the period ended December 31, 2024	827,773	821,296
For the period ended December 31, 2025	846,523	841,600
For the period ended December 31, 2026	865,517	860,551
Thereafter	2,251,381	2,478,412
Total	6,429,461	6,542,664
Less: Present value discount	(2,282,501)	(2,407,862)
Lease liability	$ 4,146,960	$ 4,134,802	$ 321,004

Debt (Details) - Schedule of _2

Debt (Details) - Schedule of Debt - USD ($)	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Debt (Details) - Schedule of Debt [Line Items]
Notes Payable		$ 738,432	$ 1,196,366
Total notes payable		1,198,838	1,656,772
Less: Discount		(150,000)	(756,795)
Notes payable - net of discount		1,048,838	899,977
Current Portion, net of discount		1,048,838	899,977
Long-term portion, net of discount		0	0
PPP Loan [Member]
Debt (Details) - Schedule of Debt [Line Items]
Notes Payable		460,406	$ 460,406
Notes payable - net of discount	$ 460,406	$ 460,406

Derivative Liabilities (Details

Derivative Liabilities (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2019
Disclosure Text Block [Abstract]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	$ 0	$ 807,682

Derivative Liabilities (Detai_2

Derivative Liabilities (Details) - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	12 Months Ended
	Dec. 31, 2020 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]
Conversion features issued	$ 1,273,463
Settled upon conversion or exercise	(1,296,416)
Settled upon payment of note	(148,949)
(Loss) Gain on revaluation	(508,839)
Balance	$ 807,682

Stockholders' Equity (Deficit_8

Stockholders' Equity (Deficit) (Details) - Share-based Payment Arrangement, Option, Exercise Price Range - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021		Dec. 31, 2020		Dec. 31, 2019
Share-Based Payment Arrangement, Option, Exercise Price Range [Abstract]
Range of exercise prices	$ 0.03	$ 0.03
Range of exercise prices	$ 0.39	$ 0.39
Number of options outstanding (in Shares)	18,671,211	18,746,211		13,453,879		67,879
Weighted average remaining contractual life (years)	8 years 10 months 6 days	9 years 1 month 6 days
Weighted average exercise price of outstanding options	$ 0.2	$ 0.2	[1]	$ 0.03	[1]	$ 0.03	[1]
Number of options exercisable (in Shares)	6,636,628	5,502,877	[2]
Weighted average exercise price of exercisable options	$ 0.14	$ 0.11	[1]
[1]On December 14, 2020, the Company reset the exercise price of all the options then outstanding options to $0.03 per share. This included 150,000 options previously priced at $0.04 per share; 7,450,000 options previously priced at $0.05 per share; 1,000,000 options previously priced at $0.06 per share; and 67,879 options previously prices at $21.40 per share. The Company valued these options as of December 14, 2020, at the original exercise price and at the new price of $0.03 per share and charged the increase in value in the amount of $4,113 to operations during the year ended December 31, 2020. The exercise prices of all options are shown at the restated price of $0.03 per share.[2]On December 28, 2020, the Company accelerated the vesting of certain of its options issued to board members, management, and consultants, resulting in a charge to operations in the amount of $164,647 during the year ended December 31, 2020.

Stockholders' Equity (Deficit_9

Stockholders' Equity (Deficit) (Details) - Share-based Payment Arrangement, Option, Activity - $ / shares							1 Months Ended	3 Months Ended	12 Months Ended
		May 12, 2021	Feb. 22, 2021	Feb. 05, 2021	Dec. 28, 2020	Mar. 02, 2020	Jun. 29, 2021	Mar. 31, 2022	Dec. 31, 2021		Dec. 31, 2020
Share-Based Payment Arrangement, Option, Activity [Abstract]
Outstanding, Number of Shares								18,746,211	13,453,879		67,879
Outstanding, Weighted-Average Exercise Price	[1]							$ 0.2	$ 0.03		$ 0.03
Exercisable, Number of Shares								6,636,628	5,502,877	[2]
Exercisable, Weighted-Average Exercise Price								$ 0.14	$ 0.11	[1]
Granted, Number of Shares								0	14,295,000		14,886,000
Granted, Weighted-Average Exercise Price					$ 0.03	$ 0.05		$ 0	$ 0.26	[1]	$ 0.03	[1]
Cancelled, Number of Shares								(75,000)	(350,000)		(1,500,000)
Cancelled, Weighted-Average Exercise Price								$ 0.03	$ 0.03	[1]	$ 0.03	[1]
Exercised, Number of Shares		(2,500,000)	(336,000)	(336,000)			(5,116,668)		(8,652,668)
Exercised, Weighted-Average Exercise Price		$ 0.03	$ 0.03	$ 0.03			$ 0.03		$ 0.03	[1]
Outstanding, Number of Shares								18,671,211	18,746,211		13,453,879
Outstanding, Weighted-Average Exercise Price								$ 0.2	$ 0.2	[1]	$ 0.03	[1]
[1]On December 14, 2020, the Company reset the exercise price of all the options then outstanding options to $0.03 per share. This included 150,000 options previously priced at $0.04 per share; 7,450,000 options previously priced at $0.05 per share; 1,000,000 options previously priced at $0.06 per share; and 67,879 options previously prices at $21.40 per share. The Company valued these options as of December 14, 2020, at the original exercise price and at the new price of $0.03 per share and charged the increase in value in the amount of $4,113 to operations during the year ended December 31, 2020. The exercise prices of all options are shown at the restated price of $0.03 per share.[2]On December 28, 2020, the Company accelerated the vesting of certain of its options issued to board members, management, and consultants, resulting in a charge to operations in the amount of $164,647 during the year ended December 31, 2020.

Stockholders' Equity (Defici_10

Stockholders' Equity (Deficit) (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Stockholders' Equity (Deficit) (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Dividends	0%	0%
Term (years)		5 years
Minimum [Member]
Stockholders' Equity (Deficit) (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Volatility	153.50%	149.40%
Risk-free interest rates	0.82%	0.55%
Term (years)	5 years
Maximum [Member]
Stockholders' Equity (Deficit) (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Volatility	183.50%	209.60%
Risk-free interest rates	1.69%	1.30%
Term (years)	6 years 6 months

Stockholders' Equity (Defici_11

Stockholders' Equity (Deficit) (Details) - Schedule of Stockholders' Equity Note, Warrants or Rights - $ / shares		3 Months Ended	12 Months Ended
	Mar. 25, 2021	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of Stockholders' Equity Note, Warrants or Rights [Abstract]
Outstanding, Number of Shares		29,820,000	0	1,800,000
Outstanding, Weighted Average Exercise Price		$ 0.625	$ 0	$ 0.00858
Granted, Number of Shares	6,300,000	1,585,000	29,820,000	6,582,382
Granted, Weighted Average Exercise Price		$ 0.558	$ 0.625	$ 0.00858
Exercised, Number of Shares		0	0	(8,382,382)
Exercised, Weighted Average Exercise Price		$ 0	$ 0	$ 0.0561
Outstanding, Number of Shares		31,405,000	29,820,000	0
Outstanding, Weighted Average Exercise Price		$ 0.622	$ 0.625	$ 0

Income Taxes (Details)

Income Taxes (Details)	Dec. 31, 2021 USD ($)
Income Tax Disclosure [Abstract]
Operating Loss Carryforwards	$ 8.1

Income Taxes (Details) - Schedu

Income Taxes (Details) - Schedule of Components of Income Tax Expense (Benefit) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Schedule of Components of Income Tax Expense (Benefit) [Abstract]
Current			$ 0	$ 0
Deferred			0	0
Total	$ 0	$ 0	$ 0	$ 0

Income Taxes (Details) - Sche_2

Income Taxes (Details) - Schedule of Effective Income Tax Rate Reconciliation - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Schedule of Effective Income Tax Rate Reconciliation [Abstract]
Expected tax at statutory rates			$ (2,351,000)	$ (617,000)
Expected tax at statutory rates			21%	21%
Permanent Differences			$ 692,000	$ (42,000)
Permanent Differences			6%	1%
State Income Tax, Net of Federal benefit			$ (612,000)	$ 0
State Income Tax, Net of Federal benefit			5%	0%
Current Year Change in Valuation Allowance			$ 2,291,000	$ 659,000
Current Year Change in Valuation Allowance			20%	22%
Prior Year True-Ups			$ (20,000)	$ 0
Prior Year True-Ups			0%	0%
Income tax expense	$ 0	$ 0	$ 0	$ 0
Income tax expense			0%	0%

Income Taxes (Details) - Sche_3

Income Taxes (Details) - Schedule of Deferred Tax Assets and Liabilities - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Schedule of Deferred Tax Assets and Liabilities [Abstract]
Accrued payroll	$ 22,000	$ 41,000
ASC842-ROU Asset	(1,117,000)	65,000
ASC842-ROU (Liability)	1,189,000	(67,000)
Gain from derivatives	(4,000)	(107,000)
Stock based compensation	398,000	119,000
Depreciation	(764,000)	(1,000)
Net operating loss	8,478,000	5,861,000
Net deferred tax assets (liabilities)	8,202,000	5,911,000
Valuation allowance	(8,202,000)	(5,911,000)
Net deferred tax assets (liabilities)	$ 0	$ 0

Fair Value of Financial Instr_3

Fair Value of Financial Instruments (Details) - Schedule of Derivative Liabilities at Fair Value - USD ($)	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Fair Value of Financial Instruments (Details) - Schedule of Derivative Liabilities at Fair Value [Line Items]
Derivative liabilities	$ 26,771	$ 0	$ 807,682
Fair Value, Inputs, Level 1 [Member]
Fair Value of Financial Instruments (Details) - Schedule of Derivative Liabilities at Fair Value [Line Items]
Derivative liabilities		0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value of Financial Instruments (Details) - Schedule of Derivative Liabilities at Fair Value [Line Items]
Derivative liabilities		0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value of Financial Instruments (Details) - Schedule of Derivative Liabilities at Fair Value [Line Items]
Derivative liabilities		$ 0	$ 807,682